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Definition & type(s) of stroke 
Stroke is a pathological entity wherein the abrupt cessation of blood supply to a part of 
the central nervous system (brain, spinal cord or retina) leads to tissue damage and 
neurological dysfunction. According to the updated definition, stroke broadly includes the 
following: CNS infarction, ischemic stroke, silent CNS infarction, intracerebral 
haemorrhage, subarachnoid haemorrhage and cerebral venous thrombosis (1). As per the 
new definition, ischemic stroke includes only focal ischemia, excluding global ischemia due 
to the differences in their pathology and mechanisms. In focal ischemia, stenosis or 
occlusion of an artery impedes the perfusion to the respective territory leading to cell 
death. In contrast, in global ischemia, a decrease in cerebral perfusion resulting from a 
reduction in blood pressure (e.g. cardiac arrest) or severely increased intracranial pressure 
(e.g. severe head trauma) leads to selective neuronal cell death in vulnerable areas such as 
hippocampus, neocortex, thalamus and basal ganglia (1). Besides, survivors of global 
ischemia always experience reperfusion of the ischemic cerebral tissue, which will 
additionally contribute to the endured neuronal damage, whereas in focal ischemia 
reperfusion may either be absent or present. The treatment modalities of focal and global 
ischemia differ also. Focal ischemia is acutely treated with reperfusion strategies to re-
establish blood flow in an artery. In contrast, correction of the systemic disorder 
underlying the hypoperfusion is the mainstay in global ischemia.  
Stroke can also be broadly classified into ischemic (80-85%) and hemorrhagic stroke (15-
20%). Ischemic stroke is further sub-classified into thrombotic and embolic stroke. 
Whereas thrombotic stroke develops by a gradually progressing clot formation within a 
cerebral artery, embolic stroke is caused by dislodging of a blood clot or atheromatous 
plaque from an extracranial site. Hemorrhagic stroke results from a rupture of a blood 
vessel in the brain parenchyma or subarachnoid space not only hampering the blood flow, 
but also leading to a rise in the intracranial pressure. 
Disease burden  
Stroke is the second most common cause of death and leading cause of adult disability, 
accounting for 11.13 % of total deaths worldwide. The prevalence of stroke was 33 million 
in 2010, with 16.9 million people having a first stroke worldwide (2). The major global 








stroke is the highest (3). Moreover, due to an increasingly aging population, the number of 
stroke patients is expected to more than double over the next 40 years (3). Stroke has a 
major impact on the quality of life of survivors and their caretakers and results in a 
significant economic impact due to health care costs and loss of productivity (4). The 
global burden from stroke is predicted to rise from around 38 million DALYs (disability 
adjusted life years) in 1990 to 61 million DALYs in 2020.  
Risk factors 
Several factors increase the risk of stroke. Hypertension contributes to about 54% of all 
stroke cases (5). Apart from hypertension, atrial fibrillation, diabetes, resident lifestyle and 
smoking account for two-thirds of all first-time stroke cases (2,6).  
PATHOPHYSIOLOGY 
Cerebral Ischemia & Reperfusion 
Brain function and viability require continuous utilization of metabolic energy in form of 
ATP, which is derived from the oxidative phosphorylation of glucose delivered via the 
arterial circulation. A complex biochemical cascade of events is initiated upon acute blood 
flow cessation ultimately resulting in the depletion of energy rich stores (ATP). At this 
stage, the brain is unable to meet its high energy demands (7). The critical reduction of 
cerebral perfusion eventually leads to ischemic infarction with a central core of 
irreversible neuronal damage (necrosis) in areas where blood flow decreases below the 
threshold of cell survival. In the central core, shortage of ATP causes failure of plasma 
membrane ionic pumps resulting in the cell being unable to maintain ionic gradients 
causing increased passive transport of water (cytotoxic edema) secondary to the increase 
in intracellular Na+ and  release of K+ into the extracellular space (7) (Fig. 1). Brain regions 
outside the central core, i.e. those with collateral blood supply, undergo a less severe 
insult, but do show dysfunctional restoration of ion gradients in turn leading to waves of 
depolarization (peri-infarct depolarizations, PIDs or spreading depressions, SDs) and 
excessive release of neurotransmitters from presynaptic nerve terminals. Together, the 
increased release of neurotransmitters such as glutamate and the extracellular released K+ 
ions initiate further generation of depolarization waves, thus initiating a vicious cycle. Such 
a region is termed the ‘ischemic penumbra’ (at-risk tissue), and constitutes predominantly 
a rim of brain tissue with its blood supply restrained between two critical thresholds, i.e., 
the threshold of electrical failure and the threshold of electrical failure and the threshold 





















Figure 1: Schematic representation of pathophysiological events in focal cerebral ischemia associated with 
reperfusion injury. COX, cyclooxygenase; iNOS, inducible nitric oxide synthase; NO, nitric oxide; NMDA, N-
methyl-D-aspartate; AMPA, α-amino-3-hydroxy-5-methly-4-isoxazoleproprionic acid; IP3, inositol 1,4,5-
triphosphate. Adapted & modified from Durukan & Tatlisumak, Pharmacol Biochem Behav. 2007, 87(1): 
179-197. 
constrained perfusion but partially preserved energy state and still salvageable, if blood 
flow is rapidly restored. If blood flow is however not restored in a due time, the infarct 
core progresses into the penumbra.  
Excitotoxicity 
The increased extracellular concentrations of glutamate, due to an impaired glial re-
uptake of neurotransmitters, induce an excessive activation of glutamate receptors 








and AMPA receptor types which mediate Ca2+ influx into the cells, resulting in an 
intracellular calcium overload (9) (Fig. 1). This excitotoxicity and imbalance of ions lead to 
activation of a variety of cellular signal transduction cascades, including protein kinase C, 
phospholipase A2, phospholipase C, cyclooxygenase, calcium-dependent nitric oxide 
synthase, calpain, various proteases, and endonucleases.  
Mitochondrial dysfunction 
The Ca2+ overload also elicits mitochondrial dysfunction, thus impairing its oxidative 
phosphorylation, increasing free radical formation and triggering the release of 
apoptogenic molecules (10). As a result of free-radical generation, irreversible 
mitochondrial damage, inflammation, and both necrotic and apoptotic cell death are 
initiated (11,12). The resulting formation of mitochondrial permeability transition pores 
causes the mitochondrial membrane to become leaky leading to a burst of free radicals 
and release of cytochrome c, a key mediator of apoptosis (13). Free radicals can react 
irreversibly with several cellular constituents such as proteins, double bonds of 
phospholipids, and nuclear DNA. Further, in conjunction with a weakened scavenger 
system, free radicals cause lipid peroxidation, membrane damage and dysregulation of 
cellular processes (Fig. 1). In the brain’s normal condition of high energy demand and 
adequate oxygen supply, increased mitochondrial calcium levels drive an increase in ATP 
production via oxidative phosphorylation. However, when oxygen is not available in 
adequate amounts to accept electrons from NADH, these electrons form superoxide 
radicals from the residual oxygen. Hydrogen sulfide (H2S) during such a condition can act 
as an electron donor to replenish the reduced ATP stores (14).  
Reperfusion injury 
Reperfusion is the phase wherein the blood flow in a previously occluded vessel is re-
established in order to perfuse relevant region(s) of the organ. Re-establishing the blood 
flow to the ischemic territory helps to restore aerobic energy metabolism (15,16), protein 
synthesis, neuronal electrical activity (17), and to mitigate tissue damage (15,18,19). 
However, sudden reperfusion into the brain tissue after hypoxia causes a series of adverse 
events, including oxygen overload, postischemic hyperperfusion, leukocyte infiltration, 
platelet and complement activation and BBB disruption which may lead to secondary 
oxidative tissue injury (reperfusion injury) (7). In fact, reperfusion may cause additional 
harm to the ischemic tissue, as the ischemia sets the stage for oxygen to generate free 








NADPH oxidase (NOX), a major source of reactive oxygen species (ROS) reacts with newly 
generated oxygen radicals during the reperfusion phase to produce superoxide radicals 
(21). These radicals react with iron-sulfur containing proteins, releasing free iron which 
results in hydroxyl radical formation. Nitric oxide in the mitochondria reacts with 
superoxide radicals readily and more efficiently than superoxide dismutase (SOD) (22). 
This reaction forms the potent free radical peroxynitrite, which irreversibly inactivates 
SOD, including complexes I and II of the mitochondrial respiratory chain. Damage to 
endothelial cells as well as platelets, leucocytes and other blood cell types is also evident 
upon reperfusion. Activated neutrophils produce superoxide radicals which can form into 
hydrogen peroxide. Subsequently, neutrophil myeloperoxidase converts hydrogen 
peroxide to hypochlorous acid, which can produce hydroxyl radicals upon reacting with 
superoxide. Eicosanoids generated from arachidonic acid on the other hand increase the 
adhesion of platelets and leucocytes to capillary walls, leading to micro-thrombi. 
Superoxide radicals and ICAM-1 (released from endothelial cells and leucocyte 
membranes during reperfusion) can potentiate the leucocyte adhesion process.  
Moreover, in some acute ischemic stroke patients, thrombolysis can lead to symptomatic 
intracranial bleeds possibly resulting from increased levels of matrix metalloproteinases 
which have deleterious effects on blood-brain barrier (BBB).  
Blood-brain barrier disruption 
Free radicals generated in detrimental amounts during the process affect cell membranes 
and other cellular components. Such damage to the endothelial lining of brain vessels 
impairs the BBB. The BBB is a dynamic interface consisting of endothelial cell, astrocyte, 
pericyte, and the adjacent neurons (23) which regulates the flow of substances into and 
out of the brain thereby maintaining the cerebral homeostasis. The endothelial damage 
results in an increased BBB permeability to plasma proteins and a fluid shift towards the 
extracellular space, leading to vasogenic edema (24). All these events cumulatively result 
in vasogenic edema, which in turn impairs blood flow and worsens the tissue ischemia, 
triggering another vicious cycle. Massive brain edema, as occurs in a subset of ischemic 
stroke cases, elevates intracranial pressure (ICP) and may progress to brain herniation, 
which is a major cause of early mortality. 
Neuroinflammation 
It has been increasingly recognized that inflammation is a key contributor to the 
pathophysiology of cerebral ischemia (9). Inflammation seems to exert a dual role, as it 
acutely worsens the ischemic injury yet in the long-term proves beneficial through 








involved in the ischemic cascade ranging from the initial acute vascular events to ultimate 
brain damage and subsequent tissue repair that occurs at later time points (9). Pro-
inflammatory signals can be generated within minutes after ischemic events (9). 
Moreover, free radicals generated activate microglia which induce peripheral immune cell 
infiltration into the ischemic brain (7). With the progression of the ischemic cascade, cell 
death ensues, leading to another stage of inflammation caused by the release of danger 
signals from those cells. Subsequent activation of purinergic receptors on microglia and 
macrophages in turn results in the production of pro-inflammatory cytokines (9). Also 
damage-associated molecular pattern molecules (DAMPs) are released by ischemic cells, 
which activate toll-like receptors (TLRs) and subsequently up-regulate pro-inflammatory 
gene expression (9).  
Taken together, knowledge of the dynamics of the pathophysiological processes occurring 
during and after ischemia is crucial to successfully design therapies and new medication. 
However, the dynamics of the interplay of these processes is largely unknown. 
Unfortunately, development of effective therapeutic strategies is confronted with a lack of 
efficient pre-clinical models mimicking one or more of the mechanisms underlying 
ischemic stroke.  
MODELLING FOCAL CEREBRAL ISCHEMIA 
Several endovascular as well as surgical-based techniques have been used in the last 
decades to model ischemic stroke (see Table), commonly in rodents (24,26,27). While the 
surgical approach mainly involves a craniectomy-based occlusion of relevant cerebral 
arteries, it may alter intracranial pressure, hemodynamics and local brain temperature 
thus possibly affecting the pathophysiological sequelae of ischemic damage. Moreover, 
specific non-craniectomy based techniques such as macrosphere injection result in a 
highly variable infarction size (28). The studies carried out in this thesis have focused on 
the endovascular mode of occlusion of a major cerebral artery using a nylon-based  
(filament approach) suture as described below. 
Middle cerebral artery (MCA) is one of the most commonly involved vessels in ischemic 
stroke patients. As rodent cerebrovascular anatomy to a large extent resembles the 
human counterpart (Fig. 2), MCA occlusion is mimicked in animal models to result in either 
a transient or permanent MCA stroke. In creating such models, the filament based 
approach is advantageous mainly for 2 reasons: i) it avoids the surgical exposure of the 
skull in order to gain access to a cerebral artery, and ii) the filament can be withdrawn at 
any time point to (re)-establish blood flow to the ischemic brain region (‘controlled’ 








experience and mortality rate are decisive in reproducibility of the ischemic lesion and 
establishing such a model.  
Table. Modalities to induce focal cerebral ischemia 
MODE OF OCCLUSION REFERENCE(S) 
Nylon suture      Aspey et al., 1998; Belayev, Alonso, Busto, Zhao, & Ginsberg, 1996, 
Longa, et al., 1989; Spratt et al., 2006; Zhao et al., 2008 (29-44) 
Autologous blood clots Overgaard et al., 2010 (34); Dinapoli, et al., 2006 (35); Jin et al., 2014 
(36) 
Polyvinyl siloxane Yang et al., 2002 (37) 
Microspheres Mayzel-Oreg et al., 2004 (38); Demura, et al., 1993 (39) 
Macrospheres Gerriets et al., 2003 (40) 
Photothrombosis Watson et al., 1985 (41); Cai et al., 1998 (42); Li et al., 2014 (43) 
Peri-arterial  injection           
of endothelin-1 
 
Nikolova et al., 2009 (44) 
 
Endovascular approach for middle cerebral artery occlusion (MCAO) in rodents 
In this thesis, stroke was produced in rats by occluding the middle cerebral artery using an 
endovascular approach using nylon filaments with a silicon tip. To familiarize the reader 
with the details of the procedure’s subsequent steps are outlined in detail below. 
Anesthetic induction & laser Doppler flow (LDF) set up 
MCAO is induced under general anesthesia. We employed the inhalational anesthetic 
isoflurane (1.5-5%) in a mixture of oxygen and air (30:70%) deliverd via a nose cone in 
spontaneously breathing rat. A temperature probe is inserted into the rectum to ensure 
constant body temperature in the physiological range by a feed-back control of a heating 
pad in the operation table. With the animal resting in a prone position and head fixed 
using a stereotactic frame, a midline incision is made over the skull and a small shallow 
burr-hole generated in the right temporal bone using a drill. The position of the hole is 
5mm lateral and 2mm caudal to the bregma overlying the territory supplied by the MCA 
(Fig. 3A). Care is taken not to break the inner bone layer. A laser Doppler flow (LDF) fiber is 
then fixed to the hole for subsequent control of ischemia induction. The LDF fiber is 
coupled to a Periflux 5000 monitor (Perimed Instruments, Jarfalla, Sweden) and connected 

























Figure 2: Vascular anatomy of the rodent and human brain. Left (upper and lower) panel depicts the 3 
major arterial supply territories (anterior, middle and posterior) as shown on dorsal surface of rodent and 
human brain. MCA supplies the major brain regions in rodent as well as in human brain. At the base of the 
brains, a well-developed arterial collateral pathway between the 3 territories exists, denoted as the circle 
of Willis, which connects the anterior circulation by anterior communicating artery (AComA; indicated by 
the asterix) and the posterior circulation by the posterior communicating artery (PcomA), as exemplified 
schematically in the right panel. ACA, anterior cerebral artery; BA, basilar artery; ICA, internal carotid 
artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; PComA, posterior communicating 
artery; SCA, superior cerebellar artery; VA, vertebral artery.  
Carotid access and filament insertion 
After positioning the LDF fiber, the animals are turned to a recumbent (supine) position 
and receive a subcutaneous injection of buprenorphine (0.05mg/kg) to reduce post-








occlusion approach described by Longa and co-workers (1989) (31) with some 
modifications. Briefly, the right common carotid artery (CCA) is exposed via a midline 
incision in the neck and dissected between the sternocleidomastoid and the sternohyoid 
muscles parallel to the trachea. The CCA is then carefully freed from its adventitial sheath 
and the vagal nerve (Fig. 3B). The carotid bifurcation is exposed, and internal carotid 
artery (ICA) dissected free from the adjacent tissue. After transiently ligating the CCA and 
ICA, the external carotid artery (ECA) is permanently ligated distally to the origin of the 
superior thyroid artery. ECA is then excised and the resulting stump (Fig. 3C) aligned in 













Figure 3: Outline of the surgical approach of filament-induced MCAO in rat. (A) Position of the Laser-
Doppler flow probe overlying the MCA supplied territory at the skull bone (5 mm lateral and 2 mm 
posterior of the bregma). (B) Carotid vasculature along with vagus nerve coursing along the lateral aspect 
of CCA. (C) Creation of ECA stump for subsequent filament insertion after electrocoagulation of STA and 
Oc.A. (D) Progression of the filament along the ICA via the ECA stump. The filament is cautiously inserted 
to prevent its entry into PPA instead advancing it medially into the intracranial ICA coursing through the 
carotid canal (E). Before the filament is fully inserted until it reaches the MCA origin, the ligature over CCA 
is removed to avoid hypoperfusion and ECA stump is tightly fixed along with the filament. ECA, external 
carotid artery; ICA, internal carotid artery; Oc. A, occipital artery; PPA, posterior parietal artery; R-CCA, 








insertion of the occluding filament (prepared using a 4-0 nyon suture with silicon-coated 
tip) into the ICA (Fig. 3D,E). The ligatures around the CCA and ICA are then removed and 
the occluding filament advanced until a sharp drop of the LDF signal indicated occlusion of 
the MCA (Fig. 4A). After ensuring the absence of intracranial bleeding, the occluder is 
tightly fixed to the ECA. Thereafter, the neck incision is closed, as is the incision over the 
skull after removal of the LDF fiber. The isoflurane is withdrawn, and after recovery from 
anesthesia, the animal is transferred to its home cage with free access to water and 
moistened food pellets. For a transient MCA occlusion (tMCAO), the occluder will be 
withdrawn after a relevant time period after re-anesthetizing the animal under isoflurane 
anesthesia. In the permanent MCA occlusion (pMCAO), the occluder will be left in place 
for the desired follow-up time. A schematic representation of a filament occluding the 






Figure 4: Laser-Doppler flow (LDF) confirmation of the correct filament position for MCA occlusion 
(MCAO). (A) Blood flow pattern as recorded perioperatively during MCAO induction in a rat. The initial 
drop in the stable baseline is caused by temporary occlusion of the CCA during filament insertion and 
reverts back to its initial level. The second and larger abrupt decline in the blood flow originates from 
occlusion at the MCA origin (MCAO). (B) Schematic representation of the final position of the filament 
with its silicon coated tip occluding the MCA origin (bold black arrow). LDF, laser Doppler flow; ACA, 
anterior cerebral artery; BA, basilar artery; ICA, internal carotid artery; MCA, middle cerebral artery; PCA, 
posterior cerebral artery; PComA, posterior communicating artery; SCA, superior cerebrallar artery; VA, 








The filament-induced MCAO, since its inception in late 1980s, has underwent several 
modifications to result in a reproducible amount of ischemic damage and avoid adverse 
effects such as accidental subarachnoid hemorrhage and hyperthermia. Consequently, it 
has evolved into a reliable tool to study the pathophysiology of stroke and therapeutics.  
CURRENT TREATMENT STRATEGIES 
The inception of thrombolysis in the mid 1990s played a crucial role in advancing the 
management of acute ischemic stroke (AIS). The aim of systemic or local application of 
thrombolytic agents or endovascular techniques is the lysis/disruption of the 
thrombus/emboli occluding brain vessels. The thrombolytic technique used initially, i.e. 
systemic (intravenous) thrombolysis, may however pose major issues with respect to 
efficacy, safety and applicability. Not only do contraindications such as history of 
intracranial haemorrhage and recent surgery (45) preclude its use, the occurrence of 
hemorrhagic transformation of the infarcted area may aggravate ischemic damage and 
can even result in worse functional outcome (46,47). Besides, intravenous thrombolysis is 
incapable of relieving proximal occlusions of major intracranial arteries, which comprise 
one-third of cases of anterior circulation stroke. Hence, the intra-arterial thrombolytic 
approach is currently regarded more appropriate in this regard (48). Intra-arterial therapy 
basically consists of chemical dissolution of clots, either with locally delivered thrombolytic 
agents or clot retrieval or thrombectomy using mechanical devices. A recent Dutch trial 
(MR CLEAN) employed endovascular therapy in patients with AIS (within 6 h of symptom 
onset) in addition to routine IV thrombolysis, consisting of arterial catheterization to the 
level of occlusion to deliver a thrombolytic agent or perform thrombectomy, or both. This 
endovascular treatment in conjunction with routine systemic thrombolysis produced 
superior outcomes (improved recanalization and functional outcome at 90 days) 
compared to the standard thrombolytic treatment, yet with a comparable mortality (48). 
Such result is compatible with the opinion that endovascular therapy has the potential of 
becoming the first-line treatment in near future (49,50). However, other studies 
comparing endovascular treatment to the current thrombolysis regimen (IMS III, MR 
RESCUE and SYNTHESIS Expansion) have failed to show superiority of endovascular 
treatment (51,50). Thus, currently, intravenous thrombolysis with rtPA is the only specific 
pharmacological reperfusion therapy for AIS proven to be effective and approved by the 
FDA (52). Its 3 hour therapeutic window has recently been extended in Europe to 4.5 
hours after the beneficial results provided by the ECASS III trial (53), which were confirmed 
in several other centers (54). Studies are now aiming a further extension of the time 
window beyond 4.5 h (55,56). Nevertheless, despite its clinical effectiveness, only a 








window and several contraindications (57,58). To extend the therapeutic window for 
thrombolysis, hypothermia has been explored as a potential treatment in several pre-
clinical models of stroke. Although hypothermic treatment has yielded promising results in 
mitigating ischemic damage both in tMCAO and pMCAO models (59), addition of 
thrombolysis on the outcome on ischemic damage has been debated (60,61,62) as 
hypothermia may influence the activity of fibrinolytic enzymes. Clinically, targeted 
temperature management (TTM) is gaining significance in the management of acute brain 
injuries, including ischemia and haemorrhage, as evident from recent trials. However, 
results of TTM are of a mixed nature. In this context, the ICTuS-L safety trial (intravenous 
thrombolysis plus hypothermia for acute treatment of ischemic stroke – longer tPA 
window) revealed no significant neurological improvement, mortality nor was able to 
extend the time window in patients of ischemic stroke arriving within 6 h from symptom 
onset (63). Based on these results, further studies are warranted to ascertain the efficacy 
of TTM in addition to rt-PA treatment. Besides, adverse effects associated with 
hypothermia and/or rewarming need to be tackled effectively, as these may potentially 
aggravate the brain insult.  
Over 1,000 neuroprotective agents have been proposed and several showed success in 
animal studies. However, none of the more than 100 agents that made it to clinical trials 
ultimately proved successful in human patients (64). Possible reasons for the failure to 
translate these treatments from animal to patient studies may include differences in 
lesion size, composition of brain tissue or timing of drug delivery (64). Because of the 
interplay of the many individual processes involved discussed above, the effect of a 
therapeutic intervention is hard to predict. Hence stroke is often considered as 
‘mechanisms in search of a treatment’ and several pre-clinical models have been 
developed and modified in the last 3 decades to mimic the clinical situation to enable 














AIMS OF THIS THESIS 
The aim of the thesis is to model focal cerebral ischemia with or without reperfusion in 
adult rats to mimic features of clinical ischemic stroke and test novel therapeutic agents 
for their neuroprotective properties. Because of the lack of a permanent focal cerebral 
ischemia model with long-term survival, we optimized the endovascular filament-based 
approach. In chapter 2, we set out to model malignant brain infarction in the rat, 
characterized by severe infarction accompanied with brain swelling, delayed growth of the 
ischemic area, yet displaying a low mortality rate. To this end, we employed the 
intravascular filament approach to occlude the proximal origin of MCA permanently. The 
rationale behind the study was to modify and develop a filament with a bowling pin-
shaped silicon coated tip, which would result in an improved collateral blood flow in 
posterior cerebral circulation in contrast to occlusion using conventional filaments. Having 
established this goal, it is of interest to longitudinally study the ischemic brain tissue, e.g. 
by assessing brain ionic imbalances through the measurement of potassium levels. 
Therefore, in chapter 3, a MR-based feasibility study was performed utilizing a cryogenic 
copper-based radio frequency surface resonator cooled down to 77 0K. The study assessed 
in vivo potassium (39K) levels in healthy and stroke-induced rat brain. Therapeutic agents 
targeting the impaired BBB observed in stroke may crucially mitigate the subsequent 
secondary brain damage. Neurotrophins apart from being involved in neuronal survival 
and synaptic plasticity, have shown to mitigate brain ischemia by limiting BBB permeability 
increase. Chapter 4 explored the role of neurotrophins (pigment epithelial-derived factor, 
PEDF and epidermal growth factor, EGF) in rats subjected to 1h of MCA occlusion followed 
by reperfusion. Effect of intravenous infusion of either EGF, PEDF or saline initiated 3 h 
post reperfusion were studied on infarct evolution and blood-brain permeability 
parameters using MRI at 1, 2, 4 and 7 days post reperfusion.  
SUL121, a novel chromanol-based compound (Sulfateq BV, Groningen, NL), has been 
shown to mitigate oxidative stress and inflammation in various in vitro and in vivo models 
including forced hypothermia-rewarming injury in rats by maintaining the level of H2S 
synthesizing enzymes (Dugbartey et al. unpublished). In addition, SUL121 improved 
systemic vascular function. We therefore aimed in chapter 5, to explore the putative 
effects of SUL121 on cerebral ischemic damage and its modulation on aortic function in 
tMCAO in rat. Finally, we explored hypothermia injury to cultured microglia, as targeted 
temperature management (TTM) has been shown to have promising results in mitigating 
brain damage in pre-clinical models and is now undergoing clinical trials in various centers 
worldwide. However, hypothermia-mediated neuroprotection carries a risk of rewarming-








targeting these effects need to be addressed and relevant therapeutic measures adopted 
to prevent such injury. Previous studies have shown dopamine to act in mitigating 
oxidative stress upon hypothermia-rewarming-induced cellular and tissue (non-neural) 
injury, meditated via the H2S signaling cascade (65,66). In this regard, we employed a 
murine microglial cell line in chapter 6 to investigate protective properties and the 
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To accomplish long-term survival in focal brain ischemia by permanent middle cerebral 
artery (MCA) occlusion, employing a newly designed filament with bowling pin-shaped tip 
(BP-tip). BP-tip filaments were compared to three conventionally tipped filaments, 
verifying occlusion with laser Doppler flow. Follow-up periods were 24h (all groups) and 
72 and 120h in BP-tip group. Ischemic damage and swelling were quantified using silver 
nitrate staining. Patency of the collateral flow by the posterior cerebral artery (PCA) was 
assessed using selective perfusion of the internal carotid artery with Evans blue. Despite a 
comparable decrease of brain perfusion over the MCA territory in all groups, ischemic 
damage was significantly smaller in BP-tips (p<0.05). Moreover, BP-tip significantly 
reduced mortality from 60% to 12.5% and widely spared the occipital region and 
hypothalamus from ischemic damage. Conventional filaments induced a vascular 
distortion, measured as gross displacement of the MCA origin, which correlated with 
occipital infarction size. However, displacement was absent in the BP-tip. Accordingly, BP-
tip occluded rats showed a significantly better collateral filling of the PCA territory. Brain 
ischemic volume significantly increased in BP-tip occlusion at 72h follow-up. BP-tip offers 
superior survival in permanent MCA occlusion, while mimicking the course of a malignant 




















Stroke is the most common cerebrovascular disease and a major cause of death and 
disability worldwide. In 2005 the estimated global incidence was approximately 70 per 
100,000 (1), which will increase steadily with expected 7.8 million cases by 2030 (2). 
Approximately 85% of all stroke cases are ischemic and present as neuronal dysfunction 
due to a critical reduction of cerebral blood flow in a circumscribed part of the brain (3). 
The pathophysiology of tissue damage in brain ischemia is highly complex and despite 
extensive basic and clinical research not yet fully understood. Moreover, there is a long-
standing translational roadblock, i.e. a clinical failure of successful experimental 
therapeutic advances (4). The reasons for this block are manifold and may include 
drawbacks of the models used. 
Currently the most widely used focal brain ischemia model is the intravascular filament 
occlusion of the middle cerebral artery (MCA) in rodents originally developed in rat (5). 
This method has repeatedly been modified, particularly by using a silicone cover of the 
filament, and we successfully used it to study the role of early hypoxia in ischemic damage 
(6,7). The intravascular filament occlusion method is preferred as its removal at any 
desired time allows superior control of the size of ischemic damage. However, such model 
may not reflect permanent occlusion, as the pathophysiological course is likely affected by 
the reperfusion injury. Indeed, a 6h MCA filament occlusion (MCAO) results in less damage 
than a 3h occlusion period followed by 3h of reperfusion (8). However, the experimental 
benefit of re-establishing blood flow, notably the improved survival of animals, usually 
exceeds the drawbacks of reperfusion injury. Unfortunately, in patients, spontaneous 
recanalization in due time occurs rarely - if at all. Moreover, therapeutic thrombolysis to 
enable reperfusion is only possible in the minority of patients, usually <10% due to the 
restricted time window of up to 4.5h after onset of symptoms. Hence, the majority of 
stroke patients functionally develop permanent focal ischemia. Therefore, models of 
thrombus-induced focal ischemia have been advocated to reproduce ischemic stroke in 
patients best. However, this experimental approach has severe disadvantages including 
partial or complete resorption of the thrombus (9). Other permanent ischemia models 
include craniectomy often followed by surgical or photothrombotic occlusion distally to 
the MCA origin generally resulting in less severe ischemic damage. Moreover, they result 
in large variation of the infarct size due to regional differences between occlusion sites 
and reduced edema compared to filament occlusion. 
Unfortunately, permanent filament occlusion produces a high mortality as described upon 







filament-based permanent occlusion are important features of the clinical picture termed 
malignant stroke which is a devastating disease pattern encountered in up to 10% of all 
stroke patients (11,12). While neuroprotective therapies have frequently produced a 
significant reduction in filament-induced brain infarction following transient MCAO, such 
protective effects were consistently absent in permanent focal ischemia (13-15). Thus, an 
experimental model to mimic malignant stroke without the ethically unacceptable 
significant mortality rate is highly warranted. We, therefore, set out to improve 
permanent MCAO (pMCAO) in rat by designing a totally new shape of occluding tip. The 
results indicate that our new method strongly reduces mortality, thus reliably extending 
the studies over days or even weeks, enabling the study of mechanisms of tissue damage, 
edema resolution and tissue remodeling. Its major features include a huge territorial 
infarction, marked brain edema and a delayed growth of ischemic damage over several 
days, suggesting that the method can well be considered a reliable and clinically relevant 
model of malignant stroke. 
MATERIAL & METHODS 
Animals 
Adult male Sprague-Dawley rats (Janvier; Isle St. Genest, France) were kept under 
standardized housing conditions with free access to standard chow and water for at least 
one week before start of the experiment. After receiving approval (Regierungspraesidium 
Karlsruhe), experiments were performed in compliance with the national laws and 
institutional guidelines. 
Study Groups 
The animals (body weight 300–350g) underwent intraluminal filament occlusion of the 
MCA (MCAO) using different types of filaments. Custom-made filaments consisted of a 
nylon suture (Monosof, 4-0, Covidien, Neustad/Donau, Germany) with silicone tips as 
described below and compared to commercially available filaments (MCAO sutures, 
Doccol Corp., Sharon, MA, USA). Four types of filaments with effective occluding 
diameters of 390-425 μm were used (Fig. 1). A total of 65 animals were used and 
randomised in various study groups. To obtain similar numbers of animals surviving the 
procedure, rats were randomized to groups based on the prior amount of surviving 























Figure 1: Filament types used in the present study. All filaments are shown on graph paper (edge length, 
1 mm) for illustration of the tip size. The shape and the length of the tip coverage can clearly be 
distinguished. L-TB, long silicon length tubing-based; tip S-TB, short silicon length tubing-based tip; BP, 
bowling pin-shaped silicon tip; DOC, commercially available filaments (Doccol). 
L-TB type: Long tubing-based silicone coated (L-TB) filament. Coating of the tip was 
performed according to Spratt and co-workers (16). Briefly, a polyethylene (PE) tubing was 
filled with a silicone rubber (Elastomer 43, Wacker Chemie Burghausen, Germany) and the 
suture introduced into the tubing. After polymerization the tubing was removed and the 
silicone coating cut to a length of approximately 3 mm. 
S-TB type: Short tubing-based silicone coated (S-TB) filament. These filaments were 
prepared similarly to L-TB with a silicone tip length < 2 mm. 
DOC type: Filaments with the shortest tip available (2-3mm in length) were obtained from 
Doccol. 
BP type: Bowling-pin shaped tip. These filaments carried two ball-shaped thickenings 
separated by approximately 1 mm with the smaller diameter at its tip. It thus resembles a 
bowling-pin with the smaller diameter ranging between 325-350 μm and the larger 
diameter between 390-425 μm. 
In initial experiments, animals were sacrificed 24h after pMCAO. In a further series of 
experiments, BP tip occluded animals were sacrificed 72h and 120h after pMCAO. In a 
third series, animals underwent selective perfusion with Evans blue (EB) dye with the 








Right-sided pMCAO was produced as previously described (10) with some modifications. 
The completeness of occlusion was checked by laser Doppler flowmetry (LDF; Perimed 
Instruments, Jarfalla, Sweden). The pMCAO was induced by inserting the filament into the 
proximal external carotid artery and advancing it via the internal carotid artery (ICA) to the 
origin of the MCA. Filaments were left in situ for relevant time points (see Supplementary 
information). 
Selective perfusion of Evans Blue  
The experiments in this group were terminated 15 min after MCA occlusion. The animals 
underwent in situ perfusion with physiological saline solution (PSS) only. Then, the right-
sided CCA was cannulated with a PE tubing (inner/outer diameter, 0.4/0.8mm; RCT; 
Heidelberg, Germany) filled with 2% EB in PSS. Prior to cannulation, the pterygopalatine 
artery was completely ligated to allow maximum flow across the ICA. The catheter was 
inserted carefully in order to not affect the position of the filament fixed in the ECA stump. 
The dye was then infused at a very slow rate, 70 μl/min for 2 minutes using a LSP1 infusion 
pump (Hugo Sachs Electronic, March-Hugstetten, Germany). After perfusion the catheter 
was removed, the brain isolated and photographed for documenting the distribution of 
the dye in the pial vasculature. The occipital poles of the right and left hemisphere were 
dissected and the remaining brain cut in the midline. The tissue samples were snap frozen 
in n-pentane and stored at -80°C until spectrophotometric analysis of the EB content. 
Spectrophotometric assay of EB content 
Brain samples were homogenised in 50% trichloroacetic (1:4 weight/weight) using an 
Ultraturrax homogenizer (Ika-Werk, Staufen, Germany) for 30 s and centrifuged at 10,000 
rpm for 20 min at 4 °C (Heraeus Biofuge Stratos, Thermo Fisher Scientific, Dreieich, 
Germany). Supernatant was collected and absolute ethanol added at a volume ratio of 1:2 
for occipital regions and 1:1 for the remaining samples. Absorbance of EB was measured 
at 615 nm (Infinite M200, Tecan, Mannedorf, Switzerland). Tissue content of EB was 
quantified with using a linear standard curve and expressed as micrograms per gram fresh 
tissue. 
Ischemic damage assessment  
Brain damage was determined using silver nitrate staining of serial coronal slices and 







occipital axis was calculated for 3 regions (frontal, middle and occipital) as area under the 
curve (AUC; see Supplementary information). 
Statistical analysis 
Data are expressed as mean ± standard deviation. Statistical analysis was performed by 
one-way analysis of variance (ANOVA) and subsequent pairwise comparison using the 
Tukey-test. Mortality and MCA displacement were compared by Chi-square test and linear 
regression by least squares method. With either test p<0.05 was considered statistically 
significant. 
RESULTS  
Survival after 24 h of pMCAO 
In BP-tip occluded rats only one out of 8 animals (12.5%) died prematurely, i.e. within the 
first 24 h after pMCAO. In contrast, the mortality rate in the L-TB group was 54% (7 out of 
13) and 65% (11 out of 17) in the S-TB group, respectively (p<0.05, BP vs. L-TB and S-TB). 
The difference in the number of included animals per group arose due to the large 
number of premature deaths encountered especially in L-TB and S-TB groups. Moreover, 
L-TB and S-TB animals surviving the 24 h presented in very bad clinical condition which 
would not appear compatible with an extended survival period. Similarly, 4 out of the 6 
animals in the DOC group showed severe worsening in their clinical state when 
approaching the end of the 24h observation period. Two deaths (one each in L-TB and S-
TB groups) were encountered due to subarachnoid haemorrhage upon filament insertion 
as indicated by LDF monitoring. These animals were excluded from the study following 
confirmation of haemorrhage on post-mortem examination. Failure of occlusion was not 
encountered in any of the groups. The volumes of ischemic damage obtained at 24 h of 







Table 1. Laser Doppler flow reduction (upon occlusion of the middle cerebral artery origin), ischemic 
volume and hemispheric swelling in different filament groups after 24h of permanent middle cerebral 
artery occlusion 










LDF reduction (%) 58.7 ± 8.9 60.9 ± 11.3 71.0 ± 5.7 67.7 ± 9.8 
Ischemic volume 
(mm3) 448.3 ± 78.3* 423.2 ± 50.6* 551.8 ± 113.8* 306.4 ± 30.0 
Hemispheric 
swelling (%) 35.9 ± 5.7 36.5 ± 7.9 37.1 ± 9.9 28.9 ± 7.4 
LDF, laser Doppler flow; L-TB, long tubing-based silicone coated filament tip; S-TB, short tubing-based 
silicone coated filament tip; DOC, commercially purchased Doccol filament; BP, bowling pin-shaped 
filament tip. 
* p < 0.05 vs. BP tip. The values of ischemic brain damage are corrected for swelling to improve 
comparison between the groups.  Values are represented as mean ± SD. Statistical significance was 
determined by a one-way ANOVA with Tukey’s test. 
Ischemic damage 24h post pMCAO 
The LDF signal measured over the MCA territory decreased by about 65% during 
introduction of the filaments without differences between groups (Table 1). Nevertheless, 
BP-tip filaments induced significantly less ischemic damage than the other 3 types of 
filaments (Table 1), while brain swelling was similar in all 4 experimental groups (Table 1). 
Next, we examined the regional distribution of ischemic damage in the occluded 
hemispheres (Fig. 2A). The AUC of ischemic damage was similar for all 4 experimental 
groups in the frontal and middle regions, but BP-tip occluded animals had a significantly 
smaller volume in the occipital region (Fig. 2B; p < 0.05 vs. L-TB and DOC tip occluded 
rats). Also, BP-tip occluded animals showed a remarkably smaller infarct size in the region 
of the hypothalamus (mostly located in the section levels 9 to 11) compared to other 
groups (Fig. 2C). 
Mortality and ischemic damage in long-term BP-tip occluded rats  
In view of the superior survival, good clinical condition and relatively restricted infarct 
area in BP-tip occluded animals the observation period was extended to analyse long-term 
effects. Animals were sacrificed after 72 (n=7) or 120 h (n=6), with no premature deaths 
encountered. Ischemic volume significantly increased by approximately 40% from 24 h to 
72 h (p<0.05), followed by a decline at 120h, when the infarcted area amounted 116% of 
the volume measured after 24 h of ischemia (Table 2). Since all volumes were corrected 
for brain swelling, these data imply a distinct delayed growth of the infarction beyond 24 h 







difference was observed in the middle region, which is largely supplied by the MCA. In 
contrast, the decline of ischemic damage from 72 h to 120 h was comparable in all brain 
regions (frontal, middle, and occipital regions) without reaching statistical significance. 
The accompanying brain swelling, however, was comparable between 24 and 72h post 
































Figure 2: Ischemic damage after 24h of permanent middle cerebral artery occlusion. (A) hemispheric 
infarction and (B) the area under curve (AUC) analysis in the different experimental groups. The sections 
were grouped into a frontal, middle, and occipital region along the fronto-occipital axis (with section 7 
assigned to the bregma for reference). (C) Representative slices depicting hypothalamic involvement 
(arrows) of infarction in different groups (bregma, -3.14mm). L-TB tip, long tubing-based silicone coated 
filament tip; S-TB tip, short tubing-based silicone coated filament tip; DOC, commercially available 
filaments (Doccol); BP, bowling pin-shaped filament tip. *p < 0.05, BP 24 h occipital  vs L-TB, DOC occipital 











Table 2. Time-related changes of ischemic damage in bowling pin-shaped tip occluded rats undergoing 









(mm3) 306 ± 30.0 434.1 ± 63.1* 355.9 ± 103.1 
Hemispheric swelling 
(%) 28.9 ± 7.4 29.1 ± 4.8 13.2 ± 1.9** 
AUC-Frontal region 
(%) 48.5 ± 9.4 55.5 ± 8.7 41.9 ± 9.5 
AUC-Middle region 
(%) 64.7 ± 5.3 68.9 ± 3.6 62.7 ± 3.5 
AUC-Occipital region 
(%) 20.1 ± 14.3 32.3 ± 15.5 22.4 ± 17.2 
BP, bowling pin-shaped filament tip; AUC, area under curve.  
*p < 0.05 vs. 24 h, **p < 0.001 vs 24 and 72 h. Values are represented as mean ± SD. Statistical significance 
was determined by a one-way ANOVA with Tukey’s test. 
Morphology of brain after 24 h of pMCAO 
The observation that, despite a comparable reduction of the LDF signal, the BP-tip 
occluded animals had a significantly smaller volume of ischemic damage at 24h of pMCAO 
suggests factors other than the mere occlusion of the MCA to contribute. Therefore, we 
carefully inspected the brains after removal. The main striking finding was a gross vascular 
distortion displacing the origin of the MCA in L-TB, S-TB, and DOC tip filaments (Fig. 3). 
However, such a displacement was never observed in BP-tip occluded animals. 
Displacement quantified by calculating the rostral shift of the origin of the right versus left 
MCA (Fig. 3) amounted to 1.4 ± 0.4 and 1.3 ± 0.2 mm in S-TB and DOC tip occluded 
animals, respectively. Additionally, ischemic damage of the occipital part strongly 
correlated with the displacement in S-TB (r2 = 0.80) and DOC-tip (r2 = 0.34) (Fig. 3). 
Filament-induced alterations of the perfusion pattern 
In view of the vascular distortion at the base of the brain and the regional differences in 
the development of ischemic damage in the conventional groups, we wondered about a 
possible impairment of collateral blood flow through the posterior cerebral artery (PCA). 
To examine this, additional experiments used selective dye perfusion of the ICA with BP 
and S-TB occluding filaments in situ. We infused a small volume of 2% EB solution and 
employed a very low infusion speed to delineate the low resistance pathways fed by the 
ICA and documented the distribution of the dye by microphotographs. Hemispheres from 
BP showed a markedly better filling of the superficial microvasculature than S-TB (Fig. 4A, 







pre-existing collateral vessels between the PCA and the MCA, easily identified by a cork-

















Figure 3: Intravascular filament occlusion of the middle cerebral artery (MCA) may lead to displacement 
of its origin. Depicted are examples in which a short tubing-based silicone coated (S-TB) filament tip, a 
commercially available filament (DOC) and a bowling pin-shaped (BP) filament tip  were used. The origin of 
the right-sided MCA is indicated by a white arrow head (right side) and a black arrow head (left side). The 
proximal and distal ball-shaped thickenings of the BP filament are indicated by curved arrows. Note the 
split origin of the MCA in the case shown on the right. Such a deviation may occur in up to 10% of a given 
batch of rats. The overlay indicates how the degree of displacement (indicated by the length of the black 
arrow) was measured. This displacement shows a good correlation (top right panel) with ischemic damage 
(as calculated from AUC in this case) produced in the occipital part of the brain in S-TB and DOC-tip 
filament groups. Scale bar = 1mm. AUC, area under curve. Linear regression was conducted by least 







retrograde filling of the MCA daughter vessels and even its main trunk. Particularly, 
supplementary figure-A shows PCA branches coursing over the occipital pole to 

















Figure 4: Vascular filling pattern after selective infusion of a small volume of physiological saline 
solution (PSS) containing 2% Evans blue (EB) into the internal carotid artery (ICA). The occluding filament 
was left in situ during the infusion. Depicted are examples in which a BP-tip filament (upper panel-A) or a 
S-TB tip filament (lower panel-B) were used for occlusion. The pictures indicate the retrograde filling of 
the main trunk and daughter vessels of the middle cerebral artery (MCA) via collateral arteries fed from 
the posterior cerebral artery. The filling of the collateral system was considerably better in the BP-tip 
occluded animal. Some dye has also entered the main trunks of the cerebral arteries in the contralateral 
hemisphere via the posterior communicating arteries. Note the displacement of the MCA origin on the 
occluded side (arrow head) in the lower panel, in comparison to the contralateral side (arrow) at the base 
of brain. A detailed outline of the collateral pathways and EB filling pattern between MCA and posterior 







S-TB-tip (Supplementary Figure-B) although the collateral anastomoses between the PCA 
and MCA branches were evident. In agreement, significantly more dye accumulated in the 
occipital pole of BP-tip occluded animals (Fig. 4A) than in S-TB occluded animals [EB 
content (μg/g tissue), 58.7 ± 8.2 with BP-tip occlusion vs. 9.0 ± 2.1 in S-TB-tip occlusion; 
p<0.001)]. Similarly, the residual hemisphere (excluding occipital pole) displayed a higher 
EB content in BP-tip occluded animals (62.3 ± 14.5 μg/g tissue) than in S-TB-tip occluded 
rats (6.1 ± 3.3 μg/g tissue, p<0.05) (n=3 in each of the two groups). Moreover, no 
differences in dye accumulation per hemispheric region between BP- and S-TB-tip 
occluded animals were observed in the contralateral occipital poles and residual 
hemispheres. Together, these data imply that the markedly impaired filling of occipital 
regions in S-TB-tip group most likely results from the observed vascular distortion (Fig. 4B 
& Supplementary Figure). 
DISCUSSION  
The current work describes a major improvement of the intravascular filament based MCA 
occlusion technique, which allows long-term survival in rats without reperfusion despite a 
large territorial infarction and marked edema. This important improvement is brought 
about by designing a completely new tip of the occluding filament. Selective perfusion 
studies demonstrate that this type of filament preserves collateral blood supply, mainly to 
the occipital part of the brain via the PCA. The apparent improvement of collateral blood 
supply delays the expansion of ischemic cell death so its maximum is reached only around 
72 h after establishing MCA occlusion. Therefore, our new model nicely reflects the main 
features of malignant stroke in patients but significantly reduces its high mortality rate. 
The model may well provide a powerful tool to study the mechanisms of infarct 
progression and tissue remodelling and eventually test novel therapeutic strategies. 
The intravascular filament occlusion of the MCA in rats is the most widely used stroke 
model, compromising the brain region most often affected in stroke patients. The 
advantages of intravascular filament occlusion have been discussed repeatedly (9,18), and 
the most notable points include (i) maintenance of the intact skull bone, (ii) ease of 
establishing reperfusion, (iii) control of the infarct size by modifying the duration of 
occlusion, and (iv) high reproducibility of the tissue injury generated. In previous studies 
employing 2h of MCAO followed by 6 or 22h of reperfusion, we found substantial ischemic 
damage with <20% coefficient of variation with an overall mortality rate of <10%. 
However, changing to pMCAO will result in a high mortality rate as described since the 
earliest reports (10), which has not improved dramatically since. Therefore, we designed a 
completely new shape of the silicone cover at the end of the filament resembling a 







mortality rate even without reperfusion. We have examined the characteristics of this new 
method and found the degree of LDF decline upon pMCAO similar to 3 conventionally 
prepared albeit different types of filaments. Nevertheless, BP-tip filaments resulted in a 
significantly smaller ischemic lesion after 24h of pMCAO, predominantly due to decreased 
occipital infarction. The latter indicates a major role of blood supply through the PCA, 
which in rodent brain originates from the intracranial part of the ICA (19,20). While one 
may expect blockade of the PCA origin by long-tipped filaments, this is not the case for 
short-tipped filaments. However, scrutinizing the base of the brain consistently revealed 
distortion of the ICA and displacement of the MCA origin in all of our experiments with 
conventional tips, independent of the length of their silicone cover. With the special 
design of the new BP-type filament such distortion and displacement were not observed, 
most probably because the smaller diameter at the tip (distal bulge) allowed the filament 
to smoothly enter the anterior cerebral artery trunk. The functional importance of arterial 
displacement is reflected by the significant correlation between the degree of MCA origin 
displacement and the volume of ischemic damage in the posterior part of the brain, 
indicating the distortion to impair PCA blood flow. To address this hypothesis, 
measurement of blood flow in the occipital cortex may be considered, e.g. by laser speckle 
methodology. Unfortunately, this method is restricted to a more or less plane surface such 
as somatosensory cortex in the temporo-parietal region of the rat brain (20-22). Thus we 
decided to study vascular filling over PCA and MCA supplied territories by selective 
perfusion of the ICA with a tracer dye with the occluding filaments in place and quantify 
the intraparenchymal dye content. We intentionally infused a small volume of EB-
containing solution at a low speed in order to delineate low resistance pathways. This 
approach markedly differs from previously used protocols in rats in which a tracer was 
systemically injected with high pressure to identify even the smallest arteries on the base 
of the brain using μCT methodology (23). Employing this technique, animals occluded with 
the newly designed BP-tip filament displayed a strikingly better filling with the dye of the 
superficial pial arteries in the occipital and the adjacent temporo-parietal region 
compared to short-tipped filaments. Moreover, improved filling of the pial vasculature 
also resulted in a significantly higher accumulation of the dye in the brain tissue. In 
contrast, the parenchymal filling was markedly less intense in S-TB-tip and DOC-tip groups, 
despite evident collateral anastomoses between the PCA and MCA branches 
(Supplementary Figure). Thus, the impaired filling of the posterior vascular bed in groups 
with conventional filaments is explained well by an obstruction of PCA inflow by the 
observed vascular distortion. Furthermore, PCA inflow obstruction appears also to reduce 
collateral blood supply to the posterior boundary zone of the ischemic core. The 







assessment of stroke patients recently (24), and it is also evident in the present 
experimental study. 
The difference in maintenance of collateral circulation was apparently of functional 
importance since the new BP-type filament not only resulted in a significantly smaller 
volume of ischemic damage 24h after permanent MCA occlusion, but also induced 
markedly lesser damage in the hypothalamic region. In fact, the hypothalamus in the rat 
receives blood supply from several sources including the PCA. Largely sparing the 
hypothalamus from ischemic damage with the new BP-tip filaments likely contributed 
substantially to the improved survival since the hypothalamus is of key importance in the 
regulation of vital physiological functions such as body temperature. In fact, hypothalamic 
damage has widely been related to early postischemic hyperthermia and occasionally 
considered an even inevitable consequence of filament-induced brain ischemia (25). 
However, studies with telemetric or repeated measurement of body temperature after 
filament-induced MCA occlusion have challenged the validity of this dogma (27, 28). On 
the other hand it is well established that hyperthermia aggravates ischemic brain damage 
in models of global and focal ischemia of transient and permanent nature (26, 27, 29). 
Similarly, in patients with ischemic stroke the occurrence of hyperthermia in the early 
ischemic phase correlates with a poor outcome (30). Although we did not measure body 
temperature over an extended period of time, our data suggest that the extensive 
protection of the hypothalamic region might well have contributed to the lower mortality 
rate in BP filament group. 
Rats undergoing MCA occlusion with our new BP-type filament presented in a markedly 
better clinical condition, allowing for extension of survival to 3 and even 5 days without 
premature deaths. In these experiments, the total volume of ischemic damage increased 
significantly from 24 to 72 h survival, particularly due to expansion in the occipital region 
supplied by the PCA. Apparently, the cells in the frontal and occipital brain areas were 
viable for an extended period after MCA occlusion before undergoing irreversible damage. 
Further studies to address the mechanisms behind this spread of cell death from the core 
region are highly desired because its mechanisms may well differ from those operating in 
the acute phase. Such studies may also help to overcome the long-standing translational 
road-block in stroke research. In addition, our new method will also allow studies on the 
mechanisms of trauma reorganisation and tissue remodelling in permanent ischemia, both 
anatomically and functionally. 
In conclusion, the model of permanent MCA occlusion using our new BP-tip filament 
results in a condition which closely resembles malignant stroke in patients. The main 







edema, and the significant lesion expansion due to delayed ischemic cell death. The BP-
tipped filament does not compromise PCA blood flow, thus maintaining collateral blood 
supply of the occipital brain region including the hypothalamus and limiting mortality rate. 
For the first time we can now mimic malignant stroke in a well-established experimental 
setting, which allows for long-term follow-up studies to better characterize the 
pathophysiology of and explore interventional strategies in this clinically devastating 
disease. 
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Suppl Figure. Collateral pathways and dye filling pattern upon selective EB perfusion via CCA. (A) With a 
BP-tip occluding filament in situ, MCA filling is observed to originate via the PCA and its branches forming 
collateral anastomoses with those of the MCA. The PCA branches (iii, white arrow heads) course over the 









Intraparenchymal filling displayed high intensity in the occipital pole, and a similar degree of filling was 
also seen in the MCA supplied territory (i, ii). (B) In contrast, the vascular filling was markedly less intense 
in S-TB-tip filament occluded animals although the collateral anastomoses between the PCA and MCA 
branches were evident (ii, black arrows and iii, arrowheads). The less intense filling (i & ii) is most probably 
due to the vascular displacement occurring in S-TB-tip occlusion leading to an inflow obstruction in the 
PCA which was absent with BP-tip filaments. EB, Evans blue; CCA, common carotid artery; BP, bowling pin-
shaped tip; MCA, middle cerebral artery; PCA, posterior cerebral artery; S-TB, short tubing-based tip.  
SUPPLEMENTARY METHODS 
Induction of pMCAO 
For induction of focal cerebral ischemia, we used the intraluminal middle cerebral artery 
(MCA) occlusion approach introduced by Longa and co-workers (1) with some 
modifications. Briefly, after a midline incision in the neck, the right common carotid artery 
(CCA) was dissected between the sternocleidomastoid and the sternohyoid muscles and 
the vagal nerve carefully disassociated from the adventitial sheath. The carotid bifurcation 
was exposed and the internal carotid artery (ICA) dissected. After transient occlusion of 
the CCA and the ICA by ligatures the external carotid artery (ECA) was permanently ligated 
distally to the origin of the superior thyroid artery. The ECA was cut next to the site of 
occlusion, a filament introduced and advanced into the ICA until a sharp drop of the LDF 
signal indicated occlusion of the MCA. After control of completeness of the occlusion and 
exclusion of intracranial bleeding (2), the filament was tightly fixed to the ECA. We 
deliberately chose LDF over laser speckle imaging for the following reasons: (i) laser 
speckle imaging requires extensive skull exploration meaning high surgical trauma which 
might further increase the ischemic trauma, and (ii) the brain surface over the occipital 
pole is not appropriately accessible and feasible for laser speckle imaging. Following MCA 
occlusion the animals received a subcutaneous injection of buprenorphine (3 μg/100 g 
body weight) for post-surgical pain control. Finally, the incisions in the neck and over the 
skull were closed after removal of the LDF fibre. Isoflurane was withdrawn and the 
animals were transferred to their home cage with free access to drinking water and 
moistened food pellets.  
Termination of experiments 
At the end of the observation period, the animals were deeply anesthetized. A large bore 
PE tubing was introduced into the abdominal aorta for in situ perfusion with physiological 
saline solution (PSS) upon severing of the inferior caval vein After 4 min perfusion was 









brain isolation, both the parieto-temporal skull bones were removed and the underlying 
dura dissected out, the animal turned supine and its head positioned with the dorsal 
surface facing downwards. Thereupon, we carefully cut the spinal cord near to the 
transition from the hindbrain using a scalpel. The cranial nerves and carotid arteries were 
cut as proximally as possible by means of a microscissor without exerting any force upon 
the vascular structures. This procedure resulted in the occluding portion of the filament 
resting within the ICA at the MCA origin without any artefactual displacement. Next, the 
brain was removed and photos were taken of the basal and dorsal aspects. The brain was 
then snap-frozen in n-pentane solution (Merck Schuchardt OHG, Hohenbrunn, Germany) 
and stored at -80°C. 
Ischemic damage assessment  
For volumetric analysis of brain damage serial coronal cryosections (thickness, 20μm) 
were taken at a distance of 1000μm (cryotome HM500, Microm GmbH, Wiesloch, 
Germany). The sections were air-dried and fixed in 4% paraformaldehyde for subsequent 
high contrast silver nitrate staining as developed by Vogel and coworkers (3) and used by 
our group previously (4,5). After staining, the slides were scanned using a flat-bed scanner 
(1640SU; Epson, Cologne, Germany). The areas of both hemispheres and of ischemic 
damage were outlined on the monitor and measured using ImageJ software (free-ware 
available under http://rsbweb.nih.gov/ij/docs/guide/index.html). The degree of 
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In order to improve comparison between the experimental groups ischemic damage was 
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In each animal, the volume of ischemic damage (in mm3) was calculated by adding the 
individual ischemic areas for each section based on the results of the planimetric analyses 
and multiplying by the distance between the sections (1000 μm). In addition, brain 
infarction size was also calculated for each section level in % of the respective hemispheric 
area. The sections were ordered from frontal to occipital and numbered consecutively. 









by Paxinos and Watson (7) the sections were aligned to 3 regions along the fronto-
occipital axis (i) frontal region, sections 1 – 4, (ii) mid region comprising sections 5 – 8, and 
(iii) occipital region comprising sections 9 – 14. An area under the curve (AUC) analysis was 
performed to determine the extent of ischemic damage in each of the 3 regions.  
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Potassium-39 (39K) magnetic resonance imaging (MRI) is a noninvasive technique which 
could potentially allow for detecting intracellular physiological variations in common 
human pathologies such as stroke and cancer. However, the low signal-to-noise ratio 
(SNR) achieved in 39K -MR images hampered data acquisition with sufficiently high spatial 
and temporal resolution in animal models so far. Full wave electromagnetic (EM) 
simulations were performed for a single-loop copper (Cu) radio frequency (RF) surface 
resonator with a diameter of 30 mm optimized for rat brain imaging at room temperature 
(RT) and at liquid nitrogen (LN2) with a temperature of 77 K. A novel cryogenic Cu RF 
surface resonator with home-built LN2 non-magnetic G10 fiberglass cryostat system for 
small animal scanner at 9.4 T was designed, built and tested in phantom and in in vivo MR 
measurements. Aerogel was used for thermal insulation in the developed LN2 cryostat. In 
this paper, we present the first in vivo 39K-MR images at 9.4 T for both healthy and stroke-
induced rats using the developed cryogenic coil at 77 K. In good agreement with EM-
simulations and bench-top measurements, the developed cryogenic coil improved the SNR 
by factor of 2.7 ± 0.2 in both phantom and in in vivo MR imaging compared with the same 
coil at RT.  
Key words: Aerogel, cryogenic cooling, electromagnetic (EM)-simulations, in vivo 39K-MRI, 
liquid nitrogen (LN2) cryostat, magnetic resonance imaging (MRI), middle cerebral artery 



















Recent magnetic resonance imaging (MRI) studies of the tissue sodium concentration 
(TSC) revealed that an irreversible increase in local TSC occurs in permanently dam- aged 
stroke tissue (1). Nevertheless, monitoring the intracellular sodium-23 (23Na) 
concentration via multiple quantum coherence filters (2) or chemical shift reagents (3) 
proved to be difficult up-to-date. The cellular sodium-potassium pump (Na+/K+ ATPase) 
regulates the intracellular and extracellular concentrations of 23Na (׽12 mM intracellular 
and ׽145 mM extracellular) and 39K (׽145 mM intracellular and ׽4 mM extracellular) 
ions in order to maintain the resting cell membrane potential and cellular volume (4). 
Since the 39K ion concentration is much higher in the intracellular space (׽30 times), 39K-
MRI could provide important information on the maintenance of transcellular ion 
gradients and Na+/K+ ATPase activity. 39K-MRI offers a unique tool to function as an 
intracellular biomarker for monitoring the tissue viability in therapy planning (5). Since K+ 
is the counterpart of Na+ in the Na+/K+ ATPase, any defects in Na+/K+ pump could be also 
visible in potassium images. However, 39K-MRI suffers from about two-million times lower 
signal compared to hydrogen-1 (1H), which is caused by an approximately 20 times lower 
gyromagnetic ratio (1.99 MHz/T), low biological in vivo concentration, lower MR 
sensitivity, and a much faster T2* decay (< 1 ms) (6). A triple resonant radio frequency (RF) 
coil setup of 1H, 23Na, and 39K was used to acquire the first in vivo 39K-MR image of a rat 
head at 9.4 T (7). A signal-to-noise ratio (SNR) of about 4 was achieved in in vivo 
experiment of a live rat head using a 3D fast low angle shot (FLASH) sequence at a 
resolution of 3 x 3 x 6 mm3 in 54 min acquisition time. 
The RF resonator plays an essential role in increasing the SNR in conjunction with fast 3-D 
imaging sequences. The SNR could be possibly improved to have a high-quality image with 
good spatial resolution in a short acquisition time. The main noise sources in a well-
designed MRI receiver RF coil are the internal coil noise due to the electrical resistance of 
the coil itself and the sample noise induced by lossy conductive samples (8). Reducing 
either one of them will improve the SNR and hence the image quality. Cryogenic cooling of 
conventional Cu using liquid nitrogen (LN2) with a temperature of 77 K or liquid helium 
(LHe) with a temperature of 4.2 K enhances the coil sensitivity by reducing its resistance 
and temperature (9). The unloaded Q-factor of a Cu RF surface resonator increases by 
factor of 2–3 through cryogenic cooling by LN2 to 77 K (10). A significant SNR gain can be 
achieved when the coil noise dominates the sample noise at lower frequencies and for 
small coil sizes. Furthermore, cryogenic cooling could be advantageous at 18.68 MHz 









studies have proven that cryogenic cooling of conventional Cu or high temperature 
superconducting (HTS) surface resonator to 77 K have a significant SNR gain at lower 
frequencies (10-12). A 2.7-fold SNR gain was achieved in in vivo 1H-MRI of a human finger 
using a 17 mm in diameter Cu surface resonator cooled down by LN2 to 77 K at 64 MHz 
(Larmor frequency for 1H-MRI at 1.5 T) (10). In a previous study, a Cu coil was cooled down 
by helium gas to 30 K and a twofold SNR gain was achieved in in vivo 1H mouse brain MRI 
at 200 MHz (11). 
To further reduce the coil resistance, the HTS YBCO or HTS tape material could be used in 
place of Cu. The HTS surface coil can improve the SNR gain depending on the relative 
contribution of the sample and coil noise (i.e., the operating frequency, B0-field, coil size, 
and sample properties). Thus, a higher SNR gain by factor of 3–4 can be achieved at 77 K 
depending on the sample properties compared to room temperature (RT) Cu coil of the 
same identical geometry. Several studies proved that an HTS surface coil have a significant 
SNR gain by cryogenic cooling to 77 K in in vivo MRI applications ranging from 0.17 to 3 T 
(13-21). A relatively large HTS spiral surface resonator of 70 mm in diameter cooled down 
to 77 K at 8 MHz (Larmor frequency for 1H-MRI at 0.17 T) and 3.2-fold SNR gain was 
achieved in in vivo human hand MR imaging (13). A small HTS surface coil of 12 mm 
effective diameter was cooled down to 77 K to improve the SNR gain by factor of 3.2 in in 
vivo human skin microscopy (14). Recently, a comparison study between electromagnetic 
(EM)-simulations and MR experimental results was presented at 128 MHz (Larmor 
frequency for 1H-MRI at 3 T) using 40-mm diameter HTS tape surface resonator (21). A 3.8-
fold SNR gain was achieved on phantom images. 
The effect of the sample parameters on the coil sensitivity such as sample conductivity, 
sample size, sample geometry, and coil-to-sample distance could be calculated accurately 
using EM-simulations (21-23). Furthermore, when determining the receive sensitivity via 
the principle of reciprocity, the (B1/I) field at a certain depth could be calculated 
accurately by taking the effect of both coil and sample resistances into account. Therefore, 
EM-simulation was used to optimize the coil diameter at 300 and 77 K to enhance the 39K 
signal for rat brain imaging at 9.4 T. Recently, an EM-simulation study as well as in vivo MR 
measurements was presented at 128 MHz using an optimized cryogenically cooled single-
loop coil with a diameter of 20 mm (22). The coil diameter was carefully optimized by 
using EM-simulations to maximize the SNR in three different areas of mouse anatomy (in 
the brain, hind legs, and liver). Furthermore, a developed single loop (24) and spiral-two-









In this paper, EM simulations were used for careful optimization of coil diameter at 300 
and 77 K for rat brain imaging at 18.68 MHz. A novel cryogenic Cu RF surface resonator 
with 30 mm in diameter with home-built LN2 nonmagnetic G10 cryostat system for small 
animal scanner at 9.4 T was designed, built, and tested in phantom and in vivo MR 
measurements. Both phantom and in vivo MR results showed that the developed 
cryogenic coil improved the SNR gain by factor of 2.7 ± 0.2 compared with the same coil at 
RT. 
MATERIAL & METHODS 
Analytical Approach 
Analytical expressions of coil resistance Rc (8) and sample resistance Rs (26) were derived 
with a solenoid surface coil loaded with an infinite homogenous half-space of a uniform 
conductivity σ located at distance d from the plane of the surface coil. The half-space 
approximation maximizes the sample losses, which means that the coil losses are typically 
underestimated relative to the sample ones (i.e., the higher the coil noise relative to the 
sample noise, the more beneficial to cool down the receiver) (9). However, the half-space 
sample approximation is inaccurate in many cases, for example, in small animal MRI 
applications (rat or mice MR imaging). This is because Rs changes significantly with sample 
size, sample geometry, sample conductivity, coil size, and coil geometry. Therefore, the 
approximation of Rs to an infinite half-space with a homogeneous conductivity will lead to 
an inaccurate estimation of SNR gain (22). 
EM-Simulations 
In order to design the optimal cryogenic Cu RF surface coil that enhances the SNR gain in 
rat brain at 18.68 MHz, full-wave EM-simulations were used. The simulations were carried 
out using CST Micro-Wave-Studio (MWS) (CST AG Darmstadt, Germany). Due to the small 
resonator dimensions in terms of the wavelength at 18.68 MHz (the free-space 
wavelength λ0 = 16 m) and due to the high Q-factors of cryogenic RF surface resonator, 
the frequency domain solver (FDS) with adaptive tetrahedral mesh refinement algorithm 
was found to be the appropriate approach for simulating an RF surface resonator at 300 
and 77 K. The simulations were computed for a series of single-loop Cu surface coils 
ranging from 10 to 50 mm with 2-mm wire thickness for both loaded and unloaded 
conditions. The desired region-of-interest (ROI) is the rat brain with an average size of 
about 10 mm from the skull, so that the desired penetration depth is about 15 mm from 









numerical simulation model for the optimal RF surface resonator for both loaded and 
unloaded conditions is shown in Fig. 1. 
Figure 1: CST simulation model 
for the optimal 30 mm in 
diameter Cu RF surface 
resonator with 2-mm wire 
thickness resonating at 18.68 
MHz: (a) unloaded and (b) 
loaded.  
 
In simulations, one series capacitor for matching and one parallel capacitor for tuning 
were used. The background material was chosen to be air to define a preferably realistic 
simulation environment. In order to save computational time, a cube-shaped boundary 
box of 50 × 50 × 50 mm3 was set in each x, y and z directions. The RF coil was placed in the 
center of the boundary box. The bandwidth was set to 2 MHz with the center frequency of 
18.68 MHz for all structures. The input power was set to 1 W for all coils. For each 
structure, the added space for open boundaries has been limited to ten times the model's 
boundary box diagonal because the structure is very small in terms of the smallest 
wavelength. 
In order to simulate the proposed RF coil at 300 and 77 K, the adaptive tetrahedral mesh 
refinement option enabled to increase the mesh accuracy and to enable curvature 
refinement. The 3-D structure was subdivided into small tetrahedrons. The CST FDS setting 
parameters greatly influence the quality of the mesh and thus the accuracy of the EM-
simulation results. The finer the mesh, the more accurate the EM-simulation results, but 
more computational time needed. The general setting mesh parameters were increased 
manually step by step until no change in Q-factor value was observed at each 
temperature. The meshing parameters were set as follows: the steps per wavelength = 15, 
the minimum number of steps = 15, minimum number of passes = 3, maximum number of 
passes = 8, the accuracy of tetrahedral mesh = 1e-4. The mesh adaptation terminated after 
three passes because the desired accuracy limit was reached. The S-parameter 
convergence criterion was defined to be 0.01 and it has been satisfied after calculating 
about six frequency samples. The CST FDS offers a reliable mesh adaptation refinement 
algorithm and several simulation convergence criteria, sufficient to obtain reliable data in 









adaptation steps. Each structure was simulated within about 30 min computational time 
using a standard personal computer (AMD Dual-Core processor 2.5 GHz, 4-GB RAM). 
To simulate an RF coil at different temperatures, we considered the resistivity of 
conventional Cu as a function of temper- ature at the residual resistivity ratio of 20 (27). 
The Cu conductivity was set to σRT = 5.8 × 107 S/m at 300 K, σ77 K = 4.65 × 108 S/m at 77 K. 
The sample load was modeled by a cylindrical phantom of 30 mm in diameter, 80 mm in 
length with εr = 78, and σ = 0.5 S/m (14). All resonators were tuned and matched to the 
resonance frequency of 39K-MRI at 9.4 T (18.68 MHz). The S11-return loss (i.e., the 
reflection coefficient measured on a network analyzer) was simulated for all coils. 
Once the steady state of EM-simulations was obtained at each temperature for each coil 
size, 1) the Q-factors were evaluated in both loaded and unloaded conditions; and 2) the 
input coil resistance (Rc) and total input resistance (Rt) were evaluated from the real part 
of the input impedances for unloaded and loaded conditions, respectively. The sample 
resistance Rs was evaluated as: Rs = Rt − Rc  (22). At each temperature, the (B1/I) field was 
evaluated at 18.68 MHz for each coil size and exported for postprocessing using MATLAB. 
The sample temperature Ts was assumed to be 310 K (9, 14). 
Cryostat Design 
Building nonmagnetic, stable temperature cryostat system is the main challenge for 
developing cryogenic coils especially for X-nuclei (nonproton) MRI such as 39K-MRI at 9.4 
T for the following reasons. 1) A certain effort is required to provide a warm environment 
for the animal with good thermal insulation to keep the animal alive during the MR 
experiment. 2) The coil-to-sample distance has a significant effect in the SNR and it has 
to be minimized in order to enhance the coil sensitivity. Therefore, the EM-simulations 
need to take this effect into account in order to estimate the real benefit of a cryogenic 
coil over an RT setup. 3) The electrical stability of the cryogenic coil in terms of uniform 
temperature cooling, stable Q-factor, and resonance frequency for long-time MR mea- 
surement are further challenges. 4) External fine tuning and matching circuits were 
required to match and tune the cryogenic coil again after cooling by LN2 to 77 K under 
different loading conditions inside the magnet. 5) Ease of handling to the animal during 
the MR measurement is an important issue. 6) Due to the limited space inside the bore 
for small animal scanner at 9.4 T, more restrictions in the developed cryostat housing 
dimensions had to be considered in RF coil design. The developed cryostat housing 










1) Reservoir: The reservoir is an insulating Styrofoam box of length, width, height, and 
thickness of 36, 26, 28, and 4 cm, respectively to be filled with LN2 as shown in Fig. 
2(a). It was fixed at the back section of the scanner for mechanical stability during 
the whole experiment time. Filling the reservoir with about 2 L of LN2 was found to 
be enough for an experiment time of 1 h with stable Q-factor, resonance frequency, 
and uniform temperature cooling. For long-time MR imaging experiments, the 
reservoir can be refilled easily. 
Figure 2. (a) Schematic representation 
of the cryostat system. (b) Prototype of 
LN2 G10 cryostat housing to cool down 
a 30 mm in diameter Cu RF surface coil 
for 39K-MRI at 9.4 T (18.68 MHz). The 
external fine tuning and matching 
circuits were fixed on the front section 
of the G10 cryostat. In the current 









2) Inlet/Outlet LN2 Pipes: To have a uniform temperature cooling and stable Q-factor 
during the whole MR experiment at 77 K, two pipes of length, diameter, and 
thickness of 45, 1.4, and 0.1 cm, respectively, were used for inlet/outlet LN2 paths. 
Pipe 1 was connected to the bottom of the external reservoir and extended to the 
front section of the G10 cryostat where the RF surface coil was fixed. Pipe 2 forms 









thermally insulated using a Styrofoam to slow down the boiling of LN2 and also for 
more mechanical stability inside the scanner as shown in Fig. 2(b). 
3) Using Aerogel for Thermal Insulation: The thermal insulation of the cryostat is one 
of the most important aspects which must be considered in order to keep the 
temperature of the coil suitable for in vivo measurement. For designing a cryogenic 
coil it is important to choose the appropriate material for thermal insulation to 
prevent the sample from freezing. Aerogel TLD 302 granules (Cabot Corporation, 
Massachusetts, USA) was used for thermal insulation. This is because it has a very 
low density and low thermal conductivity of approximately 10–20 mW/mK 
compared to Styrofoam with a value of 30–50 mW/mK. With thermal conductivity 
of—two to four times lower than that of traditional materials such as polyurethane 
foam, aerogel provides much higher thermal efficiency with the same thickness. 
The thermal conductivity of an aerogel material depends on its composition, form 
factor and density, as well as the temperature of its environment. Silica aerogel-
based materials are typically used for insulating purposes. 
4) G10 Cryostat Design: Different materials were used for building LN2 cryostats such 
as Styrofoam (28), PVC (10), Teflon (PTFE) (22), G10 fiberglass (13, 15), ceramic, 
and borosilicate glass (Pyrex glass) (21, 29, 30). In this paper, G10 fiberglass was 
selected due to its high mechanical stability under high pressure of LN2 at 77 K. The 
geometry of the developed cryostat is restricted to the small bore of the Bruker 9.4 
T animal scanner which is 11.7 cm in diameter. In addition, more effort is required 
to leave enough space for the examination object, the insulation material and the 
inlet/outlet LN2 pipes which were connected to the external reservoir for closed-
loop LN2 circulation. 
The developed cryostat system consists of two main sections. The first back section is a 
cylindrical shaped part to keep a suffi cient quantity of LN2 to cool down the RF coil. This 
section was made from two concentric 15-cm-long G10 fiberglass tubes of 4.2 and 7.4 
cm outer diameters, respectively. The wall thickness of both tubes is 1 mm. The gap 
between both cylinders (1.5 cm) was filled with aerogel particles for thermal insulation. 
The inner tube is connected directly to the second section (half-cylindrical shaped), 
where the RF coil was fixed. For more mechanical stability and more thermal insulation, 
a third 15-cm-long G10 tube of 11.2 cm outer diameter and 2 mm wall thickness was 
positioned around the 7.4-cm cylinder. The gap between both cylinders (1.7 cm) was 









The second front section is a half-cylindrically shaped part where the sample can be 
placed underneath. This section was made from two concentric 24-cm-long G10 
fiberglass tubes of 4.2 and 7.4 cm outer diameters, respectively. The gap between both 
the half-cylinders (1.5 cm) was filled with aerogel particles for thermal insulation. The 
bottom of the tubes was closed with an epoxy layer of 0.5-mm thickness as shown in Fig. 
2(a). The single-loop Cu RF coil with 30 mm in diameter was fixed at the end of the G10 
front section to have 74.8 cm total distance from the center of the coil to the end of the 
magnet. For the thermal insulation between the RF coil and rat head, 5-mm thickness 
Cryogel Z layer (Insulation GmbH Krefeld, Germany) was used. In order to decrease the 
distance between the coil and the sample, the insulation layer was compressed to about 
4.5 mm. The total distance between the RF coil and the nearest point of the sample is 5 
mm. Fig. 2(b) shows the first home-built LN2 G10 cryostat prototype designed for 
39K-MRI 
at 9.4 T. 
Cryogenic RF Surface Coil Design 
A single-loop Cu RF surface coil of 30 mm in diameter with 2-mm wire thickness was 
designed and built. The symmetric splitting tuning capacitance (Ct1 = 2446 pF) composed 
of five fixed (high Q-factor, high voltage, and nonmagnetic) capacitors of 2 × 1000 pF, 2 × 
173 pF, and 1 × 100 pF were connected in parallel. The total tuning fixed capacitance 





Figure 3. Circuit diagram of the 30 mm in diameter cryogenic Cu RF surface coil for 39K-MRI at 9.4 T with 
tuning and matching circuits. The symmetric splitting tuning capacitance Ct1 = 2446 pF composed of five 
fixed capacitors of 2 × 1000 pF, 2 × 173 pF, and 1 × 100 pF are connected in parallel. The total tuning 
capacitance (Ct1/2 = 1223 pF). The external fine tuning and matching circuits composed of Ct2 = 60 pF, Ct3 
= 1–120 pF, and Cm = 1–120 pF. The length of the semirigid RF cable is 8 cm. 
The RF coil and capacitors were fixed inside the LN2 path above an epoxy layer of 0.5-mm 
thickness and connected directly to the external fine tuning and matching circuits via a 
short semirigid RF cable of length 8 cm. The external fine tuning and matching circuits 









as shown in Fig. 2(b). The RF coil was externally fine-tuned by connecting a variable 
capacitor of Ct3 = 1–120 pF in parallel with another fixed capacitor of Ct2 = 60 pF to 
compensate for the frequency shift after cooling and with different loading conditions 
inside the magnet. The RF coil was matched to the 50 Ω coaxial cable impedance by a 
variable capacitor of Cm = 1–120 pF connected in series with the RF cable line. The 
external fine tuning and matching variable capacitors were connected with a flexible two 
nylon rods of length 100 cm for easy matching and tuning. Fig. 3 shows the equivalent 
circuit diagram of the developed cryogenic RF coil designed for 39K-MRI at 9.4 T. 
Simulated and Measured SNR Gain 
The RF sensitivity factor (SRF) that contributes to the SNR of an MR image can be written 
as (8, 9) follows:  
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where (B1/I) is the magnetic flux density in the receiving coil induced by a unit current, Rc 
is the coil resistance, Rs is the sample resistance, Tc is the coil temperature, and Ts is the 
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The SNR gain between both coils can be estimated according to (8, 10) 
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where Qun ,300 is the unloaded Q-factor at 300 K and Qun ,77 is the unloaded Q-factor at 77 K. 
Equation [2] assumes that both coils at RTand 77 K have the same (B1/I) field profiles (i.e., 
they should have the same identical geometry and the same identical size) and only 
Johnson’s noise was considered (10, 22). Both simulated and measured Rc and Rs at RT and 
77 K can be calculated from the unloaded and loaded Q-factors as follows: 
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where L is the coil inductance, C is the coil capacitance, and f is the Larmor resonance 
frequency. The developed cryogenic coil was tested first on bench by measuring the 
unloaded and loaded Q-factors at RT and 77 K. The stability of the coil at 77 K in terms of 
its Q-factor, resonance frequency, and temperature were monitored during 1 h 
experiment. The temperature at the surface of the phantom and rat head was measured 
by a Cernox CX-1050-Cu-HT temperature sensor (Lake Shore Cryotronics, Ohio) and 
displayed with a temperature monitor Model 211 (Lake Shore Cryotronics, Ohio). The Q-
factors were measured using network analyser (Rhode & Schwarz GmbH & Co. KG, 
Munich, Germany). For all Q-factors measurements at RT and 77 K, the developed 
cryogenic coil was matched and tuned at 18.68 MHz. The Q-factors were calculated from 
the S11 measurements. The phantom is a cylindrical jar of 8-cm length and 2.8-cm inner 
diameter was filled with 150-mM KCl solution. The loaded Q-factor measurements were 
repeated for the loaded condition with the rat head. 10 min after filling the reservoir by 
about 2 L of LN2, the coil was achieved a stable condition concerning its Q-factor for the 
next 1 h. 
MR Measurements 
All experiments were performed on the 9.4 T Biospec 94/20 USR (Bruker BioSpin GmbH, 
Ettlingen, Germany) small animal MR system allowing a maximum gradient strength in the 
range of 660–740 mTm−1 and a maximum slew rate of about 6000 Tm−1s−1 . For less 
sensitive X-nuclei such as 39K-MRI, a reference 1H-RF coil with a higher signal is very 
important for the following reasons. 1) It is essential for optimization and RF power 
adjustments (i.e., the B0-field homogeneity, RF pulse power, and the basic frequency). 2) It 
is necessary in our case for specifying the stroke region. 3) It is further more important to 
include 1H imaging to allow for coregistration of lower resolution 39K images with high-
resolution 1H anatomical images.  
1) 1H-MR Measurement at RT: A home-built animal bed compatible with the developed 
cryogenic coil was built using G10 half-cylinder to acquire both 1H and 39K images without 
changing the reference position. In order to keep the environment around the rat body 
warm enough for the in vivo MR measurements, a warm water circulation system of 
temperature around 40 ºC was supplied to a heating bed fixed under the animal body by 
input/output plastic pipes. The ports for isoflurane, respiration, and temperature sensors 
were connected. Two small vials of length 3 cm and diameter 1 cm filled with 150 mM KCl 
solution fixed on the G10 half cylinder around the rat head for slice coregistration. First of 









was used to acquire anatomical 1H images at RT. Then, the birdcage volume resonator was 
removed and the cryogenic coil loaded with rat was inserted at the same reference 
position. All RF coils were operated in transmit/receive (TXRX) mode. 1H T2-weighted 
images were acquired using a multislice multiecho (MSME) sequence with the following 
parameters: FOV = 6.4× 6.4 cm2, TR = 1000 ms, TE = 14 ms, (0.25 × 0.25) mm2 inplane 
resolution with 16 axial slices of 2-mm thickness, and an interslice distance of 2 mm. The 
total measurement time (TA) was 4.16 min.  
2) 39K-MR Phantom Measurement: The cryogenic coil was tested first in phantom filled 
with 150 mM KCl solution before starting the in vivo measurement. The optimum RF 
transmitted power was calibrated manually to ensure the same flip angle and to maximize 
the signal amplitude. The SNR was calculated by dividing the difference between the mean 
signal of an ROI and the mean magnitude (MEAN) of the background noise by the 





3) Three-Dimensional-Chemical Shift Imaging (CSI) Sequence: The 3-D CSI sequence was 
used for 39K-MRI since the short relaxation times T1 allow for very short repetition times 
(TRs). The CSI sequence acquires the whole free induction decay for each phase encoding 
step. The 39K-CSI measurements were performed with Hanning-weighted k-space 
acquisition to reduce Gibb’s ringing and to increase the SNR. The matrix size was increased 
to keep the same resolution as in the nonweighted case. For all measurements, the 
acquired matrix size is given together with a matrix size corresponding to a nonweighted 
CSI measurement with equal spatial resolution. A matrix size of 27 × 27 × 13 was used 
corresponding to a matrix size of 16 × 16 × 8 in a nonweighted acquisition experiment (3).  
A hard (block) RF pulse of 100 μs duration was used for excitation. Together with the 
phase encoding duration, this leads to an acquisition delay of 520 μs for all 
measurements. The acquisition delay was defined from the middle of the RF excitation 
pulse until the beginning of the acquisition window which includes the 3-D phase 
encoding gradients and a system-specific gradient delay. The RF pulse length of 100 μs and 
the corre- sponding bandwidth of 6400 Hz were calibrated to maximize the 39K signal 
intensity. In addition, 100 μs RF pulse was calibrated to prevent from higher power 
loading. The optimal RF transmit power was calibrated manually (׽3 dB) at both 










The field-of-view (FOV) of 6.4 × 6.4 × 3.2 cm3 was adapted with the nonweighted matrix 
size of 16 × 16 × 8 to save phase encoding steps in z-direction, which resulted in a spatial 
resolution of 4 × 4 × 4 mm3 if blurring due to T2כ effects is neglected. For all MR 
measurements, a TR of 20 ms was used. For both phantom and in vivo healthy MR 
measurements, the total number of repetitions of 90,000 led to a total acquisition time of  
30 min. However, for stroke-induced rat MR measurement, the total number of 
repetitions was doubled to 180,000 leading to total scan time of 60 min. The CSI data was 
reconstructed using a routine written in MATLAB. 
4) In Vivo 39K-MR Measurement:  1) The animal was fixed  on the home-built animal bed 
holder with warm water circu- lation system, and then it was fixed underneath the 
cryogenic RF coil in such a way that the rat brain was positioned exactly at the center of 
the coil as shown in Fig. 4(b). 2) The cryogenic coil was inserted at the same 1H reference 
position to acquire 39K-MR images at both RT and 77 K,  respectively. 3) The reservoir was 
filled with about 2 L of LN2 without moving the coil from its reference position. The 
developed cryogenic coil reached a stable temperature of 77 K after about 10 min. Stable 
electrical performance in terms of the Q-factor at 77 K and the resonance frequency, with 
minimal variations during the 1 h imaging experiment was obtained. In this paper, two 



























Figure 4. (a) Protocol for surgery and imaging time points for stroke-induced rat. (b) Schematic 
representation of home-built animal bed setup with warm water circulation system compatible with the 
developed cryogenic coil at 77 K. 
5) Focal Cerebral Ischemia Model: Adult male Sprague-Dawley rats (Janvier, Isle St. 
Genest, France) weighing 300 g underwent occlusion of the middle cerebral artery 
occlusion (MCAO) using an intravascular monofilament as described previously (31, 
32) under the guidance of laser Doppler flowmetry. 2 h later, the filament was 
withdrawn to allow reperfusion (REP). The animal was later allowed to recover and 
transferred to its home cage. Animal housing, care, and application of experimental 
procedures were in accordance with institutional guidelines under approved 
protocols. At 48 h post MCAO, the animal was reanesthetized with isoflurane (5% 
induction; 1.5–2.0% maintenance) in oxygen: nitrous oxide mixture (30:70%) 
delivered using a nose cone and placed in the home-built animal bed and steadily 
fixed as shown in Fig. 4(a). Subcutaneous injection of atropine (5 μg/100 g body 
weight; Essex Pharma, Munich, Germany) was given as a premedication to reduce 
bronchial secretions during the whole procedure. Both healthy and stroke- induced 















Fig. 5 shows the normalized SRF distributions of [eq.1] were plotted against coil diameter 
for a series of single-loop RF surface resonators at 300 and 77 K. For the ease of 
visualization, all SRF values at 77 K were normalized to the maximum SRF value achieved by 
the optimal 30 mm RT-coil. The optimal coil diameter for rat brain imaging at 15 mm 
depth was about 30 mm for both at 300 and 77 K as shown in Fig. 5. The predicted 
sensitivity gain was calculated to be 2.83-fold at 77 K. In addition, the 30 mm coil diameter 
was selected as an optimal coil for 39K-MRI rat brain imaging at 77 K due to its better B1-
field penetration with large FOV to cover the whole rat brain. 
Figure 5. Normalized SRF distributions of (1) are 
plotted against the coil diameter for a series of 
single-loop RF surface resonators at various 
temperatures of 300 and 77 K and evaluated at 15 
mm depth from the coil surface. Notes: 1) The SRF 
values at 77 K are normalized to the maximum 
value achieved by the 30-mm RT-coil; and 2) The 
cylindrical phantom properties are: εr  = 78, σ = 0.5 
S/m, length = 8 cm, diameter = 3 cm, and the coil-
to-sample distance = 5 mm. 
 
Simulated SNR Gain 
In EM-simulations, only the two major noise sources of Rc and Rs were considered, where 
other noise sources coming from electronic components such as capacitors and soldering 
joint connections have been neglected. This is because, for an RF coil made from Cu, the 
major noise source is due to Johnson noise in the metal (22,33). Theoretically, the 
resistivity of conventional Cu decreases by factor of 8 when it was cooled down to 77 K 
(27). Hence, the SNR should be improved by factor of 2.8 by cryogenic cooling to 77 K if 
the coil noise dominates the sample noise and the wire thickness is much greater than the 
skin depth at RT (10). At 18.68 MHz, the skin depth for Cu at RT is 15.3 μm. Therefore, 2-
mm wire thickness is about 130 times greater than the skin depth. The simulated loaded 
to unloaded Q-factor ratios of the Cu resonator at 300 and 77 K were evaluated as 
198/205 and 521/577, respectively. The nearly similar loaded to unloaded Q-factors of the 









coil losses at 18.68 MHz. From [eqs. 4–6], the coil loss Rc Tc and sample loss RsTs are 11.16 
and 0.41 ΩK, respectively, (i.e., Rc Tc / Rs Ts  = 27). This means that the coil loss is about 
96% of the total losses and cryogenic cooling to 77 K will enhance the SNR gain by factor 
of 2.8. The simulated and measured Q-factors at 300 and 77 K are listed in Table I. 
Equation [2] was used to estimate the simulated and measured SNR gain at 77 K. 
Simulation results show that the unloaded Q-factor at 77 K was improved by factor of 2.8 
compared to the same coil at RT. The predicted SNR gain by cryogenic cooling to 77 K is 
2.8-fold compared to the same coil at RT.  
Measured SNR Gain 
The measured loaded to unloaded Q-factor ratios of the Cu resonator at RT and 77 K were 
evaluated as 220/223 and 435/450, respectively. From [eqs. 4–6], the internal coil loss Rc 
Tc and sample loss RsTs are 9.28 and 0.13 ΩK,  respectively (i.e., RcTc / RsTs = 70). This 
means that the coil loss is about 98 % of the total losses and cryogenic cooling to 77 K will 
enhance the SNR gain by factor of 2.8. The measured results show that the unloaded Q-
factor at 77 K was improved by factor of 2 compared to the same coil at RT. The deviation 
of measured unloaded Q-factor is 9 % at 300 K and 28 % at 77 K. The difference between 
EM-simulations and measurements can be attributed to the following reasons. 1) It could 
be due to variations in temperature or RF coil material conductivity. 2) In the real coil 
prototype, ten-fixed capacitors were used for tuning which could add additional noise to 
the resonator compared to an ideal one capacitor in EM-simulations. However, both 
simulated and measured coils have approximately the same SNR gain as listed in Table I. 
The predicted SNR gain by cryogenic cooling to 77 K is 2.7-fold compared to the same coil 
at RT.  
Table I. Evaluations of both simulated and measured SNR gains for the developed cryogenic coil at 300 














39K-MR Phantom Measurement 
The performance of the developed cryogenic coil was tested first in phantom filled with 
150 mM KCl homogeneous solution at RT and 77 K before starting the in vivo MR 
measurements. The KCl phantom was fixed below the Cryogel Z insulation layer in such a 
way that the center of the phantom was exactly at the center of the RF coil loop. Fig. 6 
shows the 39K-MR phantom images acquired using the cryogenic coil at 300 and 77 K with 
4 × 4 × 4 mm3 spatial resolution in 30 min acquisition time. The measured SNR ± SD was 
calculated from [eq.7]. The measured SNR ± SD values at RT and 77 K are listed in Table II. 





Figure 6. Phantom MR images. (a) 39K SNR-map at 300 K. (b) 39K SNR-map at 77 K. The FOV of 6.4 × 6.4 × 
3.2 cm3 with nonweighted matrix size of 16 × 16 × 8 results in spatial resolution of 4 × 4 × 4 mm3. The TR of 
20 ms, total number of repetitions of 90,000 led to total acquisition time of 30 min. The above shown 39K-
MR images (a, b) are zero filled by factor 2. 






In Vivo 39K-MR Measurement for Healthy Rat 
As a second MR experiment, the cryogenic coil was tested for the measurement of 39K 
signal in a healthy rat brain. The T2-weighted 
1H image, 39K SNR-maps at 300 K, 77 K, and 
the superimposed 1H edge image with 39K image at 77 K were shown in Fig. 7. 39K-MR 









measured SNR ± SD values at RT and 77 K are listed in Table II. The SNR is 5.9 ± 2.7 at 300 
K and 16 ± 2.8 at 77 K. 
Figure 7. In vivo MR images for healthy rat. (a) 39K SNR-map at 300 K. (b) 39K SNR-map at 77 K. (c) T2-
weighted 1H image. (d) Coregistered 1H edge image with 39K image at 77 K, the 39K image is resized to have 
the same resolution of 1H image. The FOV of 6.4 × 6.4 × 3.2 cm3 with nonweighted matrix size of 16 × 16 × 
8 results in spatial resolution of 4 × 4 × 4 mm3. The TR of 20 ms, total number of repetitions of 90,000 led 
to total acquisition time of 30 min. The above shown 39K-MR images (a, b) are zero filled by factor 2. 
In Vivo 39K-MR Measurement for Stroke-Induced Rat  
As a third MR experiment, the cryogenic RF coil was tested for the measurement of 39K 
signal after a focal cerebral ischemic insult in an adult rat. The T2-weighted 
1H image, 39K 
SNR-maps at 300 K, 77 K, and the superimposed 1H edge image with 39K image at 77 K 
were shown in Fig. 8. The 39K-MR images were acquired with 4 × 4 × 4 mm3 spatial 
resolution in 60 min acquisition time. The measured SNR ± SD values at RT and 77 K are 
listed in Table II. The SNR is 6.8 ± 2.7 at 300 K and 18.4 ± 2.2 at 77 K.  
In good agreement with EM-simulations and bench top measurement, phantom and in 
vivo 39K-MR images show that cryogenic cooling of single-loop coil of 30 mm in diameter 
by LN2 down to 77 K enhances the SNR gain by factor of 2.7 ± 0.2. It is clear that the 
cryogenic coil at 77 K has a higher SNR gain and deeper penetration depth compared to 
the same coil at RT for all images. These results demonstrate that cryogenic cooling could 









T. Fig. 8(c) shows the two ROIs corresponding to the occluded and non-occluded 
hemispheres of the rat brain. The measured mean values of the 39K signal in the selected 











Figure 8. In vivo MR images for stroke-induced rat. (a) 39K SNR-map at 300 K. (b) 39K SNR-map at 77 K. (c) 
T2-weighted 1H image. (d) Coregistered 1H edge image with 39K image at 77 K, the 39K image is resized to 
have the same resolution of 1H image. The FOV of 6.4 × 6.4 × 3.2 cm3 with nonweighted matrix size of 16 × 
16 × 8 results in spatial resolution of 4 × 4 × 4 mm3. The TR of 20 ms, total number of repetitions of 
180,000 led to total acquisition time of 60 min. The above shown 39K-MR images (a, b) are zero filled by 
factor 2.   






hemisphere was decreased by about 40% at 300 K and 75% at 77 K compared to the non-
occluded hemisphere. This result is in good agreement with invasive measurements (34) 









cross-section plot through the center of the ROIs for 39K images at 77 K for both healthy 
and stroke-induced rats corresponding to Figs. 7(b) and 8(b), respectively. For healthy rat 
MR measurement, a relatively uniform 39K signal with minimal variations across the rat 
brain which prove the symmetric B1-field distribution of the developed single-loop 
cryogenic coil as shown in Fig. 9(a). However, for the stroke-induced rat, there is a 
significant reduction in 39K signal in the occluded hemisphere rat brain as shown in Fig. 
9(b). This significant reduction is mainly due to the reduction in 39K concentration in the 
occluded hemisphere after ischemic stroke. The significant variations in 39K signal after 
ischemic stroke were successfully measured noninvasively, which could help to 
understand the physiological variations after ischemic brain damage (35–38).  
Figure 9. Horizontal cross-section plot through the center of the ROIs for 39K images at 77 K. (a) For 
healthy rat corresponding to Fig. 7(b). (b) For stroke-induced rat corresponding to Fig. 8(b). 
DISCUSSION  
EM-Simulations 
The optimal coil diameter has been carefully optimized at 300 and 77 K by using EM-
simulations to enhance the detector sensitivity for rat brain imaging at 18.68 MHz. This 
method has been found to be reliable, cost effective, and more accurate to predict the Q-
factors and the B1-fields than building a large number of coils. The optimal coil diameter 
and geometry of the surface coil were chosen according to the desired imaging 
penetration depth where optimal SNR was desired (22). Simulation results show that, the 
optimal coil diameter that maximizes the SRF for rat brain imaging at 15 mm depth is 
about 30 mm in diameter at 300 and 77 K. As a result, the optimal coil radius 
approximately equals the required penetration depth to obtain optimal SNR at 300 and 77 
K. A larger coil radius results in excessive noise from outside the desired volume, and a 









degrading the SNR (39). The predicted sensitivity gain at 77 K has been improved by factor 
of 2.8 compared to the same coil at RT. This is because at 18.68 MHz, with small coil size 
(30 mm in diameter), and with small sample size (rat head), the internal coil noise 
dominates the sample noise. 
Development of Cryogenic Coil 
Aerogel has been used for thermal insulation in the developed cryostat system. This is 
because it has about —two to three times more insulating per unit thickness compared to 
polyurethane foam or Styrofoam. Another important issue which is strongly related to 
thermal insulation is the coil-to-sample distance. Since both cryogenic and HTS coils are 
small surface coils, the coil-to-sample distance has to be minimized to enhance the coil 
sensitivity. With the use of nonreliable insulation material such as Styrofoam, a very big 
coil-to-sample distance of 1 (13, 28), 2.4 (15), and 2.1 cm (18) has been used. In these 
designs, the big coil-to-sample distance significantly degrades the SNR gain from cryogenic 
cooling compared to the same simple RT Cu coil wrapped around the sample with good 
filling factor and small coil-to-sample distance. With the use of better insulation materials 
with vacuum cryostats, the coil-to-sample distance has been minimized to 6 mm (10), 5 
mm (21, 29, 30), 2 mm (14), and recently with 1.5 mm (22). In this paper, a Cryogel Z layer 
has been compressed to about 4.5 mm for thermal insulation in conjunction with a home-
built animal bed with warm water circulation system compatible with the developed 
cryostat. This method has enabled the animal to survive during the whole experimental 
time. The total coil-to-sample distance has been set to 5 mm. 
The filling factor of an RF coil is one of the most important parameters which have a 
significant effect on the SNR. It should be increased if the coil size is geometrically 
matching the sample size with minimized coil-to-sample distance. In addition, by bending 
the conventional Cu surface coil around the sample, the filling factor should be increased. 
The developed 30 mm in diameter cryogenic Cu surface coil has been optimized for rat 
brain imaging with a flat animal head holder without bending the coil wire around the rat 
head. This is mainly due to the difficulty to build such a complex cryostat with bended 
sections for animal head. This resulted in a reduced filling factor, which is the main 
disadvantage of our developed cryogenic coil. According to author’s knowledge, only 
Bruker has the commercial 1H and 13C CryoProbes at 9.4 T cooled down by helium gas for 
mice head MR imaging with bended RF coil structure. 
The numbers of tuning and matching capacitors have some effect on the equivalent Q-









developed cryogenic coil at 18.68 MHz, ten-fixed nonmagnetic (high voltage, high Q-
factors) capacitors have been used. There are two main reasons of designing such a 
symmetric capacitor splitting circuit for tuning. 1) To provide an optimal balanced ground 
for the induced voltage, whereby the connection point between those two capacitors acts 
as an optimal ground of the resonance circuit. 2) The developed cryogenic coil has been 
used for both transmit and receiving RF pulses (i.e., in TXRX mode). This means that, the 
high power in the TX mode may damage the capacitors. However, the main advantage of 
capacitor splitting circuit is that, the current will be divided across the capacitors which 
could prevent them from damage due to high voltage and current. The maximum 
transmitted RF power has been calibrated to prevent the cryogenic coil from damage. The 
measured unloaded Q-factor from the developed cryogenic coil has been improved at 77 K 
by factor of 2 compared to its value at 300 K. In the coil noise predominance domain (at 
18.68 MHz for rat brain imaging), the maximum floor of SNR gain by factor of 2.8 has been 
achieved. Our results are consistent with the published previously at 64 MHz with an SNR 
gain by factor of 2.7 (10).  
Future Work 
Future work could to be continued to improve the SNR for 39K-MRI at 9.4 T as follows: 1) 
the coil-to-sample distance could be decreased from 5 mm to about 2 mm by using 
vacuum for thermal insulation. 2) Due to the flat design of the developed animal head 
housing, the filling factor is low compared to bended designs. This modification could help 
to use a smaller coil size with diameter of 20–25 mm and also increase the filling factor 
which will lead to a significant improvement in the SNR. 3) It is expected that by using a 
small HTS YBCO thin-film surface coil for 39K-MRI at 9.4 T in conjunction with vacuum 
cryostat with 2 mm coil-to-sample distance, the SNR will be improved by factor of 4 
compared to Cu coil with the same identical geometry at RT (9, 14, 21, 29, 30). 4) Based on 
our EM-simulation results, it is expected that cryogenic cooling of a single-loop RF surface 
resonator of about 10–12 mm in diameter to 4 K by LHe could improve the detector 
sensitivity by factor of about 6 (25). This result indicates that, the 39K-MRI signal in 
cerebral tissue of the rat could be spatially resolved with a voxel size of 2 × 2 × 2 mm3 in 
only 10 min acquisition time. Recently, the first in vivo 39K-MR images at 9.4 T for human 
brain were presented by using a TXRX birdcage volume resonator (40). An SNR of 5.2 was 
achieved in 40 min for an isotropic spatial resolution of 10 × 10 × 10 mm3  in a  human 
brain by using a flexible twisted projection imaging acquisition. Furthermore, in vivo 39K-
MR images of human muscle and brain at 7 T were presented (41). The development of 









due to the rapid progress in HTS technology, high field magnet technology, and fast 3-D 
imaging sequences. 5) An efficient way to quantify the 39K concentration is by using a dual 
transmit only receive only RF system (42). A separate 39K-RF coil could be used for 
transmission to provide a homogeneous B1-field such as linear birdcage coil or Helmholtz 
coil to avoid the nonuniform MR excitation from a surface coil. In such a setup, the 
developed 39K cryogenic coil could be used for reception only. 6) Building 23Na and 39K 
cryogenic coils for rat brain imaging at 9.4 T could help in understanding both 23Na and 39K 
ion changes to determine the progression of ischemic damage. However, most of these 
modifications will add more restrictions to the RF coil design in terms of space limitations 
and the cryogenic cooling system.  
CONCLUSION 
A novel cryogenic Cu RF surface resonator with a home-built LN2 nonmagnetic G10 
fiberglass cryostat housing for small animal scanner at 9.4 T has been designed, built, and 
tested. The first in vivo 39K-MR images for both healthy and stroke-induced rats using the 
developed cryogenic coil cooled down by LN2 to 77 K have been presented. In good 
agreement between both EM-simulations and MR measurements, the SNR gain has been 
improved by factor of 2.7 ± 0.2 compared to the same coil at RT.  In addition, results show 
that the 39K signal in the occluded hemisphere of the rat brain has been decreased by 
about 40% at 300 K and 75% at 77 K compared to the nonoccluded hemisphere at 9.4 T. 
The significant reduction in 39K signal after stroke could be considered as a relevant 
marker for dead tissue. 
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The ‘new penumbra' concept imbues the transition between injury and repair at the 
neurovascular unit with profound implications for selecting the appropriate type and 
timing of neuroprotective interventions. In this conceptual study, we investigated the 
protective effects of pigment epithelium-derived factor (PEDF) and compared them with 
the properties of epidermal growth factor (EGF) in a rat model of ischemia–reperfusion 
injury. We initiated a delayed intervention 3 hours after reperfusion using equimolar 
amounts of PEDF and EGF. These agents were then administered intravenously for 4 hours 
following reperfusion after 1 hour of focal ischemia. Magnetic resonance imaging indices 
were characterized, and imaging was performed at multiple time points post reperfusion. 
PEDF and EGF reduced lesion volumes at all time points as observed on T2-weighted 
images (T2-LVs). In addition PEDF selectively attenuated lesion volume expansion at 48 
hours after reperfusion and persistently modulated blood–brain barrier (BBB) 
permeability at all time points. Intervention with peptides is suspected to cause edema 
formation at distant regions. The observed T2-LV reduction and BBB modulation by these 
trophic factors is probably mediated through a number of diverse mechanisms. A 
thorough evaluation of neurotrophins is still necessary to determine their time-dependent 
contributions against injury and their modulatory effects on repair after stroke. 
Keywords: blood–brain barrier, epidermal growth factor, ischemia/reperfusion injury, 















The classic concept of stroke evolution, as proposed by Dirnagl et al (1), involves a 
continuum of multiple mechanisms (from hypoxic injury to inflammation to induction of 
apoptosis) that lead to neuronal injury. To achieve neuroprotection, persistent protective 
effects must be mediated through a number of agents possessing multiple mechanisms of 
action. The ‘new penumbra' concept of Eng Lo (2) highlights the necessity to select the 
appropriate type and time of drug intervention by giving due consideration to the 
mechanisms underlying the transition from injury to repair. A prime example for this is the 
intervention with matrix metalloproteinase inhibitors. Their early administration (during 
injury phase) reduces infarction, but their delayed administration resulted in increased 
infarct volume (3). Adequate reconstruction and/or regeneration of damaged neuronal 
circuits may need to take place before satisfactory functional recovery can occur (4). 
Developing a single pharmacological agent that can meet such a plethora of demanding 
therapeutic requirements may be impossible. 
Neurotrophic factors (NTFs) are a class of proteins normally present within the 
mammalian nervous system promoting survival and/or maintenance of neurons. They may 
also stimulate axonal growth, synaptic plasticity, and neurotransmitter synthesis and 
release (5). Among neural cells, neurons are particularly sensitive to injuries such as 
ischemia, hypoxia, hypoglycemia, infection, and trauma. Episodes of acute ischemic stroke 
have been shown to cause a marked increase in cell proliferation at the subventricular 
zone as well as cell migration into severely damaged areas of the striatum, where the cells 
express markers of developing and mature medium spiny neurons (4). However, after 6 
weeks of the insult only ~0.2% of the dead striatal neurons have been replaced by new 
neurons. To a large measure this poor cell survival is most likely because of the immediate 
pathologic environment encountering the newborn neurons, and may be reflected by an 
early phase of blood–brain barrier (BBB) opening (6). Next to elevated levels of reactive 
oxygen species (ROS), cytokine release and glutamate toxicity, inflammation with its 
diverse cell types and variable activation states appears to be an important component 
and this inflammatory cascade could prove to be anything from detrimental to supportive 
for adult neurogenesis (7). We hypothesized that once this initial deleterious post-hypoxic 
response have been minimized by a suitable agent, the prevailing environment 
surrounding the ictus could provide a favorable setting for neuronal repair/replacement 
by proliferating cells. To enable this environment, we strategized an early intervention 
with the non-inhibitory member of the serine protease inhibitor (SERPIN), pigment 
epithelium-derived factor (PEDF) by considering its anti-inflammatory, anti-oxidant and 
inhibitory properties on the VEGF–NADPH oxidase pathway among others followed by 




As a first step toward such a combined therapeutic approach, we investigated the 
properties of each of these peptides separately on a rodent model of ischemia–
reperfusion (I/R) injury. This model exhibits a biphasic course of BBB permeability changes 
over time and the NTF treatment was initiated and confined to the initial phase of the 
altered BBB permeability (10,11). The entire study was performed non-invasively using a 
clinical 3 T dedicated head magnetic resonance (MR) scanner (Siemens Magnetom Allegra, 
Siemens Healthcare sector, Erlangen, Germany) customized to perform small animal 
imaging as described previously (12). 
MATERIALS & METHODS 
All animal experiments were performed in accordance with the European Community 
Council's directive (86/609/EEC) and institutional guidelines for animal care after 
obtaining approval from our local ethics committee (Ethics Committee for Animal 
Laboratories, Medical Faculty, University Hospital of Regensburg). 
Assesment of Blood-Brain permeability to Macromolecules after Ischemia-Reperfusion 
Injury 
Before any treatment with macromolecular proteins was initiated, we confirmed the BBB 
permeability changes after I/R injury to ensure the entry of NTFs into the brain 
parenchyma. As Evans blue (EB) binds to serum albumin (molecular mass 67 kDa), the dye 
serves as a reliable marker to assess characteristics of BBB permeability. The extravasation 
of the EB–albumin complex into the brain parenchyma, identified by bluish-colored tissue, 
is indicative of compromised BBB permeability resulting from I/R injury (13). 
Experimental Methods 
Male Sprague-Dawley rats (Janvier, Le Genest-St-Isle, France), weighing 250–300 g, were 
divided into three groups of three animals each. The groups were 3-, 6-, and 8-hour 
reperfusion groups (3 R, 6 R, and 8 R groups, respectively). The animals were subjected to 
60 minutes of transient middle cerebral artery occlusion (tMCAO), with modifications as 
described in a previous protocol (10). Briefly, anesthesia was induced with 5% isoflurane 
(Isofluran Baxter, Baxter Deutschland GmbH, Unterschleissheim, Germany) in a mixture of 
70% nitrous oxide/30% oxygen. After endotracheal intubation, anesthesia was maintained 
using 1.5% isoflurane with the aid of a mechanical rodent ventilator (RS Biomed, Sinzing, 
Germany). The body temperature was kept maintained constant throughout the entire 
experiment by using a feedback-regulated heating pad. A cannula was inserted into the 




bifurcation was exposed through a midline neck incision, and the occipital artery branches 
of the external CA were isolated, ligated, and dissected. After careful isolation of the 
internal CA, a 3-cm-long silicone-coated polyamide 4-0 monofilament (Ethicon, Johnson & 
Johnson Medical GmbH, Norderstedt, Germany) was advanced through the internal CA to 
the MCA until the filament met a mild resistance. The filament was tethered to the stump 
of the external CA and the neck incision was closed with a silk suture. The animal was then 
transferred to its cage and allowed to move freely after recovery from anesthesia. 
After 60 minutes, the rat was again anesthetized, neck incision was reopened, and the 
filament was gently pulled back to facilitate reperfusion. In the 3 R group, after 
reperfusion for 3 hours, EB (2 % EB in 0.9 % saline, 4 ml/kg) was administered through the 
femoral vein and was allowed to circulate for 1 hour. The same procedure was repeated 
for the 6 R and 8 R groups after reperfusion at 6 and 8 hours, respectively. Animals were 
then deeply anesthetized with pentobarbital (40 mg/kg i.p.), chest cavity opened, and the 
right atrium was punctured. Ice-cold phosphate-buffered saline (pH 7.4, <4 °C) was then 
perfused through the left ventricle at 110 mm Hg, until a colorless perfusate was obtained 
from the right atrium. The rat skull was immediately opened and the entire brain was 
removed and deep-frozen at −80 °C for 20 minutes. The frozen brain was cut into 1-mm 
slices using a rodent brain matrix (ASI Instruments, Warren, MI, USA) and the tissue 
sections were gently placed on a transparent plastic film and scanned at 1,200 dpi using 
an office document scanner (Scanjet 7,650, Hewlett-Packard, Palo Alto, CA, USA) to obtain 
a digital copy. 
Treatment Regimens with Epidermal Growth Factor and Pigment Epithelium-Derived 
Factor 
The EGF and PEDF dosing regimens were prepared to achieve an equimolar dose of brain 
derived NTF (molecular mass 28 kDa). This dose (50 μg/300 g rat) had demonstrated 
neuroprotective effects in a previous study (14). Dilutions of human recombinant PEDF 
(Creative Biomart, Shirley, NY, USA) and EGF (BIOTREND Chemikalien GmbH, Cologne, 
Germany) were prepared in cold sterile water for injection (<4 °C) to achieve final 
concentrations of 89.28 μg/1,000 μL, and 11.16 μg/1,000 μL, respectively, for a 300 g rat. 
These dilutions were prepared from previously constituted stock solutions, randomized, 
and masked from the experimenters. The intravenous dosing regimen consisted of a 10% 
bolus dose (100 μL) followed by a continuous infusion of the remaining 90% (900 μL) at 
the rate of 225 μL/h for 4 hours, administered using a micro-infusion pump (Syringe Pump 





Sample Size Calculation 
A preliminary experiment was conducted with two groups (control and PEDF, each n=5) to 
determine the differences in mean lesion volumes between the two groups as measured 
on T2-weighted MR images (T2-LVs) obtained at 24 hours after reperfusion. The test was 
performed using an unpaired t-test with a significance level (α) of 0.05. 
Exclusion Criteria 
After tMCAO, any animal without a neurologic score of at least 1 (failure to extend right 
forepaw fully) was considered an experimental failure and discarded from the study. In 
addition, any animal that exhibited labored irregular breathing after reperfusion with a 
depressed level of consciousness was examined for subarachnoid hemorrhage at the MR 
scanner and if hemorrhage was confirmed, the animal was excluded from the study. 
Experimental Design 
Three treatment groups were considered namely, EGF- (n=16), PEDF- (n=14), and control 
(saline)- (n=17) treated animals. Animal specifications and surgical procedures remains the 
same as mentioned earlier. After a 3-hour reperfusion period after an hour of ischemia, 
NTF or saline infusions maintained at a temperature <3 °C was infused for the next 4 hours 
as mentioned earlier. A schematic representation of the experimental design is provided 
in Figure 1. 
Magnetic Resonance Imaging 
To facilitate rodent imaging, the clinical MR system was equipped with a customized four-
channel phased-array receive-only radiofrequency (RF) coil assembly and a volume 
resonator was used for RF transmission (RAPID Biomedical, Rimpar, Germany). The RF 
assembly was complemented by an animal handling system including provisions for 
inhalational anesthetic supply and a feedback-regulated heating pad. T2 relaxometry was 
primarily used to detect subtle changes in edema dynamics at the infarct region and also 
at regions remote from the lesion site. To obtain normal control values, Tissue transverse 
(T2) relaxation times were estimated at the cortical and striatal regions of healthy male 
Sprague-Dawley rats (n=8), subsequently referred to as the ‘healthy' animal group. T2 
relaxometry was performed using a spin echo (SE) sequence with a repetition time (TR) of 
4,000 ms and data sets were acquired at 7 echo times (TE): 29, 58, 88, 117, 146, 175, and 
204 ms. Treated groups were subjected to serial MR imaging at pre-designated time 




TSE) sequences were used to visualize the temporal and spatial changes in vasogenic 
edema formation (T2 lesion).  
Figure 1: Schematic representation of the experimental design. Animals were subjected to 1 hour of 
ischemia followed by reperfusion. After 3 hours of reperfusion, intravenous infusions of pigment 
epithelium-derived factor, epidermal growth factor, or normal saline (control) was initiated and continued 
for 4 hours. Schedule of magnetic resonance imaging at 24, 48, 96 hours, and 1 week with respect to 
infarct evolution, blood–brain barrier permeability, and their probable underlying pathologic mechanisms 
are also provided. BBB, blood–brain barrier; MCAO, middle cerebral artery occlusion; MRI, magnetic 
resonance imaging. 
The sequence parameters were: TR = 3,000 ms, TE = 70 ms, field-of-view (FOV) = 2.5 cm2, 
image matrix (IM) = 128 × 128, and number of averages (NOA) = 4. Acquired images had 
an in-plane resolution of 200 μ and required an acquisition time of 5 minutes, 39 seconds. 
Contrast-enhanced T1-weighted SE sequences were obtained to determine BBB 
permeability to gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA), as described 
previously (10). The sequence parameters were: TR = 900 ms, TE = 10 ms, and NOA = 3; 
the FOV and IM were similar to the T2-TSE sequence. Acquired images had an in-plane 
resolution of 200 μ, requiring an acquisition time of 11 minutes, 34 seconds. 
To detect hemorrhage, susceptibility-weighted (T2*) gradient recalled echo images were 
obtained using the following sequence parameters: TR = 500 ms, TE = 30 ms, FOV = 5 cm2, 
IM = 256 × 256, and NOA = 2. Acquired images had an in-plane resolution of 200 μ and 
required an acquisition time of 4 minutes and 18 seconds. The slice thickness for all image 






Lesion volumes on T2-weighted images: T2-LVs were determined by manually outlining the 
lesion area with the aid of tools built into the Siemens SyngoMR 2004A software (Siemens 
Healthcare sector) and by multiplying the outlined area with the slice thickness. T2-LVs are 
then subsequently corrected for edema in the following manner. For each 1.5-mm-thick 
slice, the ‘original' hemispherical volume (HVo) could be determined from the total slice 
volume (TV) as this remains unchanged. 
HVo = TV/2 
The volume of the ipsilateral hemisphere (VIH) was also determined from T2-TSE images. 
An expansion factor (F) for the ipsilateral hemisphere due to edema can then be 
determined by the following: 
F = VIH/HVo 
The corrected T2-LV (LVc) is then provided by: 
LVc = T2LV/F 
and the derived LVc is then finally represented as a percentage of total brain volume. 
Characterization of edema formation: A two-tier approach was considered to characterize 
the time course of edema formation and resorption. In the first approach, we determined 
the difference between VIH and HVo (if any), and represented edema as a percentage 
increase in ipsilateral hemispheric volume represented in cubic centimeters. The second 
approach was based on quantitative T2 relaxometry, where the T2 relaxation times were 
derived from three adjacent slices and is then represented as a mean value. Those three 
slices were selected as follows; in all the treatment groups, the largest infarct volume was 
found at the slice located 6 mm posterior to the anterior tip of the frontal cortex. One 
slice preceding this (located at 4.5 mm) and another slice following this (located at 7.5 
mm) posterior to the anterior tip of the frontal cortex was then considered. 
Quantitative relaxometry was performed at three regions of interest (ROI). At the 
ipsilateral striatum, an ROI was defined over the hyperintense region depicted on the T2-
TSE image. An identical ROI was defined at the corresponding region on the contralateral 
side. Another ROI was also defined at the healthy ipsilateral cortex, well outside any 
region of infarction, if present. As the T2-LV was found expanded at 48 hours, the area of 




area remained the same for 48, 96 hours and 1 week). In situations involving those 
animals in which the 48-hour T2-LV was equal to or less than that at 24 hours, the area of 
the ROI measured at 24 hours was maintained identical throughout. 
In those cases in which hemorrhage was detected using T2*-gradient recalled echo 
sequences (Supplementary Figure S1), two strategies were considered. The first strategy 
was to completely exclude the slice in which hemorrhage was detected and rely on the 
average value of the other two slices. The second was to exclude the hemorrhagic region 
from the ROI and only consider the other region of the infarct. However, both techniques 
yielded similar if not identical values. Henceforth, data presented here consist of T2-LVs 
averaged from three slices, and in those cases in which hemorrhage was identified in any 
slice, the ROI was modified to selectively exclude that region. 
BBB permeability changes were characterized on identical slices as those considered for T2 
relaxometry. To analyze BBB permeability changes, digital subtraction maps from 
unenhanced and contrast-enhanced T1-weighted SE images were derived from the three 
slices to highlight regions of Gd-DTPA extravasation. T2-TSE images and subtraction maps 
were opened side-by-side on the viewer running Siemens SyngoMR 2004A software. 
Entire T2-LVs were selectively outlined following the same method as mentioned above. 
As the position of the animal within the scanner remained identical across image 
acquisitions, the corresponding region on the subtraction map was automatically selected. 
Furthermore, the same ROI was reproduced on the contralateral side to derive the 
corresponding values. The measured pixel intensity values (T1SIdiff) were then averaged for 
the three slices and were considered to represent the extent of Gd-DTPA extravasation or 
vascular reactivity. 
Throughout the study, values are expressed as mean ± s.d. Mono-exponential nonlinear 
curve fitting to determine the T2 relaxation values and statistical data analysis was 
performed using Graphpad Prism Version 5.00 for Windows (Graphpad Software, San 
Diego, CA, USA). Repeated-measures analysis of variance with Tukey–Kramer post-hoc 
tests were performed for within group comparisons at all time points. One-way analysis of 
variance with Tukey–Kramer post-hoc tests were performed for comparisons between all 
pairs of groups and Dunnett's multiple comparisons test was performed to compare 
values between the healthy animal and treatment groups. A P<0.05 was considered 
significant. 
RESULTS 




All animal groups demonstrated EB extravasation, as indicated by bluish-colored tissue 
after exposure to circulating EB. Representative images (Supplementary Figure S2) are 
provided. 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on Edema 
Corrected T2-LVs 
The preliminary study undertaken to determine the sample size yielded the following 
results. The PEDF and control groups had T2-LVs (uncorrected for edema) of 4.6 ± 1% and 
9.8 ± 3.9%, respectively. A sample size of 9 in each group had a 99% power to detect the 
difference in T2-LVs between the two means (5.2%) with a significance level (α) of 0.05 
(two-tailed). 
At all time points, the T2-LVs of the EGF and PEDF groups were significantly smaller 
(P<0.0001) than that of the control (saline) group. At 24 hours, T2-LVs of both EGF (5.26 ± 
1.01%) and PEDF (4.29 ± 0.73%) groups were significantly smaller (P<0.0001) than control 
(7.38 ± 0.98%). By 48 hours after reperfusion, T2-LVs of the control (10.36 ± 3.91%, 
P<0.001) and EGF group (6.7 ± 2.12%, P<0.05) increased significantly compared with 24 
hours after reperfusion, whereas there was an insignificant decrease in T2-LV (3.84 ± 
0.86%) of the PEDF group. All groups demonstrated a significant reduction (P<0.0001) in 
T2-LV by 96 hours, compared with 48 hours after reperfusion. These results are 









Figure 2: Schematic representation of the temporal changes in edema corrected infarct volumes as a 
percentage of the total brain volume across different treatment groups up to 1 week. After the delayed 
intervention with pigment epithelium-derived factor (PEDF) and epidermal growth factor (EGF) at 3 hours 




time points up to 1 week. Moreover, both the EGF and control groups demonstrated significant increases 
in T2 lesion volumes at 48 hours after reperfusion, which was completely arrested by PEDF treatment. 
***p<0.0001 control vs. EGF, PEDF groups (all time points); **p<0.001 vs. 24 h; *p<0.05 vs. 24 h; 
#p<0.0001 vs. 48 h.  
Figure 3: Representative T2-weighted turbo spin echo magnetic resonance images from the three 
different treatment groups at time points up to 1 week. Hyperintense regions of these images were 
manually outlined and were then corrected for edema. The hemispheric volumes were also determined 
from the same images to calculate the expansion factor (F) of the ipsilateral hemisphere due to edema, 
which was used later to derive the actual infarct volume. EGF, epidermal growth factor; PEDF, pigment 
epithelium-derived factor. 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on Edema 
Dynamics 
At 24 hours after reperfusion, the percentage increase in ipsilateral HVo attributed to 
edema formation in the control, EGF, and PEDF groups were 2.85 ± 2%, 3.26 ± 1.56%, and 
1.61 ± 0.55% respectively. By 48 hours, significant percentage increments were found with 
the control (5.14 ± 3.15%, P<0.001) and EGF (5 ± 2.52%, P<0.05) groups, compared with 24 
hours. The PEDF group demonstrated a nonsignificant increase (1.97 ± 0.87%) and this 
volume was significantly (P<0.05) lower than those of the EGF and control groups. At 96 
hours all the groups demonstrated significant decline [control (3.01 ± 2.1%, P<0.001), EGF 
(2.14 ± 2.13%, P<0.0001) and PEDF (1.15 ± 0.66%, P<0.05)] in edema volume compared 












Figure 4: Schematic representation of the temporal changes in ipsilateral hemispheric volumes 
(representing edema formation) across different treatment groups up to 1 week. After a delayed 
intervention with pigment epithelium-derived factor and epidermal growth factor at 3 hours after 
reperfusion, the epithelium-derived factor (PEDF) group demonstrated less edema at all time points and, 
moreover, the increase in edema formation at 48 hours when compared with 24 hours was non-
significant. EGF, epidermal growth factor. **p<0.001 vs. 48 h; *p<0.05 vs. 48 h; #p<0.001 vs. 48 h; 
***p<0.0001 vs. 48 h; # #p<0.001 vs. 48 h.  
At 24 hours after reperfusion, all the treatment groups demonstrated a significant 
elevation in T2 values (control (122.2 ± 27.04 ms, P<0.0001), EGF (130.7 ± 10.52 ms, 
P<0.0001), and PEDF (116.5 ± 8.56 ms, P<0.0001)) in comparison with the healthy animal 
group (83.21 ± 4.12 ms). By 48 hours, the T2 values of all the treatment groups were still 
significantly elevated compared with the healthy group (P<0.0001) and only the EGF group 
was found to have a significant reduction in T2 value (114.8 ± 12.58 ms, P<0.001) 
compared with 24 hours. At 96 hours after reperfusion, the T2 values continued to 
decrease for all the treatment groups compared with 48 hours but was significant only in 
those case with the neurotrophins (control 94.58 ± 16.29 ms, EGF 96.76 ± 5.72 ms, 
P<0.0001 and PEDF 92.17 ± 8.86 ms, P<0.0001). However, the T2 value of the EGF group 
remained significantly higher than that of the healthy group (P<0.001). These results are 
summarized in the Supplementary Figure S3. 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on Blood-Brain 
Barrier permeability at the Ipsilateral Striatum 
At 24 hours after reperfusion, the T1SIdiff values of the control, EGF, and PEDF groups were 
26.32 ± 6.3, 23.06 ± 2.8 and 13.74 ± 3.02, respectively. The T1SIdiff value of the PEDF group 




By 48 hours, the T1SIdiff values of the control (59.87±14.4, P<0.001), EGF (56.03 ± 21.49, 
P<0.0001), and PEDF (30.98 ± 8.52, P<0.0001) groups increased significantly compared 
with the 24-hour time point. However, the T1SIdiff value of the PEDF group remained 
significantly lower than the values of the control (P<0.0001) and EGF (P<0.001) groups.  
At 96 hours after reperfusion, a significant decrease in T1SIdiff value compared with the 
earlier time point was evident only with the PEDF group (17.99 ± 8.1, P<0.001). Moreover, 
the T1SIdiff value of the PEDF group remained significantly (P<0.0001) lower than that of 
the control group. By 1 week, only the T1SIdiff value of the control group (38.6 ± 10.34, 
P<0.05) decreased significantly. At the same time, the T1SIdiff value of the PEDF group 
remained significantly lower than that of the control (P<0.001) and EGF (P<0.001) groups. 
These data are schematically represented in Figure 5 and the subtraction maps of the 








Figure 5: Temporal profile of signal intensity (T1SIdiff) changes at the ipsilateral striatum of the different 
treatment groups at various time points. Delayed intervention with pigment epithelium-derived factor 
and epidermal growth factor at 3 hours after reperfusion resulted in a significant suppression of blood–
brain barrier permeability of the epithelium-derived factor (PEDF) group at all time points up to 1 week. 
No gross changes were observed with the epidermal growth factor (EGF) group during the considered 
time course. *p<0.0001 vs. EGF, PEDF at 24 h; **p<0.001 vs. 24 h; ***p<0.0001 vs. 24 h; #p<0.001 vs. 48 h; 










Figure 6: Subtraction T1-SE maps of different treatment groups at specific time points. Images provided 
for control (saline), pigment epithelium-derived factor, and epidermal growth factor groups at all time 
points up to 1 week were derived by subtracting the unenhanced T1-weighted images from the contrast-
enhanced T1-weighted images. EGF, epidermal growth factor; PEDF, epithelium-derived factor. 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on the 
Vasculature at the Contralateral Striatum 
On the basis of findings from a previous study (10), we also assessed the T1SIdiff value at 
the contralateral striatum. At 24 hours after reperfusion, T1SIdiff values at the contralateral 
striatum of the control, EGF, and PEDF groups were 12.4 ± 2.9, 14.26 ± 4.6, and 9.41 ± 2.7, 
respectively. The T1SIdiff value of the PEDF group remained significantly (P<0.05) lower 
than that of the EGF group. At 96 hours, the T1SIdiff value of the PEDF group remained 
significantly (P<0.001) lower than that of the EGF group. By 1 week after reperfusion the 
T1SIdiff value of the EGF group remained significantly higher than values of both the control 
(P<0.0001) and PEDF (P<0.0001) groups. These results are summarized in Figure 7. 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on T2 values at 
the Contralateral Striatum 
At 24 hours after reperfusion, the T2 value of the EGF group was significantly (89.41 ± 
5.6 ms, P<0.05) higher than the healthy (83.21 ± 4.1 ms) and control (77.66 ± 12.14 ms) 
groups. By 48 hours only the T2 value of the PEDF group increased significantly (88.44 ± 
5.1 ms, P<0.001) compared with the earlier time point. Moreover, the T2 values of the EGF 
(88.27 ± 7.1 ms) and PEDF groups were significantly higher (P<0.05) than both the healthy 
(83.21 ± 4.1 ms) and control groups (80.53 ± 8.3 ms). At 96 hours the T2 value of the EGF 




with the previous time point. By 1 week, the PEDF T2 value (88.59 ± 4.1 ms) remained 
significantly (P<0.05) higher than those of the healthy and control groups (80.99 ± 9 ms). A 









Figure 7: Temporal profile of signal intensity (T1SIdiff) changes at the contralateral striatum of the 
treatment groups at various time points. Delayed intervention with pigment epithelium-derived factor 
and epidermal growth factor at 3 hours after reperfusion also demonstrated significant changes in 
vascular reactivity. The control (saline) group presented with a rather constant value throughout all time 
points, whereas the epithelium-derived factor (PEDF) group had significantly lower values than the 
epidermal growth factor (EGF) group at all time points except 48 hours. Moreover, the EGF group values 
increased steadily from the 48-hour time point. *p<0.05 vs. EGF at 24 h; **p<0.001 vs. EGF at 96 h; 
***p<0.0001 vs. control and PEDF groups at 1 week.  
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on T2 values at 
the Ipsilateral Cortex 
At 24 hours after reperfusion, the cortical T2 value of the control group (85.16 ± 14.04 ms) 
was similar to that of the healthy group (83.87 ± 4.5 ms), whereas the cortical T2 values of 
the PEDF (91.4 ± 5.9 ms) and EGF (91.7 ± 6.3 ms) groups were significantly higher (P<0.05) 
than that of the healthy group. By 48 hours, only the T2 value of the PEDF group 
demonstrated a significant increase (97.59 ± 7.53, P<0.05) from the earlier time point. This 
value was also significantly higher than the healthy (P=0.0001), EGF (P<0.05), and control 
(P<0.05) groups. At 96 hours, the T2 value of the PEDF group (91.01 ± 4.6 ms) decreased 
significantly (P<0.05) compared with the earlier time point but still remained significantly 
higher (P<0.05) than the healthy group. By 1 week all the treatment groups exhibited 
similar values. From 96 hours up to 1 week, the PEDF T2 value remained significantly 
elevated than the healthy group (P<0.05). These data are graphically summarized in 





All the treatment groups were brought to a final strength of 10 animals each after 
mortalities and loss of animals due to experimental errors. In the control (saline) group, 
four rats died between 18 and 24 hours after reperfusion, probably because of vasogenic 
edema, one rat died because of air embolism during Gd-DTPA injection and two rats died 
of undetermined causes between 70 and 92 hours after reperfusion. In the EGF group, 
four animals died within 24 hours, probably because of vasogenic edema formation and 
another two animals died between 78 and 90 hours after reperfusion. In the PEDF group, 
one animal died of exsanguination within 24 hours because of an experimental error 
involving the internal CA. One rat died of an anesthetic overdose and another one was lost 
probably because of an air embolism. One more was found dead at 64 hours after 
reperfusion and the cause remains undetermined. 
DISCUSSION 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on Infarct 
Volume 
Reperfusion of the ischemic brain is the most effective therapy to date for acute ischemic 
stroke (15). Despite numerous studies in which neuroprotective compounds have been 
shown to reduce infarct volumes in animal stroke models and, in some instances, 
promising phase II results, no neuroprotective compound has proved efficacious on the 
basis of a positive phase III trial (16). In the present preliminary study, our aim was to 
investigate the protective properties of PEDF, if any, and compare the results with those 
obtained using EGF. Equimolar amounts of both peptides were administered during the 
early phase of BBB opening following reperfusion after 1 hour of ischemia (10,13). At 1 
week, infarct volumes in the PEDF and EGF groups were three and two times smaller, 
respectively, than those in the control (saline) group. 
PEDF, a 50-kDa glycoprotein also known as SERPIN-F1, has demonstrated profound trophic 
effects on neurons (17). The mechanisms by which PEDF exerts its protective effects 
suggest multiple modes of action. Pigment epithelium-derived factor was originally shown 
to induce a neuronal phenotype in retinoblastoma Y-79 cell line cultures and later to 
promote survival and protect cerebellar granule neurons in a rat primary culture from 
acute glutamate toxicity and apoptosis (18). PEDF also protects postnatal rat motor 
neurons from chronic glutamate-induced excitotoxicity and downregulates the pro-
inflammatory genes such as interleukin (IL)-1β, tumor necrosis factor-α, and macrophage 




cultured retinal pericytes, PEDF exerts anti-oxidative properties and suppresses ROS 
formation within microvascular endothelial cells (20).  
In contrast to PEDF, EGF is a potent mitogen that promotes cellular proliferation rather 
than maturation. Epidermal growth factor stimulates endogenous neural precursor cells at 
the subventricular zone and promotes tissue regeneration in animal models of stroke (21). 
Neurons within the MCA territory (lateral cortex and striatum) are rich in EGF receptors 
and are thus susceptible to administered EGF (22). The neuroprotective properties of EGF 
successfully prevent ferrous sulfate–induced lipid peroxidation and ensuing cell death in 
neuron cultures (23). Receptors for EGF, basic fibroblast growth factor (bFGF), BDNF, and 
NGF use similar downstream transduction pathways, and therefore it may be that EGF 
rescues ischemic neurons by enhancing activities of anti-oxidant enzymes, such as 
superoxide dismutase, glutathione peroxidase, and catalase (24).  
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on Edema 
Consistent with earlier findings (10), in this study tMCAO resulted in significant increases 
in T2 values indicative of vasogenic edema formation. In fact, the NTFs were unable to 
significantly reduce water content within the infarct region. However, edema as 
determined by changes in ipsilateral hemispheric volume readily exhibited effects of the 
various interventions. As expected, the PEDF group not only possessed lower edema 
volumes at all time points but also displayed significant suppression of edema formation 
at 48 hours. A reduction in vasogenic edema by PEDF was also observed with other 
models of experimental ischemic stroke (25) and cold brain injury (26). Overexpression of 
PEDF in a rodent model of tMCAO blocked the increased expression of aquaporin-4 mRNA 
associated with edema reduction (25). Intraperitoneal administration of PEDF in a mouse 
model of cold brain injury also led to edema reduction mediated by suppression of Rac-1 
activation, essential for NADPH oxidase activation (26). Moreover, PEDF has been shown 
to stabilize actin, maintain normal membrane occludin and N-cadherin structure, and thus 
preserve the endothelial tight junction (TJ) function of retinal pigment epithelial cells 
against oxidative stress (27). All these properties of PEDF may act in concert to reduce 
early deleterious effects of I/R injury. 
It is noteworthy that even though the percentage increase in ipsilateral HVo in the control 
and EGF groups peaked at 48 hours, indicating maximal edema accumulation, the T2 
values derived from the infarct regions of these groups demonstrated a decrease. T2 
values are influenced by many factors, including flow effects, altered levels of oxy- and 
deoxyhemoglobin, tissue oxygenation, and exchange of nuclear spin magnetization 




reperfusion time point (when the BBB remains open) also contains protein molecules and 
its infiltration not only increases water content but also the number of macromolecular 
surfaces available thereby lessening the change in relaxation rates that would be observed 
with the same increase in water alone (29). This mechanism may be the most probable 
reason for the reduction in T2 relaxation values observed at these times. 
Gross anomalies between T2 relaxation values and ipsilateral hemispheric volumes were 
not observed further and the data remains mutually compatible during subsequent time 
points even though the underlying causative mechanisms may have varied. A reduction in 
water content attributed to edema resorption is mediated by a variety of mechanisms 
including uptake of extravasated proteins by glial cells and the subsequent reduction in 
oncotic force, migration of edema into cerebrospinal fluid spaces, and effects from 
proliferating endothelium (10). Even though these factors primarily mediate the reduction 
in T2 values and ipsilateral hemispheric volume, other factors, such as necrotic tissue and 
extravasated protein clearance from the infarct region by infiltrating macrophages and 
activated microglial cells, can also have a role in altering T2 relaxation characteristics (30).  
Temporal Profile of Blood-Brain Permeability Changes at the Ipsilateral Striatum 
The 24-hour post reperfusion time point represents a phase where the BBB permeability is 
minimal for Gd-DTPA (10). PEDF demonstrated an additional suppression of permeability 
even at this early time point. The reasons behind this are believed to reside with the three 
distinct properties of PEDF; as an anti-oxidant, an anti-inflammatory agent and protective 
for TJ proteins such as occludin and cadherin (20,31). Considering the effect of ROS on TJ 
proteins, it is not surprising that an agent with anti-oxidant properties demonstrates a 
significant reduction in barrier permeability. Inflammatory mediators such as thrombin, 
histamine, and bradykinin can also cause BBB permeability changes by actin 
polymerization-dependent endothelial cell rounding resulting in increased inter-
endothelial gaps (10). As PEDF stabilizes actin and inhibits inflammatory processes, these 
mechanisms can be additive and act in a synergistic way to minimize barrier permeability. 
The dramatic increase in BBB permeability after I/R injury at 48 hours seems to 
correspond with the time course of the angiogenic response mediated by the vascular 
endothelial growth factor (VEGF) (32). Vascular hyperpermeability is intricately associated 
with and is inherent to progressive pathologic angiogenesis, marked by leaky vessels and 
increased permeability to macromolecules and water, and resulting in an uncontrolled 
delivery of solutes to the tissue (33). A wealth of data indicates PEDF as an inhibitor of 
vascular permeability and angiogenesis. PEDF counteracts VEGF-induced vascular 




inducers including platelet-derived growth factor, VEGF, IL-8, acidic FGF, and 
lysophosphatidic acid (34,35). VEGF exacerbates degradation of occludin and zona 
occludens-1 in vitro, and the loss of these proteins increases BBB leakage in the human 
brain (36). Of the three proposed mechanisms underlying angiogenesis, such as sprouting, 
intussusception, and recruitment of endothelial progenitor cells, VEGF-induced sprouting 
mediated through VEGF receptor-2 is invariably accompanied by increased permeability 
(33,37). In-vitro studies demonstrate that PEDF downregulates VEGF expression and 
competes with VEGF binding to VEGF receptor-2, thereby adding multiple pathways to 
inhibit the barrier permeability mediated by VEGF (31).  
VEGF also promotes proliferation of vascular endothelial cells and these activated 
endothelial cells upregulate surface Fas, thereby becoming sensitive to apoptosis when 
the Fas ligand is activated by inhibitors such as PEDF (38). Fas-mediated signaling mainly 
induces procaspase-8 auto-proteolytic cleavage, although it may subsequently cause 
activation of procaspase-9. PEDF increases the expression and transcriptional activity of 
peroxisome proliferator-activated receptor-γ (PPARγ) in human umbilical vein endothelial 
cells and PEDF’s action on PPARγ results in apoptosis of endothelial cells perhaps 
mediated through p53. Researchers have also demonstrated that an inhibitor to p38 
mitogen-activated protein kinase extensively blocks PPARγ mRNA and protein expression 
(39). The aforementioned properties of PEDF involved in ameliorating vascular 
permeability and angiogenesis may act in concert to arrest the progression of infarct 
volume while suppressing BBB permeability and edema formation. 
Effect of Epidermal Growth Factor and Pigment Epithelium-Derived Factor on Edema at 
Remote Sites 
Throughout the experiment, those animals receiving growth factor therapy selectively 
demonstrated significant elevations in T2 values at distant regions away from the site of 
infarct. Even though the precise underlying mechanisms remain unknown, we suspect that 
the movement of protein-rich edematous fluid from the lesion site to other regions 
(routed protein migration) is mediating this remote edema formation as stated previously 
(10). Elevated T2 values in the EGF group were observed relatively early, at 24 hours, 
whereas a persistent T2 value elevation was observed with PEDF. Epidermal growth factor 
possesses a low tortuosity (λ) value of 1.8 and this low resistance to migration may cause 
the elevated T2 value as seen at the early time point of 24 hours (40). Eight times heavier 
than EGF, PEDF might have induced a rather persistent elevation in T2 values as observed 
with this group. As the core body temperatures of all animals were maintained at 37.5–




investigation of the underlying cause was beyond the scope of this work as further efforts 
are required in this direction to clarify the observed increase in T2 values. 
Temporal Profile of T1SIdiff Changes at the Contralateral Striatum 
The fact that the T1SIdiff values were lower for the PEDF group than the EGF group, 
especially at later time points, when the values of the EGF group were increasing 
significantly presents an interesting insight into the persistent effects of PEDF. It has been 
reported that PEDF may reduce edema by interfering with the VEGF–NADPH oxidase 
pathway (26). ROS may serve as important signaling molecules in the cerebral circulation 
and, in contrast to systemic arteries, major products of superoxide metabolism, such as 
hydrogen peroxide, are powerful cerebral vasodilators raising the possibility that ROSs 
represent important molecules for increasing local cerebral blood flow (41). In cerebral 
arteries, NADPH oxidases along with cyclooxygenases and lipoxygenases, are considered 
the probable primary sources of ROS formation and activation of NADPH oxidase elicits 
both an increase in superoxide production and vasodilatation. 
PEDF’s anti-oxidant properties coupled to inhibition of the VEGF–NADPH oxidase pathway 
could effectively suppress the vasodilatory mechanism. Epidermal growth factor acting 
through the mitogen-activated protein kinase signaling cascade has already demonstrated 
a dose- and time-dependent increase in the endothelial nitric oxide synthase levels (42). 
Our earlier work also demonstrated such a vasodilatory effect from repeated exposures to 
isoflurane at the scanner (10). Thus, treatments with EGF and exposure to isoflurane may 
be additive in inducing endothelial nitric oxide synthase and resulting in the observed 
T1SIdiff increase attributed to cerebral vasodilatation. 
CONCLUSION 
To the best of our knowledge, this is the first study in which the protective properties of 
systemic PEDF were evaluated in a rodent model of transient ischemic stroke. Although 
neuroprotection is warranted immediately during or after injury, the relatively late 
intervention at 3 hours after reperfusion by selected NTFs at the time of the first BBB 
opening demonstrated protective effects after I/R injury, as evident from reduced T2-LVs 
and edema formation. The potent anti-angiogenic action of PEDF is probably the key 
factor behind the arrested infarct volume expansion observed at 48 hours after 
reperfusion. However, additional investigations are required to clarify the impact of a 
persistent inhibition of BBB permeability and/or angiogenesis because this would impact 
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Figure S1. Representative susceptibility (T2*)-weighted gradient recalled echo (GRE) images from 
different treatment groups at specific time points. GRE images were primarily used for spatial localization 
of hemorrhagic transformations (arrows) within the T2-infarct volume. T2 relaxometry was performed at 
the infarct region after selectively excluding those regions of hemorrhage from the region of interest (ROI) 








Figure S2. Representative images of brain slices depicting bluish tissue following Evans blue 
extravasation at different postreperfusion time points. To ensure entry of trophic factors into the brain 
parenchyma, Evans blue (EB) was intravenously administered and allowed to circulate for 1 hour 3, 6, and 
8 hours after reperfusion following 1 hour of ischemia. The bluish color represents the extravasated EB-












Figure S3. Temporal profile of T2 values at the infarct region of different treatment groups in 
comparison with the corresponding region in the healthy animal group up to 1 week. Following a 
delayed intervention with pigment epithelium-derived factor (PEDF) and epidermal growth factor (EGF) at 
3 hours postreperfusion, the evolution of the infarct volume differed significantly between groups (refer 
to text for additional details). T2 relaxometry was performed within the infarct regions to detect subtle 
changes in water content because that invariably occurs during edema resorption accompanying tissue 
repair. **p<0.0001 vs. 24 h; ***p<0.0001 vs. healthy; *p<0.05 vs. healthy.  
Figure S4. Temporal profile of T2 values in the contralateral striatum of healthy animals and animals in 
the various treatment groups up to 1 week. Delayed administration of pigment epithelium-derived factor 
(PEDF) and epidermal growth factor (EGF) at 3 hours postreperfusion resulted in significant alterations in 
transverse (T2)-relaxation times in the contralateral striatum. Even though direct experimental evidence 
from this work is lacking, we speculate that migration of protein-rich edematous fluid from the infarct site 
may be the principal mediator of the observed elevation in T2 values. *p<0.05 vs. control and healthy 









Figure S5. Temporal profile of T2-values at the ipsilateral cortex of healthy animals and animals in the 
various treatment groups up to 1 week. Delayed administration of pigment epithelium-derived factor 
(PEDF) and epidermal growth factor (EGF) at 3 hours postreperfusion resulted in significant alterations in 
transverse (T2)-relaxation times in the ipsilateral cortex. In the absence of direct experimental evidence, 
we speculate that the migration of protein-rich edematous fluid from the infarct site may be the principal 
mediator of the observed elevation in T2 values. *p<0.05 vs. healthy group; **p<0.05 vs. PEDF at 24 h; # 
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Background: SUL121, a novel 6-chromanol-substituted compound has been shown to 
exert protective effects in various in vitro and in vivo models of oxidative stress and 
inflammation. We therefore hypothesized a similar effect to mitigate focal cerebral 
ischemia-reperfusion in a rodent model.  
Methods: Transient middle cerebral artery occlusion (tMCAO, 2/22h) using an 
intravascular filament approach was induced in adult Sprague-Dawley rats. Intravenous 
bolus (200 μg/kg) followed by a slow infusion initiated 30 min before MCAO (25 
μg/kg/min) of either saline or SUL121 was administered until reperfusion under low 
isoflurane anesthesia. All animals were euthanized 24 h post MCAO. Ischemic damage was 
quantified using silver nitrate staining. Oxidative stress was assessed by the 
malondialdehyde assay. Immunoblotting was carried out to evaluate brain damage 
markers and H2S synthesizing enzymes (CBS, 3-MST). Contractile and relaxant effects were 
studied in aorta using isometric vessel set up.  
Results: SUL121 mitigated cerebral ischemic damage and hemispheric swelling in 
comparison to the controls (p<0.01). However, the variable infarction that developed in 
both saline and SUL121 treated rats did not produce significant differences at the level of 
ROS, ER stress, early immediate gene induction and anti-apoptotic pathways, and effects 
of SUL121 on those could thus not be assessed. With respect to H2S-synthesizing enzymes, 
infarction lowered the levels of 3-MST, while the expression level of CBS was upregulated 
by SUL121 in the ischemic brain. Finally, SUL121 treatment alleviated the impairment of 
ACh-evoked, NO-mediated aortic relaxation observed in saline treated animals.  
Conclusion: The variable induction of ischemia in both study groups precluded the firm 
assessment of SUL121 in our model. Nevertheless, lower infract volume, upregulation of 
CBS and improvement of ACh-mediated relaxation, possibly by maintenance of the H2S 
signaling cascade and its interaction with NO, could have potential therapeutic 









Ischemic stroke is one of the most frequent causes of adult disability worldwide. The 
currently available thrombolytic therapy using recombinant tissue plasminogen activator 
(rtPA) has been the mainstay in treating this condition (1), albeit with a narrow time 
window of up to 4.5 h from symptom onset (2). Several novel cerebroprotective agents 
have been tested and proved successful in various pre-clinical models of ischemic stroke in 
the quest to alleviate cerebral infarction and thereby to improve neurological outcome 
(3). However, translation to clinical care has met little success due to the complex 
pathophysiological mechanisms of infarct development and repair, warranting the 
exploration of novel therapeutic approaches.  
Hibernating animals endure ischemia/reperfusion-like phases. These phases are primarily 
cycles of suppressed metabolism along with a reduced core body temperature and 
cerebral blood flow to near-ischemic levels (4), interspersed with short duration of 
complete reversal of metabolism and body temperature. Nevertheless, animals endure 
hibernation without signs of organ damage. Hydrogen sulfide (H2S) signaling and its 
substrates have emerged as key protective compounds in hibernation, possibly by serving 
as an electron donor to replenish ATP in the presence of reduced oxygen uptake (5,6). 
Cystathionine β-synthase (CBS), 3-mercaptopyruvate sulfurtransferase (3-MST) and 
cystathionine γ-lyase (CSE) are the main enzymes involved in the production of H2S in 
mammals. Notably, the CBS/H2S signaling cascade has been shown to protect cells from 
cooling and rewarming injury (7). Further, CBS is upregulated in lung during the 
hypometabolic phase of hibernation (7) and has been implicated in reversible lung tissue 
remodeling during hibernation (5).  
However, the ability to produce H2S is not limited to the lung. In the central nervous 
system (CNS), H2S is produced predominantly by CBS and 3-MST. In conditions of 
hypoxia/ischemia with disrupted cellular energy homeostasis and metabolism as evident 
in stroke, H2S could play a key role in protecting tissue from undergoing irreversible 
damage. The role of H2S signaling in pre-clinical models of CNS disorders including brain 
ischemia and trauma has however yielded somewhat controversial results. In several 
models of focal cerebral ischemia, exogenous administration of H2S-donors was found to 
mitigate ischemic damage by inhibition of apoptosis, oxidative stress, inflammation and 
maintaining blood-brain barrier integrity (8-12). Previously, Qu and co-workers (2006) (13) 
reported increased cortical levels of H2S in a permanent model of MCA stroke under 
ketamine-xylazine anesthesia. However, infarct size aggravated further upon treatment 
with sodium hydrogen sulfide (a H2S donor). Recently, it was shown that increased brain 




Recently, we developed chromanol-based compounds, including one indicated as SUL121 
(Fig. 1A, Sulfateq BV, Groningen, the Netherlands), which alleviate cell damage in various 
conditions of oxidative stress. SUL121 has been found to prevent kidney damage in 
hypothermic rat and to reduce bronchoconstriction and inflammation in 
lipopolysaccharide (LPS)-induced lung injury in guinea pig. Moreover, we found SUL121 to 
improve cell survival in hypothermia-rewarming induced microglial cell injury (Shanbhag 
et al., unpublished). Maintenance of the function and expression of CBS and 3-MST, 
resulting in preserved H2S production, has been coined as one of the potential 
mechanisms underlying the protective effects of SUL121, as found in hypothermic injury in 








Figure 1: (A) Chemical structure of SUL121. (B) Schematic outline of experimental design. Treatment was 
initiated with an I.V. bolus of saline or 200 μg/kg SUL121 via a tail vein catheter followed by a slow 
infusion of either normal saline or SUL121 (started 30 min before MCAO, 25 μg/kg/min, at the rate of 1 
ml/hr). Animals were subjected to 2 h of brain ischemia followed by reperfusion. The whole procedure 
was carried out under isoflurane anesthesia. Upon reperfusion, the infusions with either saline or SUL121 
were discontinued. Euthanization was carried out 24 h post MCAO by in situ perfusion with normal saline 
and relevant organs were isolated. (C) Frozen brain slices were obtained using a cryotome, with an 
interslice distance of 1 mm (20 μm thick) extending fronto-occipitally and quantified using silver nitrate 
staining. Tissue in between the slices at each section level were subsequently divided into ischemic and 
contralateral hemispheres and collected in separate vials for molecular studies. I.V., intravenous; MCAO, 
middle cerebral artery occlusion; REP, reperfusion.   
Based on its action in these models, we hypothesized that SUL121 limits ischemic damage 
in a rat model of ischemic stroke. In addition to neuronal cell death, stroke per se can 
trigger a systemic inflammatory response and influence systemic vascular reactivity. The 
associated cytokine release and generation of reactive oxygen species (ROS) may affect 




influence ischemic damage. Most of the therapeutic agents tested in pre-clinical models of 
stroke (focal ischemic damage) have focused primarily on mitigating cerebral ischemic 
damage without assessing their systemic vascular and/or organ specific effects, if any. We 
therefore set out to study changes in cerebral expression of H2S synthesizing enzymes and 
investigate putative protective effects of SUL121 in a rat model of transient focal cerebral 
ischemia. Moreover, we studied whether stroke and the treatment influence the systemic 
vascular function by examining vascular reactivity in aortic rings.  
MATERIALS & METHODS 
Animals 
Adult male Sprague-Dawley rats (280-350g) obtained from Harlan (Horst, The 
Netherlands) were used. The animals were kept under standardized housing conditions for 
at least one week before the start of the experiment, with free access to standard chow 
and water. All experimental procedures were performed in accordance with the Dutch 
animal laws and institutional guidelines (DEC 6862A). 
Induction of transient ischemic stroke 
Right-side transient middle cerebral artery occlusion (tMCAO) was produced as previously 
described (15) with some modifications. Under isoflurane anesthesia (1.5-2 %), MCAO was 
induced by inserting a 4-0 monofilament coated with silicon at its tip into the proximal 
external carotid artery (ECA), navigated into the internal carotid artery and pushed 
forward until the origin of MCA. The completeness of occlusion was achieved under the 
guidance of Doppler flow probe (Perimed Instruments, Jarfalla, Sweden) placed over a 
shallow drilled burr hole positioned 5 mm lateral and 2 mm posterior to the bregma. Rats 
were included in the study if MCAO reduced laser Doppler flow (LDF) by > 50% from 
baseline. Upon achieving successful occlusion, the filament was secured tightly in the ECA 
stump, the animal turned to a prone position and allowed to undergo 2 h of occlusion 
maintained under low isoflurane anaesthesia (0.8–1%) until removal of the filament to 
establish reperfusion. This low maintenance of anesthesia was undertaken to instil 
relevant therapeutic agent(s) as a slow intravenous (I.V.) infusion as stated below. Peri-
operative monitoring of heart rate, peripheral oxygen saturation (Nonin Med Inc., 
Plymouth, MN, USA) and body temperature was carried out.  
Experimental groups & drug administration 
Animals undergoing transient MCA occlusion (2h) followed by reperfusion (22h) were 




animals received either normal saline or SUL121 via a tail vein catheter. SUL121 was 
dissolved in normal saline and administered as a bolus (200μg/kg) followed by a slow 
intravenous infusion (25μg/kg/min, 1ml/hr) initiated 30 min before onset of occlusion and 
continued until reperfusion as shown in the scheme (Fig. 1B).  
Termination of experiments 
Twenty-four hours post occlusion, the animals were deeply anesthetized using isoflurane 
and sacrificed by severing the inferior caval vein and in situ perfusion via the abdominal 
aorta with ice-cold normal saline until the venous outflow was clear. Blood was withdrawn 
from the aorta before initiating the in situ perfusion. Brain was isolated and snap-frozen in 
liquid nitrogen and stored at -80°C until further analysis. In addition, aorta was collected 
and stored separately in Krebs solution as described below.  
Ischemic damage assessment 
For quantitative determination of ischemic damage coronal cryosections were obtained at 
regular intervals. The sections were transferred onto glass slides, air-dried, and fixed with 
paraformaldehyde. The presence of ischemic damage was determined in each section 
using silver nitrate staining as described previously (16). The slides were scanned and the 
extent of damage quantified using ImageJ (free-ware available under 
http://rsbweb.nih.gov/ij/docs/guide/index.html). Finally the volume of hemispheric 
ischemic damage was calculated along the fronto-occipital axis and corrected for brain 
swelling (Fig. 1C). 
Reactive oxygen species measurement  
During cryosectioning of brain, the tissues in between the sections taken for silver nitrate 
staining were dissected and the ischemic and contralateral hemispheres collected in 
respective vials for molecular analyses. Samples from individual hemispheres were 
homogenised with phosphate buffered saline (PBS) containing butylated hydroxytoluene 
(100x BHT, Cell Biolabs, Inc. Netherlands) on ice and centrifuged (10,000 g, 5 min, 4 °C).  
From each sample 100 μl of the supernatant was taken and mixed with the same volume 
of SDS-Lysis solution. The mixture was incubated at room temperature for 5 min before 
addition of 250 μl of thiobarbituric acid (TBA) reagent. This mixture was incubated at 95 °C 
for 60 min, quickly cooled down to room temperature and centrifuged (1000 g, 15 min). 
The supernatants were then transferred to a 96-well black fluorescence microplate for 
measuring the optical density (BioTek Synergy 4 plate reader; excitation and emission 




prepared in the same manner as described above for the tissue samples and used to 
generate a standard curve. Levels of reactive oxygen species were expressed as micromole 
of MDA per milligram of tissue protein concentration. Tissue protein concentration was 
determined using a Biorad assay kit, as per the manufacturer’s guidelines (Bio-Rad, 
Germany).  
Western blotting 
Frozen brain tissue samples were homogenized in 450 μl RIPA buffer, containing protease 
inhibitor cocktail, sodium orthovanadate, sodium fluoride and β-mercaptoethanol (all 
from Sigma Aldrich, The Netherlands) prepared according to the manufacturer’s 
instructions (Roche, The Netherlands). After 30 min of incubation on ice, all homogenized 
samples were centrifuged at 14,000 g for 20 min at 4 °C. Supernatants were collected and 
protein concentrations determined as mentioned above. Samples were boiled for 5 min 
before loading onto the pre-casted SDS-polyacrylamide gel. The gel electrophoresis was 
carried out at 100 V for 70 min using 30 μg of each protein sample. Proteins were 
subsequently blotted onto nitrocellulose membranes using a transfer buffer solution 
containing 0.25 mM Tris (pH 8.5), 192 mM glycine and 10 % v/v methanol at 4 °C for 60 
min at 0.3 mA. Thereafter, the membranes were blocked in 5% w/v skimmed milk 
dissolved in TBST buffer (containing 50mM Tris-HCl, pH 6.8, 150mM NaCl, 0.05 % v/v 
Tween-20). Subsequently, the membranes were incubated overnight at 4 °C with one the 
following antibodies diluted in 5% BSA (w/v) + TBST solution: anti-phospho-eIF2α (ab5369, 
Abcam, UK), anti-phospho c-Jun (#9261, Cell Signaling Technology), anti-Iba1 (016-20001, 
Wako), anti-CBS (sc-271886, Santa Cruz), anti-3MST (HPA 001240, Sigma) and anti-Mn 
SOD (ADI-SOD-111D, Enzo). After overnight incubation, the membranes were washed 3 
times in TBST buffer and incubated with HRP-linked polyclonal secondary antibodies 
(Dako, Denmark) in 5% BSA-TBST solution for 1 h. Blots were developed using the Western 
Lighting Ultra (Perkin Elmer Inc., USA) substrates according to the manufacturer’s 
guidelines. Protein bands were visualized using the Gene Genome system (Westburg BV, 
The Netherlands) and intensities quantified using Gene Tools software. β-actin was used 
as house keeping protein to normalize protein expression.  
Vascular reactivity 
Vascular responses were measured in rat thoracic aortic rings (n=3 in each of the study 
groups) using an isometric vessel setup.  Aorta was cleaned from the surrounding fat 
tissue and dissected into 1.5-2 mm long rings and mounted into baths containing Krebs 
solution, containing (in mM): 120.4 NaCl, 5.9 KCl, 2.5 CaCl2, 1.2 MgSO4, 25.0 NaHCO3, 1.2 




with 95% O2/5 % CO2 at pH 7.4. All vascular reactivity studies were carried out in aortic 
rings with intact endothelium. Before initiating the measurements, aorta rings were 
allowed to equilibrate for an hour, followed by two consecutive exposures to potassium 
chloride (KCl, 60 mM prepared in physiological salt solution maintaining its osmolarity 
with NaCl). Vascular contraction was assessed by obtaining cumulative dose response 
curves to phenylephrine (PE, 10-9 to 10-3 mol/L) and expressed as percentage of the 
second KCl Krebs-induced contraction. Vascular relaxation and contribution of different 
vasodilators was assessed in rings pre-contracted with PE (10-6 mol/L) by obtaining 
cumulative dose response curves to acetylcholine (ACh, 10-9 to 10-5 mol/L), in absence and 
presence of L-NG-Nitroarginine methyl ester (LNAME, a NO-synthase blocker, 10-4) and/or 
indomethacin (INDO, a cyclooxygenase inhibitor, 10-4). Following the final dose of ACh, 
maximal endothelial-independent relaxation was measured in the aorta by application of 
NO-donor sodium nitroprusside (SNP, 10-5). Vascular relaxation was expressed as 
percentage of SNP relaxation.  
Statistical analysis 
Data are expressed as mean ± SD. Hemispheric damage and edema between control and 
treated groups were compared with two-tailed t-test. Two-way ANOVA analysis was used 
in comparisons for infarcted/contralateral hemispheres versus saline/SUL121 treatment. 




One out of the 6 CON animals died due to subarachnoid hemorrhage at the base of the 
brain during the filament insertion as evident from the course of the laser Doppler 
flowmetry signal and confirmed on post-mortem examination. All of the other animals 
survived the 2 h occlusion followed by 22 h reperfusion period. One out of 7 animals in the 
SUL121 group showed a drop of LDF smaller than 50 % from the baseline upon MCAO. 
Both animals were excluded from the study. Consequently, animal groups constituted of 
n=5 in CON and n=6 in the SUL121 group.  
Perioperative characteristics 
Body temperature, oxygen saturation and heart rate remained within physiological limits 




resulted in a significant and comparable reduction of laser Doppler flow (LDF) in both 
groups (Fig. 2).  
Table 1: Peri-operative monitoring of body temperature, oxygen saturation and heart rate  
 
Figure 2: Blood flow measurements by laser Doppler flowmetry 
(LDF) prior to, during and after the MCAO. Various time points 
depicted (1-5) are as follows: 1= baseline, 2= upon MCAO, 3= 1 h 
post MCAO, 4= before reperfusion, 5= upon reperfusion. A drop 
≥ 50 % of the baseline was considered as a successful occlusion. 
MCAO, middle cerebral artery occlusion; CON, control; SUL, 
SUL121-treated group. Values are calculated as percentage drop 
from the initial baseline and represented as mean ± SD. 
SUL121 mitigates cerebral ischemic/reperfusion-induced damage 
In our study, tMCAO led to small infarct sizes with a considerable variation in both groups. 
Two animals in the CON (2/5) and 4 animals in SUL121 (4/6) groups did not show a 
detectable ischemic damage as assessed by silver nitrate staining. This difference proved 
to be statistically significant. In addition, there was also a significantly reduced degree of 






Figure 3: Hemisperic ischemic damage (A) and brain swelling (B) in control (CON) and SUL121-treated 




Effect of SUL121 on cerebral oxidative stress, immediate early gene induction & 
inflammation 
Due to a potential interference of the use of isoflurane leading to a variable ischemic 
damage in our study groups, the analyses of infarcted versus non-infarcted animals would 
have led to a too low number of animals in the respective groups failing to identify 
possible treatment effects on various molecular markers of brain damage. We therefore 
employed two-way ANOVA to reveal treatment effects by comparing both treatment 
groups and infarcted versus contralateral hemispheres.  
Figure 4: Brain damage markers in control and SUL groups. (A) Oxidative stress (MDA levels), (B) ER stress 
(phospho-eIF2α), (C) immediate early gene activation (phospho-c-Jun), (D) microglial activation (Iba-1), 
and (E) anti-apoptotic phenotype (Mn-SOD) did not show any significance difference between the study 
groups. MDA, malondialdehyde; PC, positive control (LPS-stimulated microglial cells); ER, endoplasmic 
reticulum; Mn-SOD, manganese superoxide dismutase; Iba-1, ionized calcium-binding adaptor molecule 1. 
*p<0.05 ischemic vs. contralateral hemisphere. ISCH, ischemic hemisphere; CONTRA, contralateral 
hemisphere.  
Reactive oxygen species (ROS) could not be quantified, as the level of MDA was below its 
detection level in both treatment modalities and in both hemispheres (Fig. 4A). In line 
with undetectable ROS levels, the ischemic animals did not show induction of ER stress as 
assessed by the level of phopho-eIF2α (Fig. 4B). The expression of the immediate early 
gene, phospho-c-jun was observed to be significantly increased upon SUL121 treatment in 
ischemic as compared to the contralateral hemisphere (Fig. 4C). Nonetheless, the 
microglial activation marker (Iba-1) was unaffected, as was the expression level of Mn-
SOD, a key component of mitochondrial matrix (Fig. 4D, E).  Taken together, extensive 
analysis of brain damage markers failed to disclose marked differences between infarcted 




Regulation of H2S during stroke and the effect of SUL121 
In addition to damage markers, 2 key enzymes involved in H2S production in the brain 
were quantified using western blotting, i.e. CBS and 3-MST. SUL121 treatment significantly 
upregulated CBS expression in the ischemic brain compared to CON group (Fig. 5A, 
p<0.05, two-way ANOVA). The intra and inter-hemispheric differences were not evident in 
both the groups which can be attributed to a variable infliction of ischemic damage. On 
the other hand, infarction lowered the expression of 3-MST when compared to 






Figure 5: CBS and 3-MST expression level in brain following transient MCAO. SUL121 treatment resulted in 
a significant upregulation of CBS in comparison to vehicle treated groups (A). Contrary, infarction 
downregulated 3-MST level in comparison to contralateral hemispheres in both the groups (B). **p<0.05 
for CBS in SUL121 (SUL) vs. vehicle-treated (CON) groups (two-way ANOVA with Bonferoni’s test). #p<0.05 
vs CON-ischemic hemisphere; ##p<0.05 vs SUL-ischemic hemisphere (repeated measures ANOVA). Values 
are represented as mean ± SD. ISCH, ischemic hemisphere; CONTRA, contralateral hemisphere. 
SUL121 improves aortic relaxation function 
Vascular contraction and relaxation was assessed in aortic rings by obtaining cumulative 
dose response curves to phenylephrine (PE) and acetylcholine, respectively. Treatment 
with SUL121 did not affect contraction to PE (Fig. 6A), but significantly improved ACh-





Figure 6: Effect of SUL121 treatment on contractile and relaxant response in aorta of tMCAO rats. (A) 
SUL121 treatment did not affect PE-mediated contractile responses in comparison to vehicle treated 
(CON) group, while it improved the ACh-mediated aortic relaxation (B). Preincubation of aortic rings with 
L-NAME, in absence (C) and presence of INDO (D) normalize relaxation of SUL121 treated rat to that of 
vehicle infused rats. *p<0.05 vs 1.0 x 10-5 M, **p<0.05 vs 3.0 x 10-5 M CON+VEH groups. Values are 
represented as mean ± SD. Statistical significance was determined by a two-way repeated measures 
ANOVA with Bonferoni’s test. PE, phenylephrine; ACh, acetylcholine; L-NAME, L-N-Nitroarginine methyl 
ester; INDO, indomethacin. n=3 in each of the study groups.  
To explore if and which endothelial component contributed to the improved relaxation, 
dose response curves to ACh were obtained in the presence of the NO synthase blocker (L-
NAME, 10-4 mol/L) and in the presence of L-NAME and the COX inhibitor, indomethacin 
(INDO, 10-4 mol/L). Endothelial blockade of NO with L-NAME decreased the vasorelaxant 
reactivity in CON and SUL groups and abrogated the difference in relaxation between both 
groups (Fig. 6C). Preincubation with INDO, in presence of L-NAME, appeared to reduce 
vasorelaxation more in the aortas of SUL121-treated animals in comparison with vehicle-
treated group  (Fig. 6D). Thus, cerebral ischemia resulted in impairment of NO-mediated 
vasorelaxant reactivity in rat aortas, which was precluded by SUL121. Further, 







In the current study we explored the putative protective action of SUL121 in a rat focal 
cerebral ischemia/reperfusion model and also assess its impact on systemic vascular 
function. SUL121 belongs to a novel class of chromanol-based compounds which was 
proven to mitigate oxidative stress and inflammation in cellular injury models (such as 
hypothermia-rewarming) as well as in in vivo models of bronchial inflammation, forced 
hypothermia-rewarming and diabetes. In most instances, SUL121 has been shown to 
influence H2S signaling, particularly maintaining the expression of the enzymes involved in 
its production. Here we found SUL121 to mitigate the cerebral ischemic damage and 
hemispheric swelling in comparison to the controls. However, infarction itself did not 
produce significant differences at the level of ROS, ER stress, early immediate gene 
induction and anti-apoptotic pathways, and effects of SUL121 on those could thus not be 
assessed. With respect to H2S-synthesizing enzymes, infarction lowered the levels of 3-
MST, while the expression level of CBS was upregulated in the ischemic brain globally by 
SUL121 treatment. Finally, SUL121 increased endothelium dependent vascular relaxation 
by preserving its NO component. At this end, further exploration to ascertain positive 
effects of SUL121 in focal brain ischemia is highly warranted.  
In this study, tMCAO resulted in incomplete infarction in a substantial number of animals. 
As in previous studies by us and others this technique resulted in reproducible ischemic 
damage, the question arises why infarction was highly variable in this cohort. Importantly, 
the filament occlusion produced an adequate and similar MCAO occlusion in all animals, 
as evident from the similar drop in laser Doppler flow. Moreover, ischemic damage varied 
highly between animals within the control group, suggesting that the variance was not 
produced by SUL121 treatment. The key difference between the current and our previous 
studies (17,18) concerns the length of isoflurane anesthesia. Previously, isoflurane 
anesthesia was halted upon achieving successful MCAO and the animals gained full 
consciousness during the entire 2 h occlusion period. Thereafter, the animals were re-
anesthetised using isoflurane to carry out the reperfusion procedure. In contrast, ethical 
considerations led by speculation on a high discomfort level during the occlusion period in 
the absence of anesthesia, imposed constraints on the current experiment to maintain 
isoflurane anesthesia throughout the 2 h occlusion period. Although isoflurane has been 
used in several pre-clinical studies with transient and/or permanent MCAO, hitherto these 
protocols allowed the animal to recover during the occlusion period. Indeed, several 
studies have shown isoflurane treatment to mitigate infarction and neuroinflammation in 
ischemic stroke models when administered either as a pre- or postconditioning treatment 
(19-23). Such an effect of isoflurane may have been prominent in our study protocol 




period. Thus, the experimental protocol turned out to eventually exert a significant effect 
of its own on the issues of the current project.  
Despite the putative interfering effect of isoflurane our data suggest that SUL121 
treatment mitigated focal cerebral infarction and the accompanying swelling. Focal 
cerebral ischemia is known to upregulate and/or to induce various tissue reaction patterns 
including oxidative stress, early gene activation, apoptosis and inflammation (24). We 
found no significant difference in the level of oxidative stress, ER stress or activation of 
immediate early gene markers. This lack of difference can likely be attributed to the 
prolonged exposure of isoflurane and its potential neuroprotective effects as described 
above and therefore warrants detailed exploration by excluding its usage during the 
occlusion period.  
Exploration of expression of H2S synthesizing enzymes showed SUL121 to significantly 
upregulate CBS expression in the ischemic brain globally without affecting 3-MST levels. 
Such an effect of SUL121 on CBS is known from our previous (7) and ongoing work. For 
instance, Dugbartey et al (unpublished) observed that SUL121 protected kidneys from 
injury induced by forced hypothermia-rewarming while maintaining the levels of H2S-
synthesising enzymes. Moreover, permanent MCAO (using a craniectomy approach) in 
ketamine-xylazine anesthetized rats has been shown to increase the cortical H2S levels in 
the infarcted hemisphere, while exogenous administration of H2S-donors aggravated the 
infarction with an unchanged gene expression of CBS or CSE (13). Later, studies by the 
same group observed a downregulation of 3-MST in the infarcted hemisphere in 
comparison to the contralateral side, indicating that 3-MST is probably not responsible for 
the increased H2S production in the ischemic brain (25). Instead upregulation of CBS in the 
infarcted hemisphere might underlie the increased production of H2S in ischemia (26). In 
our study, CBS expression was significantly upregulated by SUL121 treatment in the 
ischemic brain. On the other hand, the lowering of 3-MST in the infarcted hemispheres in 
both untreated and SUL121 groups matches the observations by Zhao et al (2013). In 
conclusion, differences in the type of anesthetic regime and the model of focal cerebral 
ischemia induction may have influence on the expression of CBS and 3-MST. Whether 
isoflurane alone could affect the baseline levels of H2S synthesizing enzymes in brain is still 
unknown.   
Finally, the current study showed that SUL121 treatment increased the ACh-mediated 
relaxation in rat aorta after tMCAO. Ischemic stroke per se can elicit a systemic 
inflammatory response (27-29) which could also alter the systemic vascular reactivity in 
various vascular beds. The differential vascular responses in our study upon L-NAME 




H2S has been recognized recently as an important EDHF (30,31), with substantial influence 
on NO signaling, synergizing its effects and even increasing the NO bioavailability (32-34). 
As SUL121 treatment significantly affected the H2S synthesizing enzyme CBS in brain, it 
would be apt to speculate on a potential cross-talk between NO and H2S (35,36). The 
effect of SUL121 in alleviating the reduction in NO-mediated relaxation upon tMCAO 
might well be related to its maintenance of the H2S synthesizing enzymes. In this regard, 
blockade of endogenous H2S production by inhibitors such as AOAA could possibly unravel 
the link and thus needs further exploration by having a larger cohort to ascertain its role.  
CONCLUSION 
In this study, SUL121 mitigated the cerebral ischemic damage and hemispheric swelling in 
a transient MCAO model in comparison to saline treated controls. However, the degree of 
infarction produced varied markedly in both groups, likely representing the influence of 
extended isoflurane exposure in our study. As the infarction itself did not depict significant 
changes at the level of ROS, ER stress, early immediate gene induction and anti-apoptotic 
pathways, the effects of SUL121 on those could thus not be assessed. With respect to H2S-
synthesizing enzymes, infarction lowered the levels of 3-MST, while SUL121 increased the 
expression level of CBS. Finally, SUL121 preserved the ACh-mediated vasorelaxant 
reactivity in rat aorta, possible mediated by its action on NO via H2S signaling cascade. 
Further studies are warranted to explore the neuroprotective effects of SUL121 in a 
detailed manner.  
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Figure: Western blots depicting 
expression level of various 
markers employed in the study 
groups between ischemic and 
contralateral hemispheres. 
Infarct (+) and infarct (--) 
samples from ischemic and 
contralateral hemispheres were 
loaded in 2 separate gels as 
depicted in the upper and lower 
panel with the inclusion of a 
positive control on each of the 
gel (PC, using LPS stimulated BV2 
microglial cells) respectively. 
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Background: Reducing body temperature by targeted temperature management has been 
shown to be cytoprotective in various pre-clinical models of organ damage, including the 
brain. However, rewarming after systemic hypothermia may be accompanied by major 
complications. Thus, the potential clinical benefits of hypothermia call for stringent 
measures against a post-hypothermic rewarming insult. Our previous studies have 
revealed a strong association between hypothermia (both in hibernators and forced 
induction in rodents) and the endogenous hydrogen sulfide (H2S) signalling cascade. 
Moreover, dopamine was found to maintain expression of H2S synthesising enzymes (CBS, 
3-MST and CSE) in smooth muscle cells undergoing hypothermia-rewarming thus rescuing 
the cells from injury. Here we set out to investigate putative effects of dopamine in 
murine microglial (BV2) cells against this injury and to decipher potential underlying 
mechanisms. 
Materials & Methods: BV2 cells were subjected to hypothermia (24 h)-rewarming (2 h) 
injury. Dopamine was exogenously administered with or without relevant inhibitors 
(haldol, vanoxerine, fluphenazine) throughout the insult. Cell viability was assessed using 
neutral red assay. Levels of CBS and 3-MST were quantified with western blotting.  
Results: Hypothermia-rewarming injury significantly reduced cell viability and expression 
of CBS and 3-MST. Dopamine treatment concentration-dependently protected BV2 cells 
from this injury, the effect being abrogated by fluphenazine but not by haldol or 
vanoxerine, signifying a receptor-mediated action. Moreover, induction of cAMP in these 
cells mimicked the protection of dopamine. Furthermore, dopamine upregulated CBS and 
3-MST expression in BV2 cells that underwent hypothermia and rewarming.  
Conclusion: Dopamine rescued BV2 cells from hypothermia-rearming injury by a D1 type 










The controlled lowering of body temperature to levels of 32-33 oC, nowadays referred to 
as targeted temperature management (TTM), has been advocated as a measure against 
brain disorders in various pre-clinical models of central nervous system (CNS) injury, 
including cerebral ischemia, traumatic brain injury and spinal cord injury (1-6). The 
promising results found in these models have sparked the investigation of TTM in clinical 
trials for CNS disorders such as traumatic brain injury and ischemic stroke (2,7,8). Apart 
from its therapeutic use in such neurological settings, cooling and rewarming have since 
long been applied in other clinical situations such as organ transplantation, cardiac arrest 
and sepsis (9,10). Nevertheless, TTM as a part of clinical management in such disorders 
may also convey deleterious effects, particularly during and after the rewarming phase 
(11). Rewarming related cell damage is primarily attributed to an increased intracellular 
Ca2+ influx and production of reactive oxygen species (ROS) (12-14), which in turn may 
activate resident tissue macrophages and thereby initiate a cascade of events involving 
apoptosis, necrosis and inflammation. It is therefore essential to counteract these adverse 
effects of rewarming-induced injury.   
Hibernating animals undergo repeated cycles of reduced core body temperature and 
metabolism (torpor) interspersed with bouts of complete reversal of the body 
temperature and metabolism to physiological levels (arousals). While these cycles closely 
resemble hypothermia-rewarming phases, they do not result in overt damage to any 
organ including the brain. Previous research suggests that induction of endogenous H2S 
production constitutes a major mechanism in hibernators that mitigates ROS associated 
organ damage during arousals (12,15). 
Dopamine may represent a compound capable of mobilizing the endogenous H2S 
synthesis and protect organs from hypothermia and rewarming damage. Yard et al. (2004) 
observed the rescuing effects of dopamine in HEK cells exposed to hypothermic injury, 
which involved ROS scavenging. In addition, dopamine has been demonstrated to alleviate 
Ca2+ depletion in hypothermic human umbilical venous endothelial cells (HUVECs) (16) and 
to induce hemeoxygenase-1 expression in normothermic HUVECs (17). Interestingly, 
previous results from our group showed administration of dopamine to alleviate 
production of ROS and maintain endogenous H2S production in models of hypothermia 
and rewarming, both in vitro (Talaei et al., 2011) and in vivo (18). Moreover, protection is 
associated with the maintenance of expression of H2S synthesizing enzymes, including 
cystathione β-synthase (CBS) (12), 3-mercaptopyruvate sulfurtransferase (3-MST), and 
cystathione γ–lyase (CSE) (18). Notably, in cell models, dopamine protection seems to be 




Given the protective effects of dopamine in various non-CNS cells, we here set out to 
explore dopamine’s efficacy in protecting microglial cells from hypothermia and 
rewarming induced damage. Microglia represents the resident macrophages in the brain 
and get activated upon various pathological insults. We therefore employed a widely used 
microglial cell line (BV2 cells) to study whether dopamine rescues these cells from 
hypothermia and rewarming-induced injury and elucidate potential mechanisms of 
protection.  
MATERIALS & METHODS 
Cell culture 
Murine BV2 microglia cells were cultured in a T75 flask in DMEM (containing 4.5 g/l 
glucose, 584.0 mg/l L-glutamine, GIBCO) supplemented with 5% FBS, 1% penicillin-
streptomycin at 37°C in a humidified incubator supplied with 5% CO2 atmosphere. The 
cells were generously procured from the Department of Neurosciences, UMCG (Dr. B.J. 
Eggen). 70-80% confluent cells were subcultured and plated in 6 and/or 24-well plates at a 
density of 20,000 – 50,000 cells/well for relevant experiments as described below.  
Reagents 
The following reagents were used: dopamine (H8502, Sigma, USA); haloperidol (Haldol, 
Janssen-Cilag BV, Tilburg); fluphenazine (Bristol-Myers Squibb, Utrecht); vanoxerine (HY 
13217, MedChemexpress LLC); 6-benz-cyclic adeno monophosphate (6-b-cAMP; BioLOG, 
Bremen, Germany); forskolin (F-9929, LB Laboratories, MA, USA); neutral red (NR; Sigma, 
USA).  
Hypothermia-rewarming induction & treatment regimen 
Twenty-four hours after seeding, the BV2 cells were exposed to 24 h hypothermia (4-6 °C) 
followed by 2 h rewarming at 37 °C, before initiating the viability assay. Dopamine 
treatment (3 - 700 μM) was initiated 1 h prior to the hypothermic exposure and continued 
during the whole procedure including the rewarming phase. Pretreatment with respective 
antagonists (fluphenazine, 0.3 and 10 μM; vanoxerine, 0.3 and 10 μM; haldol, 0.3 and 10 
μM) was initiated 20 min prior to incubation with dopamine.  
Cell viability assay 
Cell viability was assessed by neutral red (NR) assay. Upon completion of the 2 h 




incubated at 37 °C for 3 h with NR medium prepared by diluting NR stock (4 mg/ml) 
solution in DMEM to attain a concentration of 50 μg/ml. Subsequently, the cells were 
washed with PBS and NR desorb (prepared by dissolving 98 % glacial acetic acid (100 μl), 
96 % ethanol (5 ml) in distilled water to result in a 10 ml solution) to dissolve the NR 
crystals formed during the acidification process. After incubating at room temperature for 
10 min on a shaker, the reaction mixture was assessed by measurement of absorbance 
using a microplate reader at 540 nm.  
Western blotting 
BV2 cells were harvested after giving PBS washes in 150μl RIPA buffer from 6-well plates, 
containing protease inhibitor cocktail, sodium orthovanadate, sodium fluoride and β-
mercaptoethanol (all from Sigma Aldrich, The Netherlands). The cell lysate was then 
sheared using insulin syringe and incubated on ice, before determining the protein 
concentrations using a Biorad assay kit, as per the manufacturer’s guidelines (Bio-Rad, 
Germany). Samples were boiled for 5 min before loading onto the pre-casted SDS-
polyacrylamide gel. The gel electrophoresis was carried out at 100 V for 70 min using 30 
μg of total protein for each sample. Proteins were subsequently blotted onto 
nitrocellulose membranes using a transfer buffer solution containing 0.25 mM Tris (pH 
8.5), 192 mM glycine and 10% v/v methanol at 4 °C for 60 min at 0.3mA. Thereafter, the 
membranes were blocked in 5% w/v skimmed milk dissolved in TBST buffer (containing 
50mM Tris-HCl, pH 6.8, 150mM NaCl, 0,05% v/v Tween-20). Subsequently, the 
membranes were incubated overnight at 4 °C with the following antibodies diluted in TBST 
solution containing 5% BSA (w/v): anti-CBS (sc-271886, Santa Cruz), anti-3MST (HPA 
001240, Sigma). After overnight incubation, the membranes were washed 3 times in TBST 
buffer and incubated with HRP-linked polyclonal secondary antibodies (Dako, Denmark) in 
5% BSA-TBST solution for 1 h. Blots were developed using the Western Lighting Ultra 
substrates (Perkin Elmer Inc., USA) according to the manufacturer’s guidelines. Protein 
bands were visualized using the Gene Genome system (Westburg BV, The Netherlands) 
and intensities quantified using Gene Tools software. 
Statistics 
Data are expressed as mean ± SD. Two-tailed t-test was used in comparisons for cell 
viability as well as for CBS and 3-MST levels between normothermic versus hypothermia-
rewarmed cells. One-way ANOVA analysis was used followed by posthoc analysis using 
Tukey’s test for comparisons with treatment groups. A p<0.05 was considered to be 





Hypothermia-rewarming alters BV2 cellular morphology & compromises viability 
Control BV2 cells incubated at 37 °C are shown in figure 1A. Twenty-four hours of 
hypothermia followed by 2 hours of rewarming resulted in marked detachment of cells 
with signs of cell death, including bleb formation, nuclear condensation, and cellular 
fragmentation (Fig. 1B). Further, neutral red assay documented hypothermia and 
rewarming to significantly reduce cell viability when compared to normothermic control 
cells (Fig. 1C). 
Figure 1: Morphology and viability of BV2 
cells following hypothermia and 
rewarming. (A) normothermia,  and (B) 
hypothermia (24h)  -rewarming injury 
(2h). (C) Spectrophotometric analysis of 
cell viability using neutral red assay. 
*p<0.05 normothermic (37 0C) vs 
hypothermia-rewarmed cells (HR). Values 




Dopamine rescues BV2 cells from hypothermia-rewarming injury  
The protective effect of dopamine against cooling and rewarming injury was investigated 
by generating concentration-response curves (Fig. 2). At 3 μM, dopamine did not improve 
cell survival. Increasing concentrations of dopamine (10, 30, 50 and 100 μM) instituted a 
significant rescuing effect (p<0.05 versus untreated cells). However, further increases in 
dopamine concentration (300 and 700 μM) were associated with a decrease in the cell 
survival. Thus, dopamine displayed a bell-shaped concentration-response curve on cell 







Figure 2: Bell-shaped concentration-response 
curve of dopamine to protect from cell death. 
*p<0.05 untreated vs dopamine-treated 
hypothermia-rewarmed BV2 cells. Values are 
represented as mean ± SD.  
 
 
Induction of cAMP mimics the protective effect of dopamine 
Since dopamine via its D1/D2 receptor types may affect the cAMP signaling cascade, we 
set out to investigate involvement of this cascade in dopamine’s improvement of cell 
viability in hypothermia-rewarming injury. Stimulation of cAMP signaling by activation of 
adenylyl cyclase (forskolin 0.1-100 μM) rescued BV2 cells from hypothermia-rewarming 
induced cell death in a concentration-dependent manner (Fig. 3A). Comparable results 
were obtained after administration of a cAMP analogue (6-benz-cAMP, 0.1-100 μM) (Fig. 
3B).  
Figure 3: Concentration-dependent effect of 6-benz-cyclicAMP (6b-cAMP; A) and forskolin (B) on cell 








Rescuing effect of dopamine from hypothermia-rewarming injury is partially attenuated by 
receptor blockade, but not affected by its reuptake inhibition 
To further examine whether dopamine receptor modulation conveys the beneficial effects 
of dopamine, we next examined the effects of dopamine receptor antagonists (affinity 
D2>D1: haldol, 0.3 - 100μM; affinity D2~D1: fluphenazine, 0.3 - 10μM) and dopamine re- 
Figure 4: Absence of any effect of haldol (A), fluphenazine (B) and vanoxerine (C) on cell viability in 
hypothermia-rewarming injury in BV2 cells. Values are represented as mean ± SD.  
uptake blocker (vanoxerine, 0.3 - 10μM). None of these inhibitors influenced BV2 cell 
viability following hypothermia-rewarming when compared to untreated cells (Fig. 4A-C). 
Further, both the dopamine receptor antagonist haldol as well as the dopamine re-uptake 
inhibitor, vanoxerine did not affect the improvement of cell viability by dopamine (Fig. 5A-
D). In contrast, pretreatment with the non-selective DR antagonist, fluphenazine, 
markedly abrogated dopamine’s rescuing effect on hypothermia and rewarming induced 





























Figure 5: Effect of receptor and reuptake inhibition on dopamine conferred protection in hypothermia-
rewarming injury of BV2 cells. Effect of pre-incubation of dopamine with low or high dose of haldol (A, B), 
vanoxerine (C, D) and fluphenazine (E, F) from hypothermia-rewarming injury on BV2 cell viability. HR, 
hypothermia-rewarming; HAL. Haldol; DOP, dopamine; VAN, vanoxerine; FLU, fluphenazine. Values are 
represented as mean ± SD. *p<0.05  dopamine only-treated versus antagonist-treated hypothermia-
rewarmed BV2 cells. 
Dopamine upregulated CBS and 3-MST levels in hypothermia-rewarmed BV2 cells 
As dopamine-induced maintenance of H2S production in hypothermia and rewarmed 




expression of CBS and 3-MST was examined. Hypothermia-rewarming induced a 
significant downregulation of both CBS and 3-MST levels in BV2 cells (p<0.05 versus 
normothermic control cells, Fig. 6A,B). Incubation with dopamine throughout the 
procedure induced a concentration dependent increase in both CBS and 3-MST 
expression, which ultimately normalized CBS expression at 50 μM. Whereas a higher dose 
of dopamine (300 μM) further upregulated CBS expression (Fig. 6A), it severely 
downregulated 3-MST levels (Fig. 6B).  
Figure 6: Dopamine effects on CBS and 3-MST expression in hypothermia-rewarmed BV2 cells. 
Downregulation of CBS (A) and 3-MST (B) expression level is evident upon hypothermia-rewarming injury 
when compared to normothermic cells, which is alleviated by dopamine treatment in a concentration-
dependent manner. Pairs of lanes indicated on Western blots represent successive conditions represented 
on the X-axis. *p<0.05. Values are represented as mean ± SD.  
DISCUSSION 
In this study, we demonstrated that exogenously administered dopamine improves the 
viability of BV2 cells undergoing hypothermia-rewarming injury. Dopamine protection 
seems predominantly mediated by D1-type receptor mediated cAMP production, in view 
of the actions of cAMP analogues and receptor antagonists, respectively. Further, in 
contrast to previous reports in cultured smooth muscle arterial cells (12), re-uptake of 
dopamine does not seem to be involved. Although its mechanism in BV2 cells seems 
receptor mediated rather than dependent on re-uptake as found previously (12), 
dopamine treatment was also found to upregulate CBS and 3-MST levels.  
Our results implicate a receptor-mediated rescuing effect of dopamine against 
hypothermia-rewarming injury in BV2 cells, which is accompanied by the preservation of 
the expression of key H2S synthesizing enzymes and is mimicked by cAMP analogues. In 
this context dopamine, apart from its action on α1- and β1-adrenoreceptors, can also bind 




includes D1 and D5 receptors while the D2 family comprise of D2, D3 and D4 (19) 
receptors. The activation of D1-type of receptors is coupled to G-protein Gsα activating 
adenyl cyclase and thereby increasing the level of cAMP. In contrast, D2-type receptors 
coupled to Giα activation inhibit formation of cAMP via inhibiting adenyl cyclase. An 
increased level of cAMP as evident after D1-type receptor activation can activate several 
targets such as protein kinase A (PKA), exchange proteins activated by cAMP (EPAC) and 
cyclic nucleotide gated ion channels.  
Our observation contradicts those reported by Yard et al (2004), who suggested dopamine 
to act receptor independently. In their study, dopamine-treated HUVECs were subjected 
to 24 h cold preservation injury, and the protection by dopamine appeared to be due to a 
ROS scavenging effect, possibly related to induction of heme oxygenase-1 expression. 
Moreover, the protective effect of dopamine did not appear to be mediated by β-receptor 
activation, and it was unaffected by D1 and/or D2 receptor blockade (17). Instead, 
dopamine protection was mediated by an oxidative mechanism as addition of antioxidants 
such as ascorbic acid or N-acetylcysteine blocked the protective effect of dopamine. In our 
previous study, Talaei et al (2011) observed protection by dopamine of rat smooth muscle 
aortic cells (SMAC) from hypothermia induced cell death. This protective effect was 
abrogated by the dopamine reuptake inhibitor, vanoxerine. In the current study, 
protective action of dopamine was to a large extent abrogated by fluphenazine (D1~D2) 
but not with haldol (D2>D1) or dopamine reuptake inhibition. Moreover, similar to a D1 
receptor-mediated effect via Gsα downstream signalling, receptor independent induction 
of cAMP rescued the cells, indicating that D1 type is the major dopamine receptor subtype 
expressed in the BV2 cells. Indeed, mouse microglial cells primarily express receptors of 
D1-type as shown by Faber et al (2005). Together, our results are consistent with the view 
that dopamine protection in this study is conveyed by its D1 receptor subtype.  
In accord with our previous studies (12,15), dopamine treatment in our study was shown 
to normalize the levels of CBS and 3-MST in hypothermia-rewarmed BV2 cells when 
compared to untreated cells. In CNS, CBS is one of the key H2S synthesizing enzymes 
primarily in glial cells while 3-MST is considered to be expressed mainly in neurons. Taken 
together, the D1 receptor mediated action and its downstream targets and the interplay 
with H2S synthesizing enzymes could further imply a central protective mechanism in 
determining the extent of hypothermia-rewarming injury in microglial cells and warrants 
further exploration.   
Dopamine and its related compounds (e.g. dobutamine) have been used in hypotensive 
episodes (shock) associated with conditions such as myocardial infarction, trauma, 




neurotransmitters in the CNS with a considerable amount found in peripheral tissues as 
well. With the current ongoing trials to study neuroprotection of hypothermia, the role of 
dopamine as a potential therapeutic agent in mitigating hypothermia-rewarming 
associated adverse effects (both central and peripheral) warrants further pre-clinical 
exploration. Moreover, the underlying mechanisms shown in our model needs further 
detailed study of the dopamine signalling cascade, including  downstream receptor targets 
involved in cAMP activation and their effects on the regulation of H2S producing enzymes 
and H2S production.  
CONCLUSION 
Dopamine was shown to rescue BV2 microglial cells against hypothermia-rewarming injury 
by a receptor-mediated action (mainly D1 type), independent of its reuptake. Besides, the 
induction of cAMP rescuing the cells against this insult further strengthens the protection 
via D1–type of receptors and warrants detailed studies exploring downstream targets. 
Furthermore, dopamine treatment was shown to upregulate levels of H2S synthesizing 
enzymes, mainly CBS and 3-MST, following hypothermia and rewarming as observed in 
our previous studies.  
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Summary & General Discussion 
 
























SUMMARY & GENERAL DISCUSSION 
Stroke is the leading cause of adult disability worldwide and the burden is predicted to rise 
from 38 million DALYs (disability adjusted life years) in 1990 to 61 million DALYs in 2020. 
Ischemic stroke accounts for around 80% of all stroke cases. In chapter 1, we outline the 
burden and recent terminology of stroke in general. Moreover, pathophysiological 
mechanisms underlying ischemic stroke and current treatment strategies are reviewed. In 
order to mimic some of the underlying mechanisms, pre-clinical modeling of ischemic 
stroke, especially in rodents, has been established for over 30 years. Current models have 
been focusing on induction of transient and/or permanent cerebral ischemia employing 
various approaches such as blood clot/micro-macrosphere injection, silicon coated tip 
filaments and craniectomy-based electrocoagulation of relevant brain arteries. In chapter 
1, these methods are outlined with a prime focus on filament-based approach and its 
relevant modifications.  However, despite substantial basic and clinical research efforts, to 
date the only effective therapeutic measures are early revascularization [(mostly by 
systemic thrombolysis using recombinant tissue plasminogen activator (rtPA)] and 
supportive care aimed at reducing acute complications (stroke unit concept, 
decompressive craniectomy in case of malignant stroke) (1). While a large body of 
literature has demonstrated substantial therapeutic success of many additional 
interventions in experimental models, the translation of these basic research findings has 
led to discouraging results in clinical trials (2,3). Hence, developing appropriate pre-clinical 
models and their optimization is needed to ensure better translation.  
The studies in the current thesis can be broadly divided into two parts. Firstly, in chapters 
2 and 3, we introduced a rodent focal cerebral ischemia model of occlusion of the middle 
cerebral artery (MCA) as a tool to study novel therapeutics and employed a cryogenic MRI 
coil (optimized and developed at the Department of Computer Assisted Clinical Medicine, 
Mannheim) to measure tissue potassium (K+) level in this model. In chapter 2, we 
modified the current permanent focal cerebral ischemia model using an intravascular 
filament approach in rat with the aim to substantially improve survival. To achieve this, we 
re-designed the silicon coating to create a bowling pin-shaped tip filament. We 
demonstrate this tip to still result in a severe infarction with accompanying brain swelling, 
which in contrast to previous approaches is much better confined to the region supplied 
by the MCA while maintaining collateral blood flow across the posterior cerebral artery 
(PCA) supplied territory. The modification of the tip not only resulted in gross 
improvement of survival, the resulting infarction also displayed delayed growth of 
infarction. These features thus mimic those of malignant MCA stroke as encountered in 
the clinical setting, thereby creating a model with an acceptable mortality rate to study 




experimental drugs and cell-based therapeutics. In chapter 3, we successfully used the 
new occluding tip device to study electrolyte changes in the early phase of focal ischemia. 
We employed a cryogenic copper-based surface resonator cooled down by liquid nitrogen 
to 77 oK (-196 oC) using a custom built cryostat housing to measure tissue 39K signal 
comparing healthy and stroke-affected rat brain with a 9.4 Tesla MRI. This cryogenic coil 
had an improved signal-to-noise ratio (SNR) in comparison to the measurement obtained 
at room temperature (by a factor of 2.7 ± 0.2). Moreover, the 39K signal in the infarcted 
hemisphere of the rat brain was reduced by about 75 % at 77 oK in comparison to 40 % 
reduction at 300 oK (27 oC) in comparison with the contralateral hemisphere signifying the 
improved signal detection at 77 oK. The improved assessment of ionic imbalance occurring 
in ischemic stroke may potentially be used to study progression of ischemic damage in 
combination with other X-nuclei imaging (such as sodium-MRI) for future studies.  
In the second part of the thesis, we explored the neuroprotective properties of novel 
therapeutic agents in rodent models of ischemic stroke and in an in vitro model of 
microglial injury. In chapter 4, we evaluated the effects of pigment epithelial-derived 
growth factor (PEDF) on ischemic damage and brain swelling in a transient ischemic stroke 
model by longitudinal MRI assessment. PEDF was found to significantly reduce the 
ischemic lesion volume and edema formation, which is possibly related to its potent effect 
counteracting VEGF-induced hyperpermeability and stabilizing tight junction (TJ) proteins. 
In addition, in chapter 5, the novel chromanol-based compound SUL121 was observed to 
mitigate ischemic damage in a focal cerebral ischemia model, to increase the level of 
endogenous H2S synthesizing enzymes especially CBS, and to revert the impaired NO-
mediated relaxation in aorta. Finally, in chapter 6, we demonstrate that exogenously 
administered dopamine reduces hypothermia-rewarming induced injury in cultured 
murine microglial (BV2) cells, which appeared to depend on a dopamine D1 receptor-
mediated action activating the cAMP cascade, and upregulation of the levels of the H2S 
synthesizing enzymes, CBS and 3-MST. 
Together, these studies provided an overview of the successful modelling of cerebral 
ischemia in vivo, developing a non-invasive imaging tool to assess the associated ionic 
imbalance (improved 39K signal using a cryogenic coil) and a novel occluding filament 
creating a successful model of permanent ischemia representing malignant stroke. 
Further, we investigated potential therapeutic agents (PEDF, SUL121) for their putative 
neuroprotective actions and disclosed a protective effect of dopamine in an in vitro model 
of hypothermia-rewarming injury in relation to its property to maintain expression of key 





TOWARDS OPTIMIZED MODELS OF STROKE 
With less than 10 % of ischemic stroke patients undergoing thrombolytic therapy, 
modeling chronic cerebral ischemia resulting from a substantial permanent stroke is the 
need of the hour enabling testing of new therapeutics (as outlined in the Fig. 1 & Table). 
Importantly, many experimental stroke studies feature non-progressive infarction and/or 
short-term outcome measures. In contrast, key outcome parameters of interventions in 
human stroke constitute of long-term (3-month) survival and functional recovery, as 
measured by the modified Rankin scale or Barthel index, which represent the ability of a 
patient to perform activities of daily life or the ability to communicate (4,5). Thus, similar 
to clinical trials, long-term survival with ischemic damage significantly involving cortical as 
well as striatal regions should be used as important outcome measures in experimental 
studies. Furthermore, long-term outcome analyses should also enable one to evaluate the 
success of a novel therapeutic concept or pharmacological agent.  
Improving the permanent stroke model 
In chapter 2, the spectacular increase of post-stroke survival and delayed growth of the 
infarction mimicking malignant stroke represent key major advantages of the BP-tip 
approach (Table) in a pMCAO model compared to the conventional filament groups. 
Malignant stroke is a devastating condition resulting from a blockade of blood flow either 
at the distal part of internal carotid artery (ICA) or proximal origin of MCA. This results in a 
large hemispheric ischemia involving mainly the region supplied by MCA accompanied by 
a massive brain swelling (6,7) and high mortality, eventually due to a herniation of brain 
stem. With conservative treatment, up to 80 % mortality has been observed (7) and 
therefore malignant stroke represents a neurosurgical emergency. The neurosurgical 
intervention consists of a decompressive craniectomy (DC), which provides space for the 
expanding brain tissue and relieves the ‘malignant’ edema (6). In most instances, this 
highly extensive brain exploration to tackle the severe progressing ischemic damage may 
also contribute to the ischemia-related impairment of psychosocial state of the patients 
including their quality of life in the long run. In this context, there is a lack of effective pre-
clinical models of malignant stroke with an improved survival for pathophysiological 
studies to characterize relevant therapeutics to curtail the malignant expansion of 
ischemia and edema. Most of these studies used the filament based MCAO to induce so-
called malignant MCA stroke (8). Doerfler et al (1996) reported in rats undergoing pMCAO-
induced malignant stroke using an intravascular filament a mortality rate of 35 % (evident 
between 24 – 48 h), mainly attributed to herniation of brain stem. Although not 
quantified, ischemic affliction to hypothalamic region was observed in this study.  Indeed, 























































































































































































































































   
   
   
   





















































































































































































































































































































































Table. Salient features of conventional versus our modified filament-induced middle cerebral 





(L-TB, S-TB, DOC tip) 
Mortality 
Markedly reduced  
(~12 %) at 24 h 
Severe 
(~50 %) at 24 -36 h 
Selective MCA blockade Achieved 
Apart from MCA, can interrupt 
blood flow across PCA supplied 
territory 
Vascular distortion (at base 
of brain) due to filament tip 
None Present 
Collateral blood flow Maintained 






Severe (rapid progressive) 
Invariably seen 
Brain swelling Moderate-severe Severe 
Long-term studies Possible Not possible 
Ischemic damage 
progression and relevant 
therapeutic studies 
Possible Not possible 
BP, bowling-pin shaped tip; L-TB, long tubing-based tip; S-TB, short tubing-based tip; DOC, Doccol 
tip; MCA, middle cerebral artery; PCA, posterior cerebral artery 
compromising important regulatory functions including thermoregulation, likely 
represents a key aspect of the high mortality rate. Except for data published in chapter 2, 
we have also been able to image the progression of ischemic damage and tissue 
remodeling in BP-tip occluded rats employing longitudinal MR imaging even up to 18 days, 
with the hypothalamus being completely spared from the damage (Fig. 2, unpublished 
data). Furthermore, the main alternative method to filament inclusion, i.e. craniectomy 
based pMCAO may result in alterations of intracranial pressure, hemodynamics and local 
brain temperature affecting the development of ischemic damage which localizes at a site 
supplied by the distal MCA branches compared to filament-based occlusion which blocks 
proximal branch of MCA. Moreover, specific techniques such as macrosphere injection 
result in a highly variable infarction size. Together these features restrict the suitability of 
such pMCAO models to mimic malignant MCA stroke. Thus, our model allows exploration 
of the potential of novel therapeutics mitigating the rapid progression in infarct size and 
brain swelling, such as those limiting metabolic and ionic derailment, tissue hypoxia, 
cortical spreading depression/peri-infarct depolarizations (CSD/PID), blood-brain barrier 




secondary effects due to early reperfusion) for developing malignant stroke may be 
administered with agents acting against one or more of the above events to curtail the 








Figure 2. T2-weighted images depicting of ischemic damage in a rat brain with a right-sided permanent 
middle cerebral artery occlusion using a BP-tip filament assessed longitudinally from day 1 to day 18. Note 
that the hypothalamic region (arrows) is spared from ischemic damage. BP, bowling pin-shaped tip.  
Improving selection and follow-up by MRI monitoring of ionic imbalance 
In the past decades, several therapeutic agents with proven efficacy in pre-clinical 
transient MCAO models failed to improve outcome in permanent MCAO models. One 
factor explaining this discrepancy might be that interventions target reperfusion damage 
in tMCAO, which is intrinsically absent in pMCAO models. In the former model, 
mechanisms such as ionic dysfunction, blood-brain barrier (BBB) dysfunction, metabolic 
failure, tissue hypoxia could be of relevance. Ionic disbalance is one of the initial 
consequences of an ischemic insult. Ischemia, such as in acute stroke, causes abnormal or 
impaired energy metabolism, disturbing the Na+-K+-ATPase and interrupting the ionic 
transport across the cells (9), leading to an increase in the intracellular Na+ and 
extracellular K+ concentration.  
In chapter 3, we were able to measure brain tissue K+ in healthy and ischemic rat brain 
using a custom built liquid nitrogen cooled cryogenic copper-based surface resonator coil 
designed for small animal imaging in a 9.4 Tesla MR scanner. Brain extracellular potassium 




the cells, clearance by circulating blood, as well as redistribution of potassium in the 
extracellular space. These factors which control extracellular K+ in physiologically 
functioning brain are impaired during ischemia. The development of the described K+-
based coil was preceded by the establishment of a triple resonant MR coil by the same 
group (10) for detection of Na+ and K+ along with acquisition of anatomical proton images 
(1H) coupled in a single set up for rat head in vivo, although with a very low gain in 39K 
signal detection. We showed for the first time that the cryogenic cooling of a surface 
resonator coil to significantly improve the signal-to-noise (SNR) ratio and measure 39K 
signal in vivo.  The coil seems apt to quantify progression of cerebral ischemia as observed 
in our modified pMCAO model previously described in chapter 2. Moreover, 
pathophysiological substrates involved in such a progression could lead to developing 
therapeutic targets, for instance in patients with malignant stroke. Several clinical studies 
have observed the occurrence of episodic cortical spreading depression (CSD) to play a 
significant role in progression of infarct size. Failure in brain ion homeostasis represents a 
key feature of CSD as evident by a marked increase in extracellular K+ with a reduction in 
Ca2+, Cl- and Na+ shrinking the extracellular space due to water movement into neurons, in 
response to other pathophysiological features such as altering BBB permeability and a 
massive release of excitatory amino acid such as glutamate (9). This excess glutamate in 
turn interacts with its receptors, mainly NMDA receptor (NMDAR) to trigger K+ release 
causing further depolarization of neurons propagating to neighbouring regions and initiate 
further cyclical episodes. In patients with malignant stroke, occurrence of such numerous 
episodes of depolarizations around the infarct core (peri-infarct depolarizations, PID) can 
lead to infarct progression (11,12,13). The development of a non-invasive method to 
ascertain the viability of ischemic tissue by assessing its ionic imbalance in acute stroke 
can be of relevance in two major ways: a) it would allow the identification of patients that 
do not meet the “clinical window of opportunity” but that still have a significant volume of 
viable tissue eligible for treatment with rtPA, and b) it enables the possibility of 
longitudinal assessment of potential interventions. Although cryogenic resonator coils 
have been successfully developed for human imaging (14), adopting a similar set up 
specifically for brain imaging could be of immense value.  
  
NOVEL DIRECTIVES IN ISCHEMIC STROKE THERAPEUTICS 
Although there are multiple reasons for the translational failures, a key aspect in pre-
clinical testing has primarily focused on the tMCAO model which is claimed to simulate up 
to 10 % of the clinical cases where early recanalization is established. Rapid reperfusion as 




injury via a cascade of events including hemodynamic disturbances, inflammatory 
processes, free radical formation and breakdown of the BBB. On the other hand, the 
filament-induced MCAO in our study resulting in a permanent stroke (without 
reperfusion) led to a gradual development of the ischemic damage peaking up to 72 h 
post occlusion. Such a scenario represents patients who are ineligible for thrombolysis. In 
such an instance, lesion progression may depend on several factors such as near-complete 
lack of oxygen and nutrient supply for the regions distal to the occlusion, depolarization 
waves triggered from the infarct core expanding over time and a compromised collateral 
blood flow unable to feed the at-risk tissue. Although an intricate molecular mechanisms 
interplay underlie the pathophysiology of ischemic stroke, one should comprehend its 
complexity to choose the type of therapeutic agent, appropriate time window for its 
administration and potential influence on endogenous molecular pathways, which if 
affected, could lead to adverse effects affecting the ultimate neurological outcome.  
Potential therapeutic targets in tMCAO model 
We demonstrated in chapter 4, that application of pigment epithelial-derived factor 
(PEDF) between 24 hours and 1 week after reperfusion resulted in a significant reduction 
in lesion size along with alleviated BBB opening in a rat model of transient MCAO (90 min) 
as evident from longitudinal MR imaging. BBB permeability is a critical issue and poses a 
hurdle in the research and development of new therapies for acute ischemic stroke. 
Stroke has however been shown to compromise the barrier function of BBB (15). 
Therapeutic agents targeted in alleviating the increased BBB permeability could in turn 
mitigate the progression of delayed ischemic damage and secondary injury. In this 
context, several growth factors such as erythropoietin (EPO), G-CSF, BDNF, IGF-1 have 
shown protection in pre-clinical models of ischemic stroke including mitigating BBB 
permeability (16,17). PEDF has been shown to have conflicting results in mitigating 
damage in various pre-clinical ischemic stroke models. A recent study by Zille et al (2014) 
in a mouse tMCAO model failed to show any protection on ischemic damage, cell death or 
behavioural outcome upon a continuous infusion of PEDF via a cannula placed in lateral 
ventricle (18). On the other hand, Sanagi and co-workers (2008) demonstrated that PEDF 
overexpression was neuroprotective in a rat tMCAO (70 min) model and damage assessed 
24 h after reperfusion (19). The authors injected an adenoviral vector containing the PEDF 
gene directly into the striatum. The variable results can be attributed to the different 
treatment approaches employed in these studies. A critical question whether 
administration of growth factors to mitigate BBB dysfunction also influences endogenous 
trophic factors or whether their treatment needs to be initiated only during the repair 




While exogenous growth factor therapy has been considered a promising avenue for 
treating ischemic brain injury, more studies are necessary to elucidate optimal timing, 
dosing and mode of administration, as well as possible combinations of growth factors 
and their effects when combined with current management strategies. Clinical studies in 
this regard have been unsuccessful. For instance, the phase II/III German Multicenter EPO 
Stroke Trial failed to show a beneficial effect on the neurological outcome in stroke 
patients when treated with either EPO or placebo within 6 h of symptom onset. Some of 
the factors attributed to this failure include overestimated efficacy of EPO in pre-clinical 
studies, lack of studies employing combinational use of rtPA with EPO and untoward side 
effects of EPO (20,21). The recent AXIS-2 trial, which tested 3 days i.v. infusion of 
granulocyte-colony stimulating factor (G-CSF) in patients with acute ischemic stroke 
assessing its efficacy 90 days after stroke, was unsuccessfully concluded after clinical 
Phase IIb trials (22), despite optimistic conclusions of a systematic review of the 
corresponding preclinical data (23) and successful completion of a clinical Phase I trial 
(24). Many of the growth factors share intracellular pathways and their exogenous 
administration can lead to altered expression of endogenously produced factors. In this 
regard, our modified stroke model can act as a tool in characterizing the potential use of 
growth factors, especially in sub-acute to chronic phase post occlusion.   
In chapter 5, we administered SUL121 intravenously to rats undergoing cerebral ischemia-
reperfusion injury to investigate its putative protective effects on brain damage as well as 
on systemic vascular function. We chose a pre-treatment regime as we wanted to 
investigate whether SUL121 infusion would have an effect at all in our model. Similar to a 
recent study (Dugbartey et al., unpublished), SUL121 treatment was shown to upregulate 
the level of CBS, while the infarction itself reduced the level of 3-MST. Moreover, SUL-
treated animals improved the ACh-mediated aortic relaxation compared to saline-treated 
control animals, potentially acting via preserving NO-mediated vasorelaxation. In general, 
cerebral ischemia led to an impairment of NO-mediated vasorelaxation in rat aortas. 
Besides, the excess relaxation could be contributed by boosting relaxant prostanoids 
specifically by SUL121. In line with published studies showing debatable results with 
exogenous H2S donors (25,26,27), establishment of the role of boosting of CBS by SUL121 
on brain ischemia and systemic vasculature needs further studies by employing relevant 
blockers of endogenous H2S production or knock-out models. Nevertheless, the action of 
H2S on cerebral ischemia remains controversial. Exogenously administered H2S (e.g. NaHS) 
particularly in rodent models of cerebral ischemia have been reported both to mitigate 
(26) as well as to aggravate the ischemic lesion (28) in a concentration-dependent 
manner. In line with the effects of exogenously administered H2S, inhibition of 
endogenous H2S production (AOAA, a non-specific inhibitor of H2S synthesizing enzymes) 




transient MCAO under chloral hydrate anesthesia, while a low dose (0.025, 0.05, 0.1 
mmol/kg) significantly reduced the infarction (29). The endogenous H2S under 
physiological conditions is known to act as a neuromodulator during NMDAR-mediated 
responses necessary for long-term potentiation involved in memory consolidation (30). 
Hence, either boosting endogenous H2S or inhibiting its production to the extremes may 
induce deleterious effects in brain ischemia and may warrant optimal dosing to be 
efficacious.  
Importantly, the experimental protocol in chapter 5 resulted in small brain infarct sizes 
both in control as well as in treated groups 24 h post MCAO. As discussed in the chapter, 
this mitigation of infarct size is likely attributed to the anesthetic regimen employed 
wherein the animals were exposed to isoflurane even during the occlusion period. 
Therefore, isoflurane itself may be used to mitigate ischemia development, as shown in 
various cerebral ischemia models (31). Particularly, pre- as well as post-conditioning 
effects of isoflurane are prime candidates that may have been involved in the apparent 
neuroprotective action seen in our study. Besides, it would be apt to explore whether 
isoflurane per se influences the endogenous level of H2S synthesizing enzymes in brain. 
Thus, an interplay between prolonged exposure to isoflurane, the endogenous H2S 
system, vascular NO regulation and the effects of SUL121 may exist and needs to be 
extensively studied.  
Potential therapeutic options in pMCAO model 
Permanent vascular blockade leads to cessation of blood supply resulting in tissue 
hypoxia. Several pre-clinical studies have been inconclusive in depicting a significant 
improvement using agents carrying oxygen (artificial oxygen carriers) when administered 
under normobaric oxygenation (NBO) conditions or when treated with NBO or hyperbaric 
oxygenation alone (32). While their clinical translation has not led to a satisfactory 
improvement in the neurological outcome, new generation oxygen carriers are currently 
being developed. On the other hand, inhibiting the depolarization waves using glutamate 
receptor (primarily NMDAR) antagonists has shown some promising results in pre-clinical 
models. However, the clinical translation of these antagonists has failed due to their 
psychotropic effects (33). Besides, NMDAR-mediated responses play a crucial role in post 
stroke recovery and hence, inhibition in the acute phase can worsen the outcome. 
Currently, novel antagonists (eg. PSD95 protein inhibitors) are being developed which 
circumvent adverse effects by blocking pathways such as free radical generation produced 
by the neuronal nitric oxide synthase (nNOS) without blocking NMDARs (34). PSD95 
inhibitors have shown promising results in both tMCAO as well as pMCAO models (35) 




Apart from targeting hypoxia and the generation of depolarization waves, gaseous 
anesthetics, particularly isoflurane show cerebroprotective effects as revealed by various 
pre-clinical studies of cerebral ischemia and hemorrhage. However, whether the 
protection is sustained is still controversial. A recent study by Kim et al (2015) revealed 
post treatment of isoflurane to mitigate the ischemic damage in a tMCAO model treated 
with rtPA upon reperfusion (37). Besides, rats subjected to tMCAO using 
ketamine/xylazine showed a significantly higher volume of ischemic damage compared to 
those undergoing occlusion under isoflurane (38). Potential actions of isoflurane include 
preconditioning effect leading to ischemia tolerance in rat brain by activating p38 MAPK 
(39), reduced glutamate release and enhancing GABA receptor-A mediated 
hyperpolarization (40), and inhibiting the activation of TLR 4 pathway (41). Moreover, due 
to a cerebral vasodilatory effect of isoflurane as evident from clinical studies (42,43), a 
possible role of inverse steal effect cannot be ruled out in an ischemic brain wherein the 
blood from the non-ischemic (contralateral) hemisphere is diverted to the ischemic side.  
Although most the above mentioned studies have been performed in tMCAO models, 
exploring isoflurane effects in pMCAO models could be of relevance from a clinical 
perspective and warrants further exploration. For instance, the inverse steal effect of 
isoflurane could aid in improving collateral blood flow in ischemic hemisphere in cases of 
malignant stroke. An immediate possibility would be to administer isoflurane as a sedative 
or blood pressure lowering agent in an ICU setting under intense cardiac and respiratory 
monitoring, particularly in patients at-risk of developing malignant infarction. 
Furthermore, investigating the effects of isoflurane (only) treatment on the endogenous 
gasotransmitters (NO, CO and H2S) in the CNS could be of major relevance to reveal 
potential interplay in such pathological states. 
Boosting H2S – a potential factor to mitigate hypothermia-rewarming associated adverse 
effects  
At the end, in chapter 6, we observed that murine (BV2) microglial cells revealed a 
significant reduction in their viability when exposed to HR injury. Levels of CBS and 3-MST 
were significantly downregulated upon the insult. In this scenario of reduced viability and 
downregulated CBS and 3-MST levels, dopamine treatment was shown to rescue the cells 
and upregulate the enzyme levels. Furthermore, dopamine was shown to mediate this 
protection via a D1 receptor type-mediated action, but unaffected by its reuptake 
inhibition. This is in contrast to previous studies (44,45). The protective effect of dopamine 
in our study was primarily observed in brain microglial cells in contrast to the above 




hypothermia/rewarming – dopamine warrants further studies which could be of immense 
relevance when considering hypothermia as a therapeutic approach in CNS disorders.  
Targeted temperature management (TTM) is currently gaining attention in the 
management of CNS disorders especially trauma and ischemia. Although mild to moderate 
degree of hypothermia is widely accepted in clinics, severe hypothermia in accidental 
cases (with a core body temperature reaching upto 15-20 °C) has been nevertheless 
reported worldwide. The latter can have deleterious effects especially on the CNS upon 
rewarming. In line with our preliminary in vitro results, boosting the endogenous levels of 
H2S synthesizing enzymes in CNS, primarily CBS (abundantly expressed in brain), can be an 
alternative to mitigate such adverse effects and dopamine could prove to be a potential 
candidate.  
With sparse literature on potential protective effects of dopamine to mitigate CNS injury, 
studies have revealed mixed results (46). One such study by Park and co-workers (2003) 
(47) observed dopamine infusion to prevent cerebral ischemia by maintaining adequate 
cerebral perfusion pressure while attenuating brain injury in a neonatal swine model of 
bacterial meningitis. Further, administration of levodopa (a dopamine precursor) initiated 
2 days after tMCAO and continued for 12 consecutive days significantly improved 
sensorimotor function in rats undergoing tMCAO, however, without affecting the ischemic 
damage (48). Moreover, in a clinical study, a single dose levodopa and physiotherapy (49) 
improved motor recovery in thrombo-embolic stroke patients. In addition, levodopa 
treatment improved procedural motor learning in patients with chronic stroke (≥1 y after 
stroke) in comparison to placebo treated group (50). Nonetheless, further studies are 
warranted to investigate molecular pathways underlying ischemia progression spatio-
temporally, especially in a permanent stroke model. 
 
PARADIGM SHIFT IN STROKE RESEARCH – NEED OF THE HOUR 
It has been more than 30 years since the inception of pre-clinical modelling of cerebral 
ischemia (51) to mimic features of clinical ischemic stroke. Although numerous studies 
have been able to delineate the underlying pathophysiological mechanisms and decipher 
novel targets, clinical translation for potential neuroprotectants (esp. blockade of incipient 
neuronal cell death) has failed until now except for thrombolytic intervention. The strive 
for an ideal pre-clinical stroke model still continues (51). Several guidelines have been put 
forth to improve pre-clinical models of ischemic stroke, bridge the gap between the pre-




including the design and implementation of stroke trials (52) with a focus on pre-clinical 
multi-centric ischemic stroke trials (53). Exploring avenues such as induced pluripotent 
stem cell (iPSC)-derived neuronal and glial cells from stroke patients for prognostic as well 
as for drug screening, gut-brain axis and hypoxia-tolerant species could pave the way to 
overcome the translational roadblock. 
One major aspect of improving pre-clinical models encompasses the study of the 
pathophysiology of chronic ischemic stroke and the development of relevant therapeutics. 
Our pMCAO model induced by BP-tip filament can be of substantial relevance. 
Importantly, this model allows the delineation of mechanisms pertaining to ischemia 
alone without the interference of events related to reperfusion injury. Clinically, such a 
condition would be more akin to majority of patients who are unable to undergo 
thrombolysis. Our model can thus assist in testing novel therapeutics in such cases which 
are crucial in targeting specific molecular events evident in ischemia-only condition with 
the absence of reperfusion-mediated injury. 
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Beroerte ontstaat wanneer de bloedtoevoer naar een deel van de hersenen is 
onderbroken of sterk verminderd, hersenweefsel is dan beroofd van zuurstof en 
voedingsstoffen wat leidt tot weefselbeschadiging en neurologische disfunctie. Het is de 
tweede meest voorkomende oorzaak van de dood en de belangrijkste oorzaak van 
volwassen gehandicapten in de wereld. Beroerte kan het gevolg zijn van een 
hersenbloeding of een herseninfarct. Een herseninfarct is een ischemische beroerte en 
bepaalt ongeveer 80% van alle beroertes. Een ischemische beroerte komt door vorming 
van bloedstolsels in een bloedvat in de  hersenen of in een bloedvat naar de hersenen toe. 
De middelste cerebrale slagader (MCA) is in de meeste gevallen betrokken bij de beroerte. 
De processen die leiden tot hersenschade na een beroerte zijn complex en beslaan veel 
biochemische routes. Veel medicijnen die voorkomen dat hersencellen sterven hebben 
goed gewerkt in (dier)modellen van een beroerte. Echter, wanneer deze geneesmiddelen 
werden gegeven aan patiënten met een acute beroerte, waren ze niet succesvol. Er is 
behoefte aan nieuwe therapieën aangezien de enig bekende effectieve therapie, d.w.z. 
revascularisatie van de geblokkeerde cerebralis media, hoogstens 15% van patiënten met 
een ischemische beroerte dient. De aanvang van trombolyse in het midden van de jaren 
1990 heeft een cruciale rol gespeeld bij het bevorderen van de behandeling van acute 
ischemische beroerte. Het doel van systemische of lokale toediening van trombolytica of 
endovasculaire technieken is het afbreken van de trombus/embolieën die de 
bloedaanvoer naar het hersenweefsel onderbreken. De trombolytische techniek die in 
eerste instantie wordt gebruikt is systemische (intraveneuze) trombolyse maar kan echter 
grote problemen opleveren met betrekking tot de werkzaamheid, veiligheid en 
toepasbaarheid. Niet alleen contraindicaties zoals een voorgeschiedenis van intracraniale 
bloeding en recente operatie sluiten het gebruik uit, maar ook het optreden van 
hemorragische transformatie van het ischemische gebied kan de ischemische schade 
verergeren en zelfs leiden tot slechtere functionele uitkomst. De aanpak van intra-
arteriële trombolyse wordt momenteel als meer geschikt beschouwd. Intra-arteriële 
therapie bestaat in principe uit de ontbinding van stolsels, ofwel met lokaal geleverde 
trombolytica dan wel met behulp van mechanische apparaten. Hoewel intraveneuze 
trombolyse met recombinant weefsel plasminogeen activator (rtPA, Actilyse®) de enige 
specifieke farmacologische reperfusie therapie is voor acute ischemische beroerte (AIS) 
die bewezen effectief is en door de FDA goedgekeurd is, heeft het een smalle 
therapeutische breedte. Het therapeutisch venster van 3 uur na het begin van de 
symptomen is onlangs uitgebreid in Europa tot 4,5 uur na de gunstige resultaten van de 
ECASS III trial (European Cooperative Acute Stroke Study). Studies zijn nu gericht op een 
verdere uitbreiding van het tijdvenster dan 4,5 uur. Ondanks de klinische effectiviteit komt 
slechts een minderheid van de patiënten in aanmerking voor intraveneuze trombolyse 
vanwege het beperkte therapeutische venster en verschillende contraindicaties. Vanwege 
de complexe onderliggende mechanismen bij beroerte is het effect van een 




preklinische modellen ontwikkeld en aangepast om de klinische situatie na te bootsen om 
de ontwikkeling van effectieve therapeutische middelen mogelijk te maken en om de 
bestaande translationele blokkade te overwinnen.  
In hoofdstuk 1 schetsen we de lasten en recente terminologie van een beroerte in het 
algemeen. Bovendien worden pathofysiologische mechanismen die ten grondslag liggen 
aan ischemische beroerte en huidige behandeling strategieën beoordeeld. Om sommige 
onderliggende mechanismen na te bootsen, zijn preklinische modellen van ischemische 
beroerte al meer dan 30 jaar opgesteld met name in knaagdieren (ratten en muizen). 
Huidige modellen zijn gericht op de inductie van voorbijgaande aard en/of permanente 
cerebrale ischemie met gebruik van verschillende benaderingen zoals bloedstolsel/micro-
macrosphere injectie, silicium gecoate tip filamenten en craniectomy-gebaseerde (via 
verwijdereing van een deel van de schedel) electrocoagulatie van relevante hersen 
slagaders. In hoofdstuk 1 worden deze methoden geschetst met een primaire focus op de 
filament gebaseerde aanpak en de relevante wijzigingen. Terwijl een grote hoeveelheid 
literatuur aanzienlijk therapeutisch succes heeft aangetoond van veel interventiesin 
experimentele modellen, heeft de vertaling van deze fundamentele onderzoeksresultaten 
helaas geleid tot ontmoedigende resultaten in klinische studies. Vandaar dat het 
ontwikkelen van de juiste pre-klinische modellen en hun optimalisatie nodig is om betere 
vertaling te verzekeren. 
De studies in dit proefschrift kunnen grofweg worden verdeeld in twee delen. In het 
eerste deel van het proefschrift inhoofdstukken 2 en 3, introduceren we een model in een 
knaagdier met focale cerebrale ischemie via occlusie van de MCA als een instrument om 
nieuwe therapieën te bestuderen. Dit model maakt gebruik van een cryogene MRI 
(magnetic resonance imaging) spoel (geoptimaliseerd en ontwikkeld door de afdeling 
Computer Assisted Clinical Medicine, Mannheim) om weefsel kalium (K+) niveau te meten. 
In hoofdstuk 2, hebben we het huidige permanente focale cerebrale ischemie model 
bewerkt met behulp van een intravasculaire filament aanpak in de rat met het doel om de 
overleving aanzienlijk te verbeteren. Om dit te bereiken, ontworpen we opnieuw de 
silicium coating om een bowling pin-vormige filament tip te creëren. We demonstreren 
dat deze tip nog steeds leidt tot een sterk infarct met bijbehorende hersenen zwelling. 
Deze methode is, in tegenstelling tot eerdere benaderingen, veel beter beperkt is tot de 
bloedvoorziening aan het hersenweefsel door de MCA en behoudt collaterale 
bloedvoorziening via de arteria cerebralis posterior. De modificatie van de tip resulteerde 
niet alleen in verbetering van de overleving, maar ook in vertraagde groei van het infarct. 
Deze functies lijken dus meer op die van kwaadaardige MCA beroerte zoals aangetroffen 
in de klinische setting. Hiermee hebben we duseen model neergezet met een acceptabele 
sterfte om mechanismen te bestuderen die ten grondslag liggen aan vertraagde celdood 
en om effectiviteit van nieuwe experimentele drugs eb cel gebaseerde therapie te 
onderzoeken. In hoofdstuk 3 hebben we met succes gebruik gemaakt van de nieuwe 




bestuderen. We gebruikten een cryogene oppervlak resonator met een basis van een 
koper die afgekoeld werd door vloeibare stikstof tot 77 oK (-196 °C) met behulp van een 
speciaal gemaakte cryostaat huisvesting om het 39K signaal van rat weefsel te meten van 
gezonde hersenen en hersenen getroffen door beroerte met een 9.4 Tesla MRI. Deze 
cryogene spoel had een verbeterde signaal-ruisverhouding (SNR) ten opzichte van de 
meting verkregen bij kamertemperatuur (met een factor 2.7 ± 0.2). Bovendien werd het 
39K signaal in de geïnfarceerde hemisfeer van de rattenhersenen verminderd met 
ongeveer 75% bij 77 oK vergeleken met 40% reductie bij 300 oK (27 °C) ten opzichte van de 
contralaterale hemisfeer, wat wijst op de verbeterde signaaldetectie bij 77 oK. De 
verbeterde beoordeling van ionische onbalans die optreedt bij ischemische beroerte kan 
eventueel worden gebruikt om de progressie van ischemische schade te bestuderen in 
combinatie met andere X-kernen imaging (zoals natrium-MRI) in toekomstige studies. 
In het tweede deel van het proefschrift hebben we de neuroprotectieve eigenschappen 
van nieuwe therapeutische middelen getest in knaagdier modellen van ischemische 
beroerte en in een in vitro model van microglia letsel. In hoofdstuk 4 evalueerden we het 
effect van een groeifactor, pigment epitheel-derived growth factor (PEDF), op ischemische 
schade en zwelling van de hersenen in een voorbijgaand ischemische beroerte model met 
seriële MRI beoordeling. PEDF verminderde significant de vorming het ischemische laesie 
volume en oedeem. Bovendien, in hoofdstuk 5, werd waargenomen dat de nieuwe 
chromanol gebaseerde verbinding SUL121 ischemische schade in een focaal cerebrale 
ischemie model beperkt, tevens endogene H2S synthetiserende enzymen, met name CBS, 
doet toenemen en de systemische vasculaire functie verbetert zoals bestudeerd in de 
aorta. Tenslotte laten we in hoofdstuk 6 zien dat exogeen toegediende dopamine 
hypothermie-opwarming geïnduceerd letsel vermindert in gekweekte muizen microglia 
(BV2) cellen. Deze vermindering in letsel leek af te hangen van een dopamine D1-receptor-
gemedieerde activatie van de cAMP cascade en opregulatie van de niveaus van H2S 
synthetiserende enzymen, CBS en 3-MST. 
Samen vormen deze studies een overzicht van de succesvolle modellen van cerebrale 
ischemie in vivo, welke de ontwikkeling mogelijk maakte van een niet-invasief beeldvormd 
hulpmiddel voor de geassocieerde ionische onbalans (verbeterd 39K signaal via een 
cryogene spoel) en de ontwikkeling van een nieuw occlusie filament wat een succesvol 
model heeft gegenereerd voor permanente ischemie die kwaadaardige beroerte 
vertegenwoordigt. Verder onderzochten we potentiële therapeutische middelen (PEDF, 
SUL121) voor hun vermeende neuroprotectieve eigenschappen en beschreven we een 
beschermend effect van dopamine in een in vitro model van hypothermie-opwarming 
geïnduceerdeschade met betrekking tot zijn eigenschap om de expressie van belangrijke 
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